Patent Application
20230078913
The present disclosure generally relates to bifunctional Proteolysis Targeting Chimeric ligands (Protac compounds) comprising a ligase modulator/binder and a molecule that binds to a protein target of interest, and methods of treating various diseases and conditions with the Protac compounds. Generally, the molecule that binds to a protein target is an androgen receptor modulator.
Androgens mediate their effects through the androgen receptor (AR). Androgens play a role in a wide range of developmental and physiological responses and are involved in male sexual differentiation, maintenance of spermatogenesis, and male gonadotropin regulation (R. K. Ross, G. A. Coetzee, C. L. Pearce, J. K. Reichardt, P. Bretsky, L. N. Kolonel, B. E. Henderson, E. Lander, D. Altshuler & G. Daley, Eur Urol 35, 355-361 (1999); A. A. Thomson, Reproduction 121, 187-195 (2001); N. Tanji, K. Aoki & M. Yokoyama, Arch Androl 47, 1-7 (2001)). Several lines of evidence show that androgens are associated with the development of prostate carcinogenesis. Firstly, androgens induce prostatic carcinogenesis in rodent models (R. L. Noble, Cancer Res 37, 1929-1933 (1977); R. L. Noble, Oncology 34, 138-141 (1977)) and men receiving androgens in the form of anabolic steroids have a higher incidence of prostate cancer (J. T. Roberts & D. M. Essenhigh, Lancet 2, 742 (1986); J. A. Jackson, J. Waxman & A. M. Spiekerman, Arch Intern Med 149, 2365-2366 (1989); P. D. Guinan, W. Sadoughi, H. Alsheik, R. J. Ablin, D. Alrenga & I. M. Bush, Am J Surg 131, 599-600 (1976)). Secondly, prostate cancer does not develop if humans or dogs are castrated before puberty (J. D. Wilson & C. Roehrborn, J Clin Endocrinol Metab 84, 4324-4331 (1999); G. Wilding, Cancer Surv 14, 113-130 (1992)). Castration of adult males causes involution of the prostate and apoptosis of prostatic epithelium while eliciting no effect on other male external genitalia (E. M. Bruckheimer & N. Kyprianou, Cell Tissue Res 301, 153-162 (2000); J. T. Isaacs, Prostate 5, 545-557 (1984)). This dependency on androgens provides the underlying rationale for treating prostate cancer with chemical or surgical castration (androgen ablation), also known as androgen ablation therapy (ABT) or androgen depravation therapy (ADT).
Androgens also play a role in female diseases such as polycystic ovary syndrome as well as cancers. One example is ovarian cancer where elevated levels of androgens are associated with an increased risk of developing ovarian cancer (K. J. Helzlsouer, A. J. Alberg, G. B. Gordon, C. Longcope, T. L. Bush, S. C. Hoffman & G. W. Comstock, JAMA 274, 1926-1930 (1995); R. J. Edmondson, J. M. Monaghan & B. R. Davies, Br J Cancer 86, 879-885 (2002)). The AR has been detected in a majority of ovarian cancers (H. A. Risch, J Natl Cancer Inst 90, 1774-1786 (1998); B. R. Rao & B. J. Slotman, Endocr Rev 12, 14-26 (1991); G. M. Clinton & W. Hua, Crit Rev Oncol Hematol 25, 1-9 (1997)), whereas estrogen receptor-alpha (ERa) and the progesterone receptor are detected in less than 50% of ovarian tumors.
The only effective treatment available for advanced prostate cancer is the withdrawal of androgens which are essential for the survival of prostate luminal cells. Androgen ablation therapy causes a temporary reduction in tumor burden concomitant with a decrease in serum prostate-specific antigen (PSA). Unfortunately prostate cancer can eventually grow again in the absence of testicular androgens (castration-resistant disease) (Huber et al 1987 Scand J. Urol Nephrol. 104, 33-39). Castration-resistant prostate cancer that is still driven by AR is biochemically characterized before the onset of symptoms by a rising titre of serum PSA (Miller et al 1992 J Urol. 147, 956-961). Once the disease becomes castration-resistant most patients succumb to their disease within two years.
The AR has distinct functional domains that include the carboxy-terminal ligand-binding domain (LBD), a DNA-binding domain (DBD) comprising two zinc finger motifs, and an N-terminus domain (NTD) that contains two transcriptional activation units (tau1 and tau5) within activation function-1 (AF-1). Binding of androgen (ligand) to the LBD of the AR results in its activation such that the receptor can effectively bind to its specific DNA consensus site, termed the androgen response element (ARE), on the promoter and enhancer regions of “normally” androgen regulated genes, such as PSA, to initiate transcription. The AR can be activated in the absence of androgen by stimulation of the cAMP-dependent protein kinase (PKA) pathway, with interleukin-6 (IL-6) and by various growth factors (Culig et al 1994 Cancer Res. 54, 5474-5478; Nazareth et al 1996 J. Biol. Chem. 271, 19900-19907; Sadar 1999 J Biol. Chem. 274, 7777-7783; Ueda et al 2002 A J Biol. Chem. 277, 7076-7085; and Ueda et al 2002 B J Biol. Chem. 277, 38087-38094). The mechanism of ligand-independent transformation of the AR has been shown to involve: 1) increased nuclear AR protein suggesting nuclear translocation; 2) increased AR/ARE complex formation; and 3) the AR-NTD (Sadar 1999 J. Biol. Chem. 274, 7777-7783; Ueda et al 2002 A J. Biol. Chem. 277, 7076-7085; and Ueda et al 2002 B J Biol. Chem. 277, 38087-38094). The AR can be activated in the absence of testicular androgens by alternative signal transduction pathways in castration-resistant disease, which is consistent with the finding that nuclear AR protein is present in secondary prostate cancer tumors (Kim et al 2002 Am. J Pathol. 160, 219-226; and van der Kwast et al 1991 Inter. J Cancer 48, 189-193).
Clinically available inhibitors of the AR include nonsteroidal antiandrogens such as bicalutamide (Casodex™), nilutamide, flutamide, and enzalutamide. There is also a class of steroidal antiandrogens, such as cyproterone acetate and spironolactone. Both steroidal and non-steroidal antiandrogens target the LBD of the AR and predominantly fail presumably due to poor affinity and mutations that lead to activation of the AR by these same antiandrogens (Taplin, M. E., Bubley, G. J., Kom Y. J., Small E. J., Uptonm M., Rajeshkumarm B., Balkm S. P., Cancer Res., 59, 2511-2515 (1999)), and constitutively active AR splice variants. Antiandrogens have no effect on the constitutively active AR splice variants that lack the ligand-binding domain (LBD) and are associated with castration-recurrent prostate cancer (Dehm S M, Schmidt L J, Heemers H V, Vessella R L, Tindall D J., Cancer Res 68, 5469-77, 2008; Guo Z, Yang X, Sun F, Jiang R, Linn D E, Chen H, Chen H, Kong X, Melamed J, Tepper C G, Kung H J, Brodie A M, Edwards J, Qiu Y., Cancer Res. 69, 2305-13, 2009; Hu et al 2009 Cancer Res. 69, 16-22; Sun et al 2010 J Clin Invest. 2010 120, 2715-30) and resistant to abiraterone and enzalutamide (Antonarakis et al., N Engl J Med. 2014, 371, 1028-38; Scher et al JAMA Oncol. 2016 doi: 10.1001). Conventional therapy has concentrated on androgen-dependent activation of the AR through its C-terminal domain.
Other relevant AR antagonists previously reported (see, WO 2010/000066, WO 2011/082487; WO 2011/082488; WO 2012/145330; WO 2015/031984; WO 2016/058080; and WO 2016/058082) that bind to full-length AR and/or truncated AR splice variants that are currently being developed include: AR degraders such as niclosamide (Liu C et al 2014), galeterone (Njar et al 2015; Yu Z at al 2014), and ARV-330/Androgen receptor PROTAC (Neklesa et al 2016 J Clin Oncol 34 suppl 2S; abstr 267); AR DBD inhibitor VPC-14449 (Dalal K et al 2014 J Biol Chem. 289(38):26417-29; Li H et al 2014 J Med Chem. 57(15):6458-67); antiandrogens apalutamide (Clegg N J et al 2012), ODM-201 (Moilanen A M et al 2015), ODM-204 (Kallio et al J Clin Oncol 2016 vol. 34 no. 2_suppl 230), TAS3681 (Minamiguchi et al 2015 J Clin Oncol 33, suppl 7; abstr 266); and AR NTD inhibitors 3E10-AR441bsAb (Goicochea N L et al 2015), and sintokamide (Sadar et al 2008; Banuelos et al 2016).
The AR-NTD is also a target for drug development (e.g. WO 2000/001813; Myung et al. J. Clin. Invest 2013, 123, 2948), since the NTD contains Activation-Function-1 (AF-1) which is the essential region required for AR transcriptional activity (Jenster et al 1991. Mol Endocrinol. 5, 1396-404). The AR-NTD importantly plays a role in activation of the AR in the absence of androgens (Sadar, M. D. 1999 J Biol. Chem. 274, 7777-7783; Sadar M D et al 1999 Endocr Relat Cancer. 6, 487-502; Ueda et al 2002 J Biol. Chem. 277, 7076-7085; Ueda 2002 J Biol. Chem. 277, 38087-38094; Blaszczyk et al 2004 Clin Cancer Res. 10, 1860-9; Dehm et al 2006 J Biol Chem. 28, 27882-93; Gregory et al 2004 J Biol Chem. 279, 7119-30). The AR-NTD is important in hormonal progression of prostate cancer as shown by application of decoy molecules (Quayle et al 2007, Proc Natl Acad Sci USA. 104, 1331-1336).
While the crystal structure has been resolved for the AR C-terminus LBD, this has not been the case for the NTD due to its high flexibility and intrinsic disorder in solution (Reid et al 2002 J. Biol. Chem. 277, 20079-20086) thereby hampering virtual docking drug discovery approaches. Compounds that modulate AR, potentially through interaction with NTD domain, include the bisphenol compounds disclosed in published PCT Nos: WO 2010/000066, WO 2011/082487; WO 2011/082488; WO 2012/145330; WO 2012/139039; WO 2012/145328; WO 2013/028572; WO 2013/028791; WO 2014/179867; WO 2015/031984; WO 2016/058080; WO 2016/058082; WO 2016/112455; WO 2016/141458; WO 2017/177307; WO 2017/210771; and WO 2018/045450, and which are hereby incorporated by reference in their entireties.
Transcriptionally active androgen receptor plays a major role in CRPC in spite of reduced blood levels of androgen (Karantanos, T. et al Oncogene 2013, 32, 5501-5511; Harris, W. P. et al Nature Clinical Practice Urology, 2009, 6, 76-85). AR mechanisms of resistance to ADT include: overexpression of AR (Visakorpi, T. et al Nature Genetics 1995, 9, 401-406; Koivisto, P. et al Scandinavian Journal of Clinical and Laboratory Investigation Supplementum 1996, 226, 57-63); gain-of-function mutations in the AR LBD (Culig Z. et al Molecular Endocrinology 1993, 7, 1541-1550); intratumoral androgen synthesis (Cai, C. et al Cancer Research 2011, 71, 6503-6513); altered expression and function of AR coactivators (Ueda, T. et al The Journal of Biological Chemistry 2002, 277, 38087-38094; Xu J. et al Nature Reviews Cancer 2009, 9, 615-630); aberrant post-translational modifications of AR (Gioeli D. et al Molecular and Cellular Endocrinology 2012, 352, 70-78; van der Steen T. et al International Journal of Molecular Sciences 2013, 14, 14833-14859); and expression of AR splice variants (AR-Vs) which lack the ligand-binding domain (LBD) (Karantanos, T. et al Oncogene 2013, 32, 5501-5511; Andersen R. J. et al Cancer Cell 2010, 17, 535-546; Myung J. K. et al The Journal of Clinical Investigation 2013, 123, 2948-2960; Sun S. et al The Journal of Clinical Investigation 2010, 120, 2715-2730). Anti-androgens such as bicalutamide and enzalutamide target AR LBD, but have no effect on truncated constitutively active AR-Vs such as AR-V7 (Li Y. et al Cancer Research 2013, 73, 483-489). Expression of AR-V7 is associated with resistance to current hormone therapies (Li Y. et al Cancer Research 2013, 73, 483-489; Antonarakis E. S. et al The New England Journal of Medicine 2014, 371, 1028-1038).
While significant advances have been made in this field, there remains a need for improved treatment for AR-mediated disorders including prostate cancer, especially metastatic castration-resistant prostate cancer. Development of compounds and complexes that can selectively act to inhibit AR activity or degrade AR proteins that promotes cell proliferation, via unique interactions with AR NTD, would provide patients alternative options and new hope.
Ubiquitin-Proteasome Pathway System (UPS) is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPS is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. Posttranslational modification of proteins by ubiquitin is a fundamental cellular mechanism that regulates protein stability and activity and underlies a multitude of functions, from almost every aspect of biology. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases. These ligases comprise over 500 different proteins and are categorized into multiple classes defined by the structural element of their E3 functional activity.
Deubiquitinating proteins and ubiquitin-specific proteases (DUBs and USPs) and E3 Ligases play a vital role in the UPS. These proteins are supported by flexible Zinc Finger (ZnF) domains which stabilize the binding of ubiquitin (Ub) for specialized functions.
The present invention relates to bifunctional compounds, also known as Proteolysis Targeting Chimeric molecules (Protac) that induce ubiquitination and degrade a protein of interest. Protac compounds are typically designed with three parts: 1) a ligand/molecule that binds to and/or modulates ubiquitin ligases; 2) a small molecule that binds to the target protein of interest for proteolysis; and 3) a linker that links the two molecules together. Protacs thus function by allowing the ligand/molecule to bind to the ubiquitin ligases, thereby recruiting the target of protein of interest to the ligase for ubiquitination and ultimately proteolysis and degradation.
The present invention discloses Protac compounds intended to degrade and/or inhibit AR proteins associated with cancer, especially prostate cancer.
The compound of the present disclosure can be useful for modifying the ubiquitination and subsequent degradation of androgen receptor proteins. In one embodiment of the present invention, the compound is a bifunctional compound wherein a E3 ligase binding group (“PLM”) is covalently attached to one end of a Linker (“LI”), and the androgen receptor modulatr (“PTC”) is covalently attached to the other end of the linker (LI).
In one embodiment, the compound of the present disclosure is represented by formula (Q):
PLM-LI-PTC (Q);
or a pharmaceutically acceptable salt thereof, wherein:
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
In some embodiments of the compound of formula (Q), the linker LI corresponds to the formula:
-LI-LII(q)-,
wherein:
In some embodiments of the compound of formula (Q), q is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24.
In some embodiments of the compound of formula Q, the PLM is a von Hippel-Lindau (VHL) binding group, an E3 ligase substrate receptor cereblon (CRBN), a mouse double minute 2 homolog (MDM2), or an inhibitor of apoptosis (IAP). In some embodiments, the PLM is a von Hippel-Lindau (VHL) binding group.
In some embodiments of the compound of formula (Q), the PLM has the formula (E3B):
In some embodiments of the compound of formula (Q), the PLM has the formula (E3D):
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In some embodiments of the compound of formula (Q), the PLM is represented by formula (W-II):
wherein the PLM is covalently bound to the LI via
In some embodiments of the compound of formula (Q), the PLM is represented by formula (W-IIIA):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
In some embodiments of the compound of formula (Q), the PLM is represented by formula (W-IIIB):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the PLM is covalently bound to the LI via
In some embodiments of the compound of formula (Q), the PTC has the structure of formula (IVA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In some embodiments of the compound of formula (Q), the PTC has the structure of formula (A-I)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In some embodiments of the compound of formula (Q), the PTC has the structure of formula (G-II):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-IV):
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-IVA):
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-V):
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-VA):
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-VI):
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-VIA):
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound of formula (Q) is a compound of formula (W-VII):
or a pharmaceutically acceptable salt thereof.
In one embodiment of the present disclosure, a pharmaceutical composition comprising a compound of formula (Q) and a pharmaceutically acceptable carrier is provided.
In one embodiment of the pharmaceutical composition as disclosed herein, the composition further comprising one or more additional therapeutic agents.
In one embodiment, the present disclosure relates to methods for modulating androgen receptor activity, comprising administering a compound of formula (Q), to a subject in need thereof.
In one embodiment of any one of the method as disclosed herein, the modulating androgen receptor activity is for treating a condition or disease selected from prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
In one embodiment, the present disclosure relates to methods for treating cancer, comprising administering a compound of formula (Q), to a subject in need thereof. In one embodiment, the cancer is selected from prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, or salivary gland carcinoma. In one embodiment, the cancer is prostate cancer.
All publications, patents and patent applications, including any drawings and appendices therein are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application, drawing, or appendix was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
While the following terms are believed to be well understood by one of ordinary skill in the art, the following definitions are set forth to facilitate explanation of the presently disclosed subject matter.
Throughout the present specification, the terms “about” and/or “approximately” may be used in conjunction with numerical values and/or ranges. The term “about” is understood to mean those values near to a recited value. Furthermore, the phrases “less than about [a value]” or “greater than about [a value]” should be understood in view of the definition of the term “about” provided herein. The terms “about” and “approximately” may be used interchangeably.
Throughout the present specification, numerical ranges are provided for certain quantities. It is to be understood that these ranges comprise all subranges therein. Thus, the range “from 50 to 80” includes all possible ranges therein (e.g., 51-79, 52-78, 53-77, 54-76, 55-75, 60-70, etc.). Furthermore, all values within a given range may be an endpoint for the range encompassed thereby (e.g., the range 50-80 includes the ranges with endpoints such as 55-80, 50-75, etc.).
The term “a” or “an” refers to one or more of that entity; for example, “a androgen receptor modulator” refers to one or more androgen receptor modulators or at least one androgen receptor modulator. As such, the terms “a” (or “an”), “one or more” and “at least one” are used interchangeably herein. In addition, reference to “an inhibitor” by the indefinite article “a” or “an” does not exclude the possibility that more than one of the inhibitors is present, unless the context clearly requires that there is one and only one of the inhibitors.
As used herein, the verb “comprise” as is used in this description and in the claims and its conjugations are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. The present invention may suitably “comprise”, “consist of”, or “consist essentially of”, the steps, elements, and/or reagents described in the claims.
It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely”, “only” and the like in connection with the recitation of claim elements, or the use of a “negative” limitation.
The term “pharmaceutically acceptable salts” includes both acid and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. Those skilled in the art will further recognize that acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
The term “treating” means one or more of relieving, alleviating, delaying, reducing, improving, or managing at least one symptom of a condition in a subject. The term “treating” may also mean one or more of arresting, delaying the onset (i.e., the period prior to clinical manifestation of the condition) or reducing the risk of developing or worsening a condition.
The compounds of the invention, or their pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms whether or not they are specifically depicted herein. Optically active (+) and (−), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.
A “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any said compounds.
A “prodrug” refers to a derivative of a compound of the present disclosure that will be converted to the compound in vivo. In one embodiment of the present disclosure, a prodrug includes a PTC of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (A-I), (B)-(D), (E), (E-I)-(E-VII), (F), (G), (G-I), (G-II), (H), and (H-I) (“formula (I)-(VI) and (A)-(H-I)”) and (a), having a free hydroxyl group (—OH) that is acetylated (—OCOMe) at one or more positions.
An “effective amount” means the amount of a formulation according to the invention that, when administered to a patient for treating a state, disorder or condition is sufficient to effect such treatment. The “effective amount” will vary depending on the active ingredient, the state, disorder, or condition to be treated and its severity, and the age, weight, physical condition and responsiveness of the mammal to be treated.
The term “therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof.
As used herein, a “subject” can be a human, non-human primate, mammal, rat, mouse, cow, horse, pig, sheep, goat, dog, cat and the like. The subject can be suspected of having or at risk for having a cancer, such as prostate cancer, breast cancer, ovarian cancer, salivary gland carcinoma, or endometrial cancer, or suspected of having or at risk for having acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration. Diagnostic methods for various cancers, such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, salivary gland carcinoma, or endometrial cancer, and diagnostic methods for acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration and the clinical delineation of cancer, such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, salivary gland carcinoma, or endometrial cancer, diagnoses and the clinical delineation of acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration are known to those of ordinary skill in the art.
“Mammal” includes humans and both domestic animals such as laboratory animals (e.g., mice, rats, monkeys, dogs, etc.) and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
All weight percentages (i.e., “% by weight” and “wt. %” and w/w) referenced herein, unless otherwise indicated, are measured relative to the total weight of the pharmaceutical composition.
As used herein, “substantially” or “substantial” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking, the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained. The use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of action, characteristic, property, state, structure, item, or result. For example, a composition that is “substantially free of” other active agents would either completely lack other active agents, or so nearly completely lack other active agents that the effect would be the same as if it completely lacked other active agents. In other words, a composition that is “substantially free of” an ingredient or element or another active agent may still contain such an item as long as there is no measurable effect thereof
“Ubiquitin Proteasome Pathway System (UPS)” as used herein relates to the ubiquitin proteasome pathway, conserved from yeast to mammals, and is required for the targeted degradation of most short-lived proteins in the eukaryotic cell. Targets include cell cycle regulatory proteins, whose timely destruction is vital for controlled cell division, as well as proteins unable to fold properly within the endoplasmic reticulum. Ubiquitin modification is an ATP-dependent process carried out by three classes of enzymes. An “ubiquitin activating enzyme” (E1) forms a thio-ester bond with ubiquitin, a highly conserved 76-amino acid protein. This reaction allows subsequent binding of ubiquitin to a “ubiquitin conjugating enzyme” (E2), followed by the formation of an isopeptide bond between the carboxy-terminus of ubiquitin and a lysine residue on the substrate protein. The latter reaction requires a “ubiquitin ligase” (E3). E3 ligases can be single- or multi-subunit enzymes. In some cases, the ubiquitin-binding and substrate binding domains reside on separate polypeptides brought together by adaptor proteins or culling. Numerous E3 ligases provide specificity in that each can modify only a subset of substrate proteins. Further specificity is achieved by post-translational modification of substrate proteins, including, but not limited to, phosphorylation. Effects of monoubiquitination include changes in subcellular localization. However, multiple ubiquitination cycles resulting in a polyubiquitin chain are required for targeting a protein to the proteasome for degradation. The multisubunit 26S proteasome recognizes, unfolds, and degrades polyubiquitinated substrates into small peptides. The reaction occurs within the cylindrical core of the proteasome complex, and peptide bond hydrolysis employs a core threonine residue as the catalytic nucleophile. It has been shown that an additional layer of complexity, in the form of multiubiquitin chain receptors, may lie between the polyubiquitination and degradation steps. These receptors react with a subset of polyubiquitinated substrates, aiding in their recognition by the 26S proteasome, and thereby promoting their degradation. This pathway is not only important in cellular homeostasis, but also in human disease. Because ubiquitin/proteasome-dependent degradation is often employed in control of the cell division cycle and cell growth, researchers have found that proteasome inhibitors hold some promise of being developed into potential cancer therapeutic agents.
Protein degradation through the ubiquitin-proteasome system is the major pathway of non-lysosomal proteolysis of intracellular proteins. It plays important roles in a variety of fundamental cellular processes such as regulation of cell cycle progression, division, development and differentiation, apoptosis, cell trafficking, and modulation of the immune and inflammatory responses. The central element of this system is the covalent linkage of ubiquitin to targeted proteins, which are then recognized by the 26S proteasome, an adenosine triphosphate-dependent, multi-catalytic protease. Damaged, oxidized, or misfolded proteins as well as regulatory proteins that control many critical cellular functions are among the targets of this degradation process. Aberration of this system leads to the dysregulation of cellular homeostasis and the development of multiple diseases (Wang et al. Cell Mol Immunol. 2006 August; 3(4):255-61).
“Ligase” as used herein, is an enzyme that can catalyze the joining of two or more compounds or biomolecules by bonding them together with a new chemical bond. The “ligation” of the two usually with accompanying hydrolysis of a small chemical group dependent to one of the larger compounds or biomolecules, or the enzyme catalyzing the linking together of two compounds, e.g., enzymes that catalyze joining of groups C—O, C—S, C—N, etc. Ubiquitin-protein (E3) ligases are a large family of highly diverse enzymes selecting proteins for ubiquitination.
“Ub Ligases” are involved in disease pathogenesis for oncology, inflammation & infectious disease. E3 ligase belonging to the RING-between-RING (RBR) family of E3 ligases containing both canonical RING domains and a catalytic cysteine residue usually restricted to HECT E3 ligases; termed ‘RING/HECT hybrid’ enzymes. Mutations in Parkin linked to Parkinson's disease, cancer and mycobacterial infection. Parkin is recognized as a neuroprotective protein with a role in mitochondrial integrity.
“Ligands” as used herein bind to metal via one or more atoms in the ligand, and are often termed as chelating ligands. A ligand that binds through two sites is classified as bidentate, and three sites as tridentate. The “bite angle” refers to the angle between the two bonds of a bidentate chelate. Chelating ligands are commonly formed by linking donor groups via organic linkers. A classic bidentate ligand is ethylenediamine, which is derived by the linking of two ammonia groups with an ethylene (—CH2CH2—) linker. A classic example of a polydentate ligand is the hexadentate chelating agent EDTA, which is able to bond through six sites, completely surrounding some metals. The binding affinity of a chelating system depends on the chelating angle or bite angle. Many ligands are capable of binding metal ions through multiple sites, usually because the ligands have lone pairs on more than one atom. Some ligands can bond to a metal center through the same atom but with a different number of lone pairs. The bond order of the metal ligand bond can be in part distinguished through the metal ligand bond angle (M-X—R). This bond angle is often referred to as being linear or bent with further discussion concerning the degree to which the angle is bent. For example, an imido ligand in the ionic form has three lone pairs. One lone pair is used as a sigma X donor, the other two lone pairs are available as L type pi donors. If both lone pairs are used in pi bonds then the M-N—R geometry is linear. However, if one or both of these lone pairs are non-bonding then the M-N—R bond is bent and the extent of the bend speaks to how much pi bonding there may be. It was found that few heteroatoms, such as nitrogen, oxygen, and sulfur atoms, interacted with zinc, ideal distances between the zinc and these heteroatoms were identified. Whereas carboxylates bound to the zinc via both monodentate and bidentate interactions, the hydroxamates bound dominantly in a bidentate manner. These results aid in the design of new inhibitors with the potential to interact with zinc in the target protein. Virtually every molecule and every ion can serve as a ligand for (or “coordinate to”) metals. Monodentate ligands include virtually all anions and all simple Lewis bases. Thus, the halides and pseudohalides are important anionic ligands whereas ammonia, carbon monoxide, and water are particularly common charge-neutral ligands. Simple organic species are also very common, be they anionic (RO− and RCO2−) or neutral (R2O, R2S, R3-xNHx, and R3P). Complexes of polydentate ligands are called chelate complexes. They tend to be more stable than complexes derived from monodentate ligands. This enhanced stability, the chelate effect, is usually attributed to effects of entropy, which favors the displacement of many ligands by one polydentate ligand. When the chelating ligand forms a large ring that at least partially surrounds the central atom and bonds to it, leaving the central atom at the center of a large ring. The more rigid and the higher its denticity, the more inert will be the macrocyclic complex.
“Chelator” as used herein relates to a binding agent that suppresses chemical activity by forming a chelate (a coordination compound in which a metal atom or ion is bound to a ligand at two or more points on the ligand, so as to form, for example, a heterocyclic ring containing a metal atom).
“Chelation” as used herein relates to a particular way that ions and molecules bind metal ions. According to the International Union of Pure and Applied Chemistry (IUPAC), chelation involves the formation or presence of two or more separate coordinate bonds between a polydentate (multiple bonded) ligand and a single central atom. Usually these ligands are organic compounds, and are called chelants, chelators, chelating agents, or sequestering agents.
“Electrophile” as used herein relates to species that is attracted to an electron rich center. In chemistry, an electrophile is a reagent attracted to electrons. It participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile. Because electrophiles accept electrons, they are Lewis acids. Most electrophiles are positively charged, have an atom that carries a partial positive charge, or have an atom that does not have an octet of electrons.
The terms below, as used herein, have the following meanings, unless indicated otherwise:
“Amino” refers to the —NH2 radical.
“Cyano” refers to the —CN radical.
“Halo” or “halogen” refers to bromo, chloro, fluoro or iodo radical, including their radioisotopes. “123I” refers to the radioactive isotope of iodine having atomic mass 123. The compounds of Formula I can comprise at least one 123I moiety. Throughout the present application, where structures depict a 123I moiety at a certain position it is meant that the I moiety at this position is enriched for 123I. In other words, the compounds contain more than the natural abundance of 123I at the indicated position(s). It is not required that the compounds comprise 100% 123I at the indicated positions, provided 123I is present in more than the natural abundance. Typically the 123I isotope is enriched to greater than 50%, greater than 60%, greater than 70%, greater than, 80% or greater than 90%, relative to 127I. “18F” refers to the radioactive isotope of fluorine having atomic mass 18. “F” or “19F” refers to the abundant, non-radioactive fluorine isotope having atomic mass 19. The compounds of Formula I can comprise at least one 18F moiety. Throughout the present application, where structures depict a 18F moiety at a certain position it is meant that the F moiety at this position is enriched for 18F. In other words, the compounds contain more than the natural abundance of 18F at the indicated position(s). It is not required that the compounds comprise 100% 18F at the indicated positions, provided 18F is present in more than the natural abundance. Typically the 18F isotope is enriched to greater than 50%, greater than 60%, greater than 70%, greater than 80% or greater than 90%, relative to 19F.
“Hydroxy” or “hydroxyl” refers to the —OH radical.
“Imino” refers to the ═NH substituent.
“Nitro” refers to the —NO2 radical.
“Oxo” refers to the ═O substituent.
“Thioxo” refers to the ═S substituent.
“Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a C1-C6 alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl. A C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and C1 alkyl (i.e., methyl). A C1-C6 alkyl includes all moieties described above for C1-C5 alkyls but also includes C6 alkyls. A C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and C1-C6 alkyls, but also includes C7, C8, C9 and C10 alkyls. Similarly, a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls. Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
“Alkylene” or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms. Non-limiting examples of C1-C12 alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.
“Alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included. An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl, an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl, an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl and an alkenyl comprising up to 5 carbon atoms is a C2-C5 alkenyl. A C2-C5 alkenyl includes C5 alkenyls, C4 alkenyls, C3 alkenyls, and C2 alkenyls. A C2-C6 alkenyl includes all moieties described above for C2-C5 alkenyls but also includes C6 alkenyls. A C2-C10 alkenyl includes all moieties described above for C2-C5 alkenyls and C2-C6 alkenyls, but also includes C7, C8, C9 and C10 alkenyls. Similarly, a C2-C12 alkenyl includes all the foregoing moieties, but also includes C11 and C12 alkenyls. Non-limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
“Alkenylene” or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Non-limiting examples of C2-C12 alkenylene include ethene, propene, butene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.
“Alkynyl” or “alkynyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included. An alkynyl group comprising up to 12 carbon atoms is a C2-C12 alkynyl, an alkynyl comprising up to 10 carbon atoms is a C2-C10 alkynyl, an alkynyl group comprising up to 6 carbon atoms is a C2-C6 alkynyl and an alkynyl comprising up to 5 carbon atoms is a C2-C5 alkynyl. A C2-C5 alkynyl includes C5 alkynyls, C4 alkynyls, C3 alkynyls, and C2 alkynyls. A C2-C6 alkynyl includes all moieties described above for C2-C5 alkynyls but also includes C6 alkynyls. A C2-C10 alkynyl includes all moieties described above for C2-C5 alkynyls and C2-C6 alkynyls, but also includes C7, C8, C9 and C10 alkynyls. Similarly, a C2-C12 alkynyl includes all the foregoing moieties, but also includes C11 and C12 alkynyls. Non-limiting examples of C2-C12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
“Alkynylene” or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Non-limiting examples of C2-C12 alkynylene include ethynylene, propargylene and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.
“Alkoxy” refers to a radical of the formula —ORa where Ra is an alkyl, alkenyl or alknyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.
“Alkylamino” refers to a radical of the formula —NHRa or —NRaRa where each Ra is, independently, an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.
“Alkylcarbonyl” refers to the —C(═O)Ra moiety, wherein Ra is an alkyl, alkenyl or alkynyl radical as defined above. A non-limiting example of an alkyl carbonyl is the methyl carbonyl (“acetal”) moiety. Alkylcarbonyl groups can also be referred to as “Cw-Cz acyl” where w and z depicts the range of the number of carbon in Ra, as defined above. For example, “C1-C10 acyl” refers to alkylcarbonyl group as defined above, where Ra is C1-C10 alkyl, C1-C10 alkenyl, or C1-C10 alkynyl radical as defined above. Unless stated otherwise specifically in the specification, an alkyl carbonyl group can be optionally substituted.
“Aryl” refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term “aryl” is meant to include aryl radicals that are optionally substituted.
“Aralkyl” or “arylalkyl” refers to a radical of the formula —Rb-Rc where Rb is an alkylene group as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group can be optionally substituted.
“Aralkenyl” or “arylalkenyl” refers to a radical of the formula —Rb-Rc where Rb is an alkenylene o group as defined above and Rc is one or more aryl radicals as defined above. Unless stated otherwise specifically in the specification, an aralkenyl group can be optionally substituted.
“Aralkynyl” or “arylalkynyl” refers to a radical of the formula —Rb-Rc where Rb is an alkynylene group as defined above and Rc is one or more aryl radicals as defined above. Unless stated otherwise specifically in the specification, an aralkynyl group can be optionally substituted.
“Carbocyclyl,” “carbocyclic ring” or “carbocycle” refers to a rings structure, wherein the atoms which form the ring are each carbon. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include aryls and cycloalkyl. cycloalkenyl and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.
“Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
“Cycloalkenyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like. Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.
“Cycloalkynyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused or bridged ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.
“Cycloalkylalkyl” refers to a radical of the formula —Rb-Rd where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Rd is a cycloalkyl, cycloalkenyl, cycloalkynyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group can be optionally substituted.
“Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.
“Haloalkenyl” refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropenyl, 1,1-difluorobutenyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
“Haloalkynyl” refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropynyl, 1-fluorobutynyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
“Heterocyclyl,” “heterocyclic ring” or “heterocycle” refers to a stable 3- to 20-membered non-aromatic, partially aromatic, or aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Heterocyclycl or heterocyclic rings include heteroaryls as defined below. Unless stated otherwise specifically in the specification, the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted.
“Heterocyclylalkyl” refers to a radical of the formula —Rb-Rc where Rb is an alkylene group as defined above and Rc is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkyl group can be optionally substituted.
“Heterocyclylalkenyl” refers to a radical of the formula —Rb-Rc where Rb is an alkenylene group as defined above and Rc is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkenyl group can be optionally substituted.
“Heterocyclylalkynyl” refers to a radical of the formula —Rb-Rc where Rb is an alkynylene group as defined above and Rc is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkynyl group can be optionally substituted.
“N-heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a N-heterocyclyl group can be optionally substituted.
“Heteroaryl” refers to a 5- to 20-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophene), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophene, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophene (i.e. thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group can be optionally substituted.
“N-heteroaryl” refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group can be optionally substituted.
“Heteroarylalkyl” refers to a radical of the formula —Rb-Rf where Rb is an alkylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group can be optionally substituted.
“Heteroarylalkenyl” refers to a radical of the formula —Rb-Rf where Rb is an alkenylene, chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkenyl group can be optionally substituted.
“Heteroarylalkynyl” refers to a radical of the formula —Rb-Rf where Rb is an alkynylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkynyl group can be optionally substituted.
“Ring” refers to a cyclic group which can be fully saturated, partially saturated, or fully unsaturated. A ring can be monocyclic, bicyclic, tricyclic, or tetracyclic. Unless stated otherwise specifically in the specification, a ring can be optionally substituted.
“Thioalkyl” refers to a radical of the formula —SRa where Ra is an alkyl, alkenyl, or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group can be optionally substituted.
The term “substituted” used herein means any of the above groups (i.e., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, alkylcarbonyl, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups.
“Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with —NRgRh, —NRgC(═O)Rh, —NRgC(═O)NRgRh, —NRgC(═O)ORh, —NRgSO2Rh, —OC(═O)NRg Rh, —ORg, —SRg, —SORg, —SO2Rg, —OSO2Rg, —SO2ORg, ═NSO2Rg, and —SO2NRgRh. “Substituted also means any of the above groups in which one or more hydrogen atoms are replaced with —C(═O)Rg, —C(═O)ORg, —C(═O)NRgRh, —CH2SO2Rg, —CH2SO2NRgRh. In the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
As used herein, the symbol
(hereinafter can be referred to as “a point of attachment bond”) denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond. For example,
indicates that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond. Furthermore, the specific point of attachment to the non-depicted chemical entity can be specified by inference. For example, the compound CH3—R3, wherein R3 is H or
infers that when R3 is “XY”, the point of attachment bond is the same bond as the bond by which R3 is depicted as being bonded to CH3.
“Fused” refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring can be replaced with a nitrogen atom.
Ubiquitination is crucial for a plethora of physiological processes, including cell survival and differentiation and innate and adaptive immunity. Proteins are built-up to cater for the structural and biochemical requirements of the cell and they are also broken-down in a highly-regulated process serving more purposes than just destruction and space management. Proteins have different half-lives, determined by the nature of the amino acids present at their N-termini. Some will be long-lived, while other will rapidly be degraded. Proteolysis not only enables the cell to dispose of misfolded or damaged proteins, but also to fine-tune the concentration of essential proteins within the cell, such as the proteins involved in the cell cycle. This rapid, highly specific degradation can be achieved through the addition of one to several ubiquitin molecules to a target protein. The process is called ubiquitination.
In recent years, considerable progress has been made in the understanding of the molecular action of ubiquitin in signaling pathways and how alterations in the ubiquitin system lead to the development of distinct human diseases. It has been shown that ubiquitination plays a role in the onset and progression of cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infection and muscle dystrophies (Popovic et al. Nature Medicine 20, 1242-1253 (2014)).
Ubiquitin-protein (E3) ligases are a large family of enzymes that select various proteins for ubiquitination. These ubiquitin ligases, called “Ub ligases” are known to have a role in various diseases and conditions, including but not limited to, cancer, inflammation and infectious diseases.
Further, there are various known methods for regulating ligases known in the art. Many ligases, particularly ligases involved in the Ubiquitin-Proteasome Pathway System (UPS), are known to have Zinc Finger (ZnF) domains that stabilize critical protein binding regions in that ligase. ZnF domains coordinate zinc ions and this coordination stabilizes functional activity of the protein. The functional activity provided by proteins with ZnF domains can include the regulation of important cellular signaling pathways, such as recognizing ubiquitins, regulation of DNA, such as transcription and repair, and acting as cellular redox sensors. The binding of zinc to ZnF domains, or simply just regulating how zinc interacts with the ZnF domains, are essential to ligases involved in the UPS.
The present invention relates to bifunctional compounds, also known as Proteolysis Targeting Chimeric ligands (Protac compounds) that induce ubiquitination by the use of a ligase, such as E3 ligase and degrade a protein of interest. Protac compounds are typically designed with three parts: 1) a ligand/molecule that binds to and/or modulates ubiquitin ligases; 2) a small molecule that binds to the target protein of interest for proteolysis; and 3) a linker that links the two molecules together. Protacs thus function by allowing the ligand/molecule to bind to the ubiquitin ligases, thereby recruiting the target of protein of interest to the ligase for ubiquitination and ultimately proteolysis and degradation. The present invention thus exhibits a broad array of applications in the pharmaceutical arts for degradation and/or inhibition of target proteins associated with disease, such as prostate cancer.
In certain embodiments, the compounds of the present invention can be used to treat diseases associated with overexpression and/or uncontrolled activation of a protein/enzyme. In a specific embodiment, the compounds are bifunctional by binding to both a ligase and a target protein of interest for inhibitition or degredation, thereby reducing and/or inhibiting the undesirable overexpression and/or uncontrolled activation of said protein target. In another specific embodiment, the compounds of the present invention include molecules that are selective in binding to a ligase, such as an E3 ligase. The present invention also also provides various options of linking the ligand/molecule that binds to and/or modulates ubiquitin ligases to the small molecule that binds to the target protein of interest. Specifically, the compounds of the present invention, are linked in such a way so that the target protein is close enough in proximity to the ligase and thus effect degradation of the target protein, such as androgen receptor proteins.
The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed inventions, or that any publication specifically or implicitly referenced is prior art.
The compound of the present disclosure can be useful for modifying the ubiquitination and subsequent degradation of androgen receptor proteins. In one embodiment of the present invention, the compound is a bifunctional compound wherein a ligase modulator (“PLM”), such as E3 ligase binding group, is covalently attached to one end of a Linker (“LI”), and the androgen receptor modulator (“PTC”) is covalently attached to the other end of the linker (LI). In one embodiment, androgen receptor modulator is androgen receptor N-terminal domain inhibitor. Further, the compound of the present disclosure can be useful for treating various diseases and conditions including, but not limited to, cancer.
In some embodiments, the linker is independently covalently bonded to the PLM and the PTC for example, through an amide, ester, thioester, keto, carbamate, carbon or ether, wherein the linking position can be anywhere on the PLM and/or PTC. In some embodiments, suitable linking positions provide maximum binding of the PLM to the E3 ligase and PTC to the androgen receptor protein to be degraded, as well as maximum target ubiquitination.
The linker (LI) is of a length appropriate to bring together the androgen receptor protein and E3 ligase and thereby elicit the ubiquitination of the protein of interest and it's subsequent degradation in the proteasome. It is therefore understood that the LI of the present disclosure serves as a spacer, physically separating the PLM and the PTC to a degree sufficient to ensure that binding with their respective targets occurs. In some embodiments, the length of the linker is optimized to maximize binding affinity between the PTC and androgen receptor protein, and the PLM and E3 ligase, as well as maximize target ubiquitination.
In one embodiment of the present disclosure, a compound of the invention comprises a ligase modulater moiety, a linker moiety, and a protein target compound moiety.
In one embodiment of the present disclosure, a compound of the invention has the structure of formula (Q):
PLM-LI-PTC (Q);
or a pharmaceutically acceptable salt thereof, wherein:
PLM is a ligase modulator, such as a parkin ligase modulator
LI is a linker, and
PTC is a protein target compound, i.e., a molecule that binds to and/or inhibits/activates a protein target of interest.
In some embodiments, the dash “-” indicated between PLM and LI or LI and PTC in formula (Q) represents each component's spacial orientation and not strictly as a C—C bond. In one embodiment, the PLM can be discussed as its own component having a chemical group necessary to covalently attach to LI. In one embodiment, the PTC can be discussed as its own component having a chemical group necessary to covalently attach to LI. One skilled in the art would readily understand how each component, described separately, can covalently attach to one another to provide a compound of formula (Q).
In one embodiment, the compound of the present disclosure is represented by formula (Q):
PLM-LI-PTC (Q);
or a pharmaceutically acceptable salt thereof, wherein:
PLM is a E3 ligase binding group,
LI is a linker, and
PTC is an androgen receptor modulator represented by formula (IIIA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7;
Y is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, —NR7—, or —N(COCH3)—;
W is a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
V is —CH2— and L is halogen, —NH2, —CHCl2, —CCl3, or —CF3; or
V is —CH2CH2— and L is halogen or —NH2;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR4SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalky, or phenyl;
each m is independently 0, 1, or 2;
n1 and n2 are each independently 0, 1, or 2;
n3 is 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, PTC in formula Q is a compound of formula (IIIA) minus any functional group that was involved in making the PTC-LI bond.
In some embodiments of the present disclosure, PLM is an E3 ligase modulator.
In some embodiments, the dash “-” indicated between PLM and LI or LI and PTC in formula (Q) represents each component's spacial orientation and not strictly as a C—C bond. In one embodiment, the PLM can be discussed as its own component having a chemical group necessary to covalently attach to LI. In one embodiment, the PTC can be discussed as its own component having a chemical group necessary to covalently attach to LI. One skilled in the art would readily understand how each component, described separately, can covalently attach to one another to provide a compound of formula (Q).
In some embodiments, the compound of formula (Q) is a compound of formula (W-IV), (W-IVA), (W-V), (W-VA), (W-VI), (W-VIA), (VII), (VIII), (IX) or (X):
or a pharmaceutically acceptable salt thereof, wherein A, B, C, R1, R2, R3, Z, V, L, Y, W, LI, PLM, n1, n2, and n3 are as defined herein.
In some embodiments the compound is selected from Table P:
Linkers (LI)
In one embodiment, any of the LI disclosed herein can be the linker as covalently attached to the PLM and/or to the PTC. In certain embodiments, any of the LI disclosed herein can describe the linker moiety before covalently attaching it to the PLM and/or to the PTC. In anon limited example, LI can comprise a chemical group (e.g., alcohol, amine, azides, —C≡CH, etc) which can be reacted with another chemical group on or attached to the PLM or the PTC in order to form a covalent bond, e.g., amine bond, ether bond, amide bond, ester bond, triazole (Click chemistry). In one embodiment, a chemical group already present in the LI as described herein can be used to covalently attach the LI to the PLM and/or to the PTC. The chemistry used to covalently attach the PLM to the LI and LI to the PTC can be readily understood by one skilled in the art.
In one embodiment, any of the LI disclosed herein can further comprise a chemical group useful in covalently attaching LI to the PLM and/or to the PTC.
In some embodiments of the compound of formula (Q), the linker LI corresponds to formula
-LXA-(CH2)m1—(CH2—CH2-LXB)m2—(CH2)m3-LXC-, wherein:
-LXA is covalently bound to the PTC or PLM, and LXC- is covalently bound to the PLM or PTC;
each m1 and m2 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
m3 is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
LXA is absent (a bond), —CH2C(O)NR20—, or —NR20C(O)CH2—;
LXB and LXC are each independently absent (a bond), —CH2—, —O—, —S—, —S(O)—, —S(O)2, or —N(R20)—;
wherein each R20 is independently selected from the group consisting of hydrogen, deuterium, halogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C8 cycloalkyl, and optionally substituted C3-C8 heterocyclyl; and
wherein each —CH2— in the linker is optionally substituted.
In some embodiments of the compound of formula (Q), LXA is absent (a bond), —CH2C(O)NR20—, or —NR20C(O)CH2—; wherein R20 is hydrogen or C1-C3 alkyl.
In some embodiments of the compound of formula (Q), LXA is absent (a bond), —CH2C(O)NR20—, or —NR20C(O)CH2—; wherein R20 is hydrogen, deuterium, halogen, or C1-C3 alkyl.
In some embodiments of the compound of formula (Q), LXA is absent (a bond), —CH2C(O)NH—, —NHC(O)CH2—.
In one embodiment, LXB is absent (a bond), —CH2—, —O—, or —N(R20)—; wherein R20 is hydrogen, deuterium, halogen, or C1-C3 alkyl.
In some embodiments of the compound of formula (Q), LXB is absent (a bond), —CH2—, —O— or —N(R20)—; wherein R20 is hydrogen or C1-C3 alkyl.
In some embodiments of the compound of formula (Q), LXC is absent (a bond), —CH2—, —O—, or —NH—.
In some embodiments of the compound of formula (Q), m1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, m2 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, m3 is 1, 2, 3, 4, 5, or 6.
In one embodiment, the sum of m1, m2, and m3 is less than or equal to 24. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 24, less than or equal to 23, less than or equal to 22, less than or equal to 21, less than or equal to 20, less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16, less than or equal to 15, less than or equal to 14, less than or equal to 13, or less than or equal to 12.
In one embodiment, the sum of m1, m2, and m3 is less than or equal to 12. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 13. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 12. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 11. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 10. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 9. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 8. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 7. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 6. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 5.
In one embodiment, the total number of atoms in a straight chain between PTC and PLM is 20 or less.
In some embodiments of the compound of formula (Q), the linker LI corresponds to formula:
—(CH2—CH2—O)m2—CH2CH2-LXC-;
—CH2C(O)NH—(CH2—CH2)m2—CH2CH2-LXC-;
—CH2C(O)NH—(CH2—CH2—O)m2—CH2-LXC-;
—CH2C(O)NH—(CH2—CH2—O)m2—CH2CH2-LXC-; or
—CH2C(O)NH—CH2—(CH2—CH2—O)m2—CH2CH2CH2-LXC-; wherein —(CH2—CH2—O)m2 or —CH2C(O)NH or is covalently bound to the PTC or PLM, and LXC- is covalently bound to the PLM or PTC;
m2 is independently 1, 2, 3, 4, 5, or 6;
LXC are each independently absent (a bond), —CH2—, —O—, —S—, —S(O)—, —S(O)2—, or —N(R20)—;
wherein each R20 is hydrogen or C1-C3 alkyl; and
wherein each —CH2— in the linker is optionally substituted.
In some embodiments of the compound of formula (Q), the linker LI corresponds to formula
—(CH2)m1-LX1-(CH2—CH2-LX2)m2—(CH2)m3—C(LX3)-, wherein:
—(CH2)m1 is covalently bound to the PTC or PLM, and C(LX3)- is covalently bound to the PLM or PTC;
each m1, m2, and m3 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
each LX1, LX2, and LX3 is independently absent (a bond), —O—, —S—, —S(O)—, —S(O)2—, or —N(R20)—, wherein each R20 is independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C8 cycloalkyl, and optionally substituted C3-C8 heterocyclyl; and
wherein each —CH2— in the linker is optionally substituted. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 24. In one embodiment, the sum of m1, m2, and m3 is less than or equal to 24, less than or equal to 23, less than or equal to 22, less than or equal to 21, less than or equal to 20, less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16, less than or equal to 15, less than or equal to 14, less than or equal to 13, or less than or equal to 12.
In some embodiments of the compound of formula (Q), LX1, LX2, and LX3 are —O—.
In some embodiments of the compound of formula (Q), the Linker corresponds to formula
—(CH2)m1-LXB-(CH2)m2-LXC-(CH2)m3-LXD-(CH2)m4—C(O)—, wherein:
(CH2)m1 is covalently bound to the PTC or PLM, and C(O) is covalently bound to the PLM or PTC;
each m1, and m2 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
m3 is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
m4 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
LXB, LXC, and LXD are each independently absent (a bond), —CH2—, —O—, —S—, —S(O)—, —S(O)2, or —N(R20)—;
wherein each R20 is independently selected from the group consisting of hydrogen, deuterium, halogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C8 cycloalkyl, and optionally substituted C3-C8 heterocyclyl; and
wherein each —CH2— in the linker is optionally substituted. In one embodiment, the sum of m1, m2, m3 and m4 is less than or equal to 24. In one embodiment, the sum of m1, m2, m3, and m4 is less than or equal to 23, less than or equal to 22, less than or equal to 21, less than or equal to 20, less than or equal to 19, less than or equal to 18, less than or equal to 17, less than or equal to 16, less than or equal to 15, less than or equal to 14, less than or equal to 13, or less than or equal to 12.
In some embodiments of the compound of formula (Q), the Linker corresponds to formula
—(CH2)m1-LXB-(CH2)m2-LXC-(CH2)m3—O—(CH2)m4—C(O)—, wherein:
(CH2)m1 is covalently bound to the PTC, and C(O) is covalently bound to the PLM;
m1 is 0, 1, 2, or 3;
m2 is independently 0, 1, 2, 3, 4, or 5;
m3 is independently 1, 2, 3, 4, or 5;
m4 is 1, 2 or 3;
LXB and LXC are each independently absent (a bond), —O— or —N(R20)—;
wherein each R20 is independently selected from the group consisting of hydrogen, deuterium, and C1-C6 alkyl.
In some embodiments of the compound of formula (Q), the linker LI is a polyethylene glycol chain ranging in size from about 1 to about 12 ethylene glycol units, wherein each —CH2— in the polyethylene glycol is optionally substituted. In some embodiments, the linker LI is a polyethylene glycol chain ranging in size from about 2 to about 10 ethylene glycol units, wherein each —CH2— in the polyethylene glycol is optionally substituted. In some embodiments, the linker LI is a polyethylene glycol chain ranging in size from about 3 to about 5 ethylene glycol units, wherein each —CH2— in the polyethylene glycol is optionally substituted.
In some embodiments of the compound of formula (Q), the linker LI corresponds to the formula:
-LI-LII(q)-,
wherein:
LI is a bond or a chemical group coupled to at least one of a PLM, a PTC or a combination thereof,
LII is a bond or a chemical group coupled to at least one of a PLM, a PTC, and q is an integer greater than or equal to 0;
wherein each LI and LII is independently selected from a bond, CRL1RL2, —(CH2)i—O—, —(CH2)i—O—, —O—(CH2)i—, —(CH2)i—S—, —(CH2)i—N—(CH2)i—, —S—, —S(O)—, —S(O)2—, —OP(O)O—(CH2)i—, —Si—(CH2)i—, NRL3 SO2NRL3, SONRL3CONRL3, NRL3CONRL4, NRL3SO2NRL4, CO, CRL1═CRL2, C≡C, SiRL1RL2, P(O)RL1, P(O)ORL1, NRL3C(═NCN)NRL4, NRL3C(═NCN), NRL3C(═CNO2)NRL4, C3-11 cycloalkyl optionally substituted with 0-6 RL1 and/or RL2 groups, C3-11 heterocyclyl optionally substituted with 0-6 RL1 and/or RL2 groups, aryl optionally substituted with 0-6 RL1 and/or RL2 groups, heteroaryl optionally substituted with 0-6 RL1 and/or RL2 groups;
wherein i is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
wherein RL1, RL2, RL3, RL4 and RL5 are, each independently, H, halo, —C1-8 alkyl, —OC1-8 alkyl, —SC1-8 alkyl, —NHC1-8 alkyl, —N(C1-8 alkyl)2, —C3-11 cycloalkyl, aryl, heteroaryl, —C3-11 heterocyclyl, —OC1-8 cycloalkyl, —SC1-8 cycloalkyl, —NHC1-8 cycloalkyl, —N(C1-8 cycloalkyl)2, —N(C1-8 cycloalkyl)(C1-8 alkyl), —OH, —NH2, —SH, —SO2C1-8 alkyl, —P(O)(OC1-8 alkyl)(C1-8 alkyl), —P(O)(OC1-8 alkyl)2, —C≡C—C1-8 alkyl, —CCH, —CH═CH(C1-8 alkyl), —C(C1-8 alkyl)=CH(C1-8 alkyl), —C(C1-8 alkyl)=C(C1-8 alkyl)2, —Si(OH)3, —Si(C1-8 alkyl)3, —Si(OH)(C1-8 alkyl)2, —C(═O)C1-8 alkyl, —CO2H, halogen, —CN, —CF3, —CHF2, —CH2F, —NO2, —SF5, —SO2NHC1-8 alkyl, —SO2N(C1-8 alkyl)2, —SONHC1-8 alkyl, —SON(C1-8 alkyl)2, —CONHC1-8 alkyl, —CON(C1-8 alkyl)2, —N(C1-8 alkyl)CONH(C1-8 alkyl), —N(C1-8 alkyl)CON(C1-8 alkyl)2, —NHCONH(C1-8 alkyl), —NHCON(C1-8 alkyl)2, —NHCONH2, —N(C1-8 alkyl)SO2NH(C1-8 alkyl), —N(C1-8 alkyl)SO2N(C1-8 alkyl)2, —NHSO2NH(C1-8 alkyl), —NHSO2N(C1-8 alkyl)2, or —NHSO2NH2.
In some embodiments of the compound of formula (Q), q is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24.
In some embodiments of the compound of formula (Q), LI and LII are independently selected from a bond, —(CH2)i—O—, —(CH2)i—O—, —O—(CH2)i—, —(CH2)i—S—, —(CH2)i—N—(CH2)i—, —S—, —S(O)—, —S(O)2—, —OP(O)O—(CH2)i—, —Si—(CH2)i—, wherein i is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and at least one of LI and LII is not a bond.
In some embodiments of the compound of formula (Q), the linker LI is selected from Table L1, wherein LI is covalently bound to PLM by replacing a hydrogen from LI with a covalent bond to the PLM; and wherein LI is covalently bound to PTC by replacing a hydrogen from LI with a covalent bond the PTC.
In some embodiments of the compound of formula (Q), the linker LI is selected from Table L2:
In some embodiments of the compound of formula (Q), the linker LI is selected from Table L3:
Protein Target Compounds (PTCs)
The PTCs of the present disclosure can be useful for modulating androgen receptor (AR). Further, the PTCs of the present disclosure can be useful for treating various diseases and conditions including, but not limited to, cancer. In some embodiments, the cancer is prostate cancer or breast cancer. In some embodiments, any of the PTCs disclosed herein can be a compound depicted as the compound before covalently attaching it to the LI.
In some embodiments, the present disclosure provides PTCs comprising the structure of formula (I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently aryl or heteroaryl;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, —NR7—, —N(R7)CO—, —CON(R7)—, or —NSO2R7—;
Y and Z are each independently a bond, —(CR8R9)m—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—;
W and V are each independently a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
L is hydrogen, halogen, —CF2R10, —CF3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R3 is hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R5 and R6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R5 and R6 taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —OCO(C1-C6 alkyl), —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R8a and R8b taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R7, R10 and R16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R7 and R8a taken together form an optionally substituted heterocyclyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or (R11 and R12) or (R14 and R15) taken together form an optionally substituted heterocyclyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, 2, 3, or 4;
n3 is 0, 1, 2, 3, 4 or 5;
each t is independently 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (IA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently aryl or heteroaryl;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, —NR7—, —N(R7)CO—, —CON(R7)—, or —NSO2R7—;
Y and Z are each independently a bond, —(CR8R9)m—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—;
W and V are each independently a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
L is hydrogen, halogen, —CF2R10, —CF3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R3 is hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COOR16, —NR14COR16, —NR14CONR14R15, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R5 and R6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R5 and R6 taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —OCO(C1-C6 alkyl), —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R8a and R8b taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R7, R10 and R16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, optionally substituted carbocyclyl, optionally substituted —CO(C1-C6 alkyl), —CO (optionally substituted heterocyclyl), optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R7 and R8a taken together form an optionally substituted heterocyclyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —COO(C1-C6 alkyl), optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or (R11 and R12) or (R14 and R15) taken together form an optionally substituted heterocyclyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, 2, 3, or 4;
n3 is 0, 1, 2, 3, 4 or 5;
each t is independently 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (IB):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently aryl or heteroaryl;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, —NR7—, —N(R7)CO—, —CON(R7)—, or —NSO2R7—;
Y is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
W is a bond, —(CR8aR9a)m—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
V is —CH2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, or —CH2CH2CH2—;
L is hydrogen, halogen, —CF2R10, —CF3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R3 is hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COOR16, —NR14COR16, —NR14CONR14R15, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R5 and R6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R5 and R6 taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R8a and R8b taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R7, R10 and R16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkyl-NH2, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, optionally substituted carbocyclyl, optionally substituted —CO(C1-C6 alkyl), —CO(optionally substituted heterocyclyl), optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R7 and R8a taken together form an optionally substituted heterocyclyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —COO(C1-C6 alkyl), optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or (R11 and R12) or (R14 and R15) or (R14 and R16) taken together form an optionally substituted heterocyclyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, 2, 3, or 4;
n3 is 0, 1, 2, 3, 4 or 5;
each t is independently 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising comprising the structure of formula (IC)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently aryl or heteroaryl;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, —NR7—, —N(R7)CO—, —CON(R7)—, or —NSO2R7—;
Y is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
W is a bond, —(CR8aR9a)m—, —C(═O)—, N(R7)CO—, —CONR7—, or —NSO2R7—;
Z is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
V is —CH2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, or —CH2CH2CH2—;
L is hydrogen, halogen, —CF2R10, —CF3, —CCl2R10, —CCl3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R3 is hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COOR16, —NR14COR16, —NR14CONR14R15, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R5 and R6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R5 and R6 taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R8a and R8b taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
R7, R10 and R16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkyl-NH2, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, optionally substituted carbocyclyl, optionally substituted —CO(C1-C6 alkyl), —CO(optionally substituted heterocyclyl), optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R7 and R8a taken together form an optionally substituted heterocyclyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —COO(C1-C6 alkyl), optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or (R11 and R12) or (R14 and R15) or (R14 and R16) taken together form an optionally substituted heterocyclyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, 2, 3, or 4;
n3 is 0, 1, 2, 3, 4 or 5;
each t is independently 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (II):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —NHCO—, —N(C1-C3 alkyl)CO—, or —CONH—, or —CON(C1-C3 alkyl)-;
V is a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
L is hydrogen, halogen, —CF2R10, —CF3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R7, R10 and R16 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (IIA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
W is a bond, —CH2—, —C(CH3)H—, —NHCO—, —N(C1-C3 alkyl)CO—, or —CONH—, or —CON(C1-C3 alkyl)-;
V is —CH2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, or —CH2CH2CH2—;
L is hydrogen, halogen, —CF2R10, —CF3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R7, R10 and R16 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 alkyl-NH2; or R14 and R16 taken together form a 3- to 6-membered heterocyclyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (IIB):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
W is a bond, —CH2—, or —C(CH3)H—;
V is a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
L is hydrogen, halogen, —CF2R10, —CF3, —CN, —OR10; —NR11R12, or —CONR11R12;
R1 and R2 are each independently hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R11, R12, R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R7, R10 and R16 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 alkyl-NH2; or R14 and R16 taken together form a 3- to 6-membered heterocyclyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, or 2;
n3 is 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (III):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, or —NR7—;
W is a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (IIIA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7;
Y is a bond, —(CR8R9)m—, —O—, —S—, —S(═O)—, —SO2—, —NR7— or —N(COCH3)—;
W is a bond, —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
V is —CH2— and L is halogen, —NH2, —CHCl2, —CCl3, or —CF3; or
V is —CH2CH2— and L is halogen or —NH2;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl;
R8a and R9a are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalkyl, or phenyl;
each m is independently 0, 1 or 2;
n1 and n2 are each independently 0, 1, or 2;
n3 is 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (IV):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 3- to 10-membered ring;
X is a bond, —(CR5R6)t—, or —NR7—;
Y and Z are each independently a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is H or C1-C6 alkyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5; and
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (V):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 5- to 10-membered heteroaryl or aryl;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is H or C1-C6 alkyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (VA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 5- to 10-membered heteroaryl or aryl;
X is a bond, —(CR5R6)t—, or —NR7;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, or —CH2CH2CH2—;
L is hydrogen, halogen, —OH, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —NR14COOR16, —NR14CONR14R15, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, —NH2, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is H, C1-C6 alkyl, —CO(C1-C6 alkyl);
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or —COO(C1-C6 alkyl); or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (VI):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
C is a 5- to 10-membered heterocyclyl;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is H or C1-C6 alkyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (A):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is a phenyl or a 5- to 7-membered monocyclic heteroaryl comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (B)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is a 5- to 7-membered saturated or partially saturated monocyclic heterocycle comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member;
X is a bond, —(CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
R7 is H or C1-C6 alkyl;
R16 is hydrogen or C1-C3 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment of the PTCs of formula (I), (IC), (II), (III), (IIIA), (IV), (V), (VI), (A), or (B), —V-L is —CH2CH2Cl, —CH2CH2CH2Cl, —CH2CH2NH2, or —CH2CH2CH2NH2.
In one embodiment of the PTCs of formula (I), (IC), (II), (III), (IIIA), (IV), (V), (VI), (A), or (B), —Y—W— is a bond, —OCH2—, —OCH2CH2—, —OCH(CH3)—, —NH—, —NHCH2—, —NHC(═O)—, or —C(═O)NH—.
In one embodiment of the PTCs of formula (I), (IC), (II), (III), (IIIA), (IV), (V), (VI), (A), or (B), X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, or —CH2CH2—.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (C):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
X is a bond, (CR5R6)t—, or —NR7—;
Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—;
W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen, —NH2, or —CF3;
D is —NH or —NR3;
U is each independently O, S, or NR16;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR13R14, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16 or optionally substituted —(C1-C6 alkyl)-SO2R16;
R3 is selected from hydrogen, halogen, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
R7 is H or C1-C6 alkyl;
R13, R14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl; or R14 and R15 taken together form a 3- to 6-membered heterocyclyl;
R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, or 3;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (D):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is a 5- or 6-membered heteroaryl comprising 1 or 2 heteroatoms selected from O, S, or N as a ring member;
X is —(CR5R6)t— or —NR7—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is hydrogen, halogen, —NH2, or —CF3;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, 2, 3, 4 or 5;
t is 0, 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (E):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)t— or —NR7—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is hydrogen or halogen;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, or 2;
t is 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)t— or —NR7—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, —CH2CH2CH2—, or —CH2CHClCH2—;
L is hydrogen, —OH, or halogen;
R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, or 2;
t is 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment of the PTCs of formula (A)-(C) or (E-1), R3 is selected from hydrogen, F, Cl, Br, I, —CN, —CF3, —OH, methyl, methoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —NHCO(C1-C3 alkyl).
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (F):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)t— or —NR7—;
Y is —O—;
Z is —O—;
W is —CH2— or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is hydrogen or halogen;
R1 and R2 are each independently halogen or —CN;
R3 is selected from —NHSO2CH3, —N(CH3)SO2CH3, or —SO2CH3;
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 0, 1, or 2;
t is 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (G):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)t— or —NR7—;
Y is —O—;
Z is —O—;
W is —CH2— or —C(CH3)H—;
V is —CH2— and L is hydrogen; or alternatively, V is —CH2CH2— or —CH2CH2CH2—, and L is halogen;
R1 and R2 are each independently Cl or —CN;
R3 is selected from —NHSO2CH3, —N(CH3)SO2CH3, or —SO2CH3;
R5 and R6 are each independently hydrogen or methyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 1, or 2;
t is 1; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of (G-I)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)t—;
Y is —O—;
Z is —O—;
W is —CH2— or —C(CH3)H—;
V is —CH2CH2— or —CH2CH2CH2—;
L is halogen;
R1 and R2 are each independently Cl or —CN;
R3 is selected from —NHSO2CH3, —N(CH3)SO2CH3, or —SO2CH3;
R5 and R6 are each independently hydrogen or methyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 1 or 2;
t is 1; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (G-II)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)t—;
Y is —O—;
Z is —O—;
W is —CH2— or —C(CH3)H—;
V is —CH2CH2—;
L is halogen;
R1 and R2 are each independently Cl or —CN;
at least one R3 is selected from —CN, C1-C3 alkoxy, —CONH2, —NHSO2CH3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, or —SO2CH3 and the other R3, if present, is selected from —CN, —CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —(C1-C3 alkyl)NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or methyl;
n1 and n2 are each independently 0, 1, or 2;
n3 is 1 or 2;
t is 1; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (H):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C-I is
X is —(CR5R6)t— or —NR7—;
Y is —O—;
Z is —O—;
W is —CH2— or —C(CH3)H—;
V is —CH2—, —CH2CH2— or —CH2CH2CH2—;
L is halogen;
R1 and R2 are each independently Cl or —CN;
R5 and R6 are each independently hydrogen or methyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
t is 1; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (H-I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C-I is
X is —(CR5R6)t—;
Y is —O—;
Z is —O—;
W is —CH2— or —C(CH3)H—;
V is —CH2—, —CH2CH2— or —CH2CH2CH2—;
L is halogen;
R1 and R2 are each independently Cl or —CN;
R5 and R6 are each independently hydrogen or methyl;
R7 is H or C1-C6 alkyl;
n1 and n2 are each independently 0, 1, or 2;
t is 1; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-II):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen;
R1, R2A and R2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
n1 is 0, 1, or 2;
n3 is 1 or 2;
wherein when C—R3 is
R2A and R2B are not both Cl; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-III):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen;
R1, R2A and R2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
n1 is 0, 1, or 2;
n3 is 1 or 2;
wherein when C—R3 is
and one of R2A and R2B is Cl, then the other of R2A and R2B is not —CN; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-IV):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen;
R1, R2A and R2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
n1 is 0, 1, or 2;
n3 is 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-V):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen;
R1, R2A and R2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
n1 is 0, 1, or 2;
n3 is 1 or 2;
wherein when C—R3 is
R2A and R2B are not both Cl; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-VI):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen;
R1, R2A and R2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
n1 is 0, 1, or 2;
n3 is 1 or 2;
wherein when C—R3 is
and one of R2A and R2B is Cl, then the other of R2A and R2B is not —CN; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment the present disclosure provides PTCs comprising the structure of formula (E-VII):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
C is
X is —(CR5R6)—;
Y is a bond, —CH2—, —O—, or —NH—;
Z is a bond, —CH2—, —O—, or —NH—;
W is a bond, —CH2—, or —C(CH3)H—;
V is —CH2—, —CH2CH2—, or —CH2CH2CH2—;
L is halogen;
R1, R2A and R2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl);
R5 and R6 are each independently hydrogen or C1-C3 alkyl;
n1 is 0, 1, or 2;
n3 is 1 or 2; and
wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PTC is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PTC is replaced to form a covalent bond to the LI.
In one embodiment of the PTCs of formula (I), (IA), (IB), (IC), (II), (IIA), (IIB), (III), (IIIA), (IV), (V), (VA), or (VI) (denoted as formula “(I)-(VI)”), A and B are each independently 5- or 6-membered aryl or heteroaryl. In one embodiment, A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene. In one embodiment, A and B are each phenyl.
In another embodiment, A has a meta or para connectivity with X and Y. In some embodiments, B has a meta or para connectivity with X and Z.
In one embodiment of the PTCs of formula (I)-(VI), A and B are phenyl and has one of the connectivity as shown:
In one embodiment of the PTCs of formula (I)-(VA) and (A) (e.g., formula (I), (IA), (IB), (IC), (II), (IIA), (IIB), (III), (IIIA), (IV), (V) (VA), and (A)), C is aryl or heteroaryl. In some embodiments, C is 5- to 10-membered aryl or heteroaryl. In other embodiments, C is aryl. In some embodiments, C is phenyl or naphthyl. In other embodiments, C is aryl. In some embodiments, C is phenyl.
In one embodiment of the PTCs of formula (I)-(VA) and (A), C is heteroaryl. In one embodiment, C monocyclic or bicyclic heteroaryl. In another embodiment, C is monocyclic heteroaryl. In some embodiments, C is 5- or 10-membered heteroaryl. In some embodiments, C is 5- or 6-membered heteroaryl, which is optionally substituted with 1, 2, 3, 4, or 5 R3. In some embodiments, C is 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms selected from O, S, or N, wherein the heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 R3. In some embodiments, C is 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from O, S, or N, wherein the heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 R3.
In one embodiment of the PTCs of formula (I)-(VA), (A), or (D), C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, or pyrimidyl, which are each optionally substituted with 1, 2, 3, 4, or 5 R3. In one embodiment, C, which is substituted with (R3)n3, is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, pyrazine, furan or pyrimidyl. In one embodiment, C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, pyrazine, furan or pyrimidyl, which are each substituted with 1, 2, 3, 4, or 5 R3.
In one embodiment of the PTCs of formula (I)-(VA), (A), or (D), C is selected from
wherein R3a is C1-C3 alkyl. In one embodiment of the PTCs of formula (I)-(VA), (A) or (D), C is selected from
wherein R3a is C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(VA), (A), or (D), C is
In one embodiment, C is
or in its tautomeric form
In one embodiment, C is
or in its tautomeric form
In one embodiment of the PTCs of formula (I)-(IV), C is heterocyclyl. In one embodiment, C is saturated or partially saturated heterocycle. In some embodiments, C is monocyclic or bicyclic. In some embodiments, C is 5- to 7-membered heterocyclyl comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member.
In one embodiment of the PTCs of formula (I)-(VA), (B) and (C), C is imidazolidine, imidazolidine-dione, or dihydrooxazole. In one embodiment, C is selected from
In one embodiment of the PTCs of formula (I)-(VA), (B) and (C), C is
D is —O—, —NH— or —NR3—; and U is each independently O, S, or NR16. In one embodiment, D is —NH— or —NR3—. In some embodiments, at least one U is O. In other embodiments, each U is O. In some embodiments, at least one R3 is —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3.
In one embodiment of the PTCs of formula (I)-(VA), C is aryl. In some embodiments, C is phenyl or naphthyl. In one embodiment of the PTCs of formula (I)-(VA) or (A), C is phenyl.
In on embodiment PTCs of formula (I)-(VI), C is bicyclic heteroaryl or heterocyclyl. In one embodiment, C is
In one embodiment of the PTCs of formula (I), Z is a bond, —(CR8R9)m—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—. In one embodiment, Z is —(CR8R9)m—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—. In some embodiments, Z is —C(═O)—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In one embodiment, Z is —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In some embodiments, Z is a bond, —CH2—, —O—, or —NCH3—. In some embodiments, Z is a bond, —CH2—, —O—, or —NH—. In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), Z is —O—. As used herein, “PTCs of formula (I)-(IV) and (A)-(H-I)” refers to PTCs of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (A-I), (B)-(D), (E), (E-I)-(E-VII), (F), (G), (G-I), (G-II), (H), and (H-I).
In one embodiment of the PTCs of formula (I), Y is a bond, —(CR8R9)m—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—. In one embodiment, Y is —(CR8R9)m—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—. In some embodiments, Y is —C(═O)—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In one embodiment, Y is —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In some embodiments, Y is a bond, —CH2—, —O—, or —NCH3—. In some embodiments, Y is a bond, —CH2—, —O—, or —NH—. In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), Y is —O—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), V is a bond, —(CR8aR9a)m—, or —C(═O)—. In some embodiments, V is bond, or —(CR8aR9a)m—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), V is —(CR8aR9a)m—, wherein m is 1, 2, or 3. In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), V is —(CR8aR9a)m—, wherein R8a and R8b are each independently hydrogen, —OH, halogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, optionally substituted —(C1-C3 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or optionally substituted —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl. In one embodiment, V is —(CR8aR9a)m—, wherein R8a and R8b are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b, on the same carbon atom or on a different carbon atom, taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl.
In one embodiment of the PTCs of formula (I)-(IIB) and (VA), V is —CH2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, or —CH2CH2CH2—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), V is —CH2—, —CH2CH2—, or —CH2CH2CH2—, each optionally substituted with one or more of —OH, halogen, or C1-C3 alkyl. In other embodiments, V is —CH2—, —CH2CH2—, —CH2CH(OH)CH2— or —CH2CH2CH2—. In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), V is —CH2—, —CH2CH2—, or —CH2CH2CH2—. In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), V is —CH2— or —CH2CH2—.
In some embodiments of the PTCs of formula (I)-(VI) and (A)-(D), V is —CH2— and L is halogen, —NH2, or —CF3; or V is —CH2CH2— and L is halogen or —NH2.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), L is hydrogen, halogen, —CF2H, —CF3, —CN, —O(C1-C3 alkyl), —NR11R12, or —CONR11R12. In one embodiment, L is hydrogen, halogen, —CF2H, —CF3, —CN, —O(C1-C3 alkyl), —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —CONH2, —CONH(C1-C3 alkyl), or —CON(C1-C3 alkyl)2. In some embodiments, L is hydrogen, halogen, —CF3, or —NH2.
In some embodiments of the PTCs of formula (IC) and (IIIA), L is halogen, —CCl3, —CCl2, —CF3, or —NH2. In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), L is halogen, —CF3, or —NH2. In one embodiment, L is hydrogen or halogen. In one embodiment, L is halogen. In other embodiments, L is Cl, or Br. In one embodiment, L is Cl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), W is a bond. In one embodiment, W is —(CR8aR9a)m—, —C(═O)—, —N(R7)CO—, —CONR7—, or —NSO2R7—. In one embodiment, W is —(CR8aR9a)m—, wherein m is 1, 2, or 3. In some embodiments, W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—, wherein R7 is H or C1-C6 alkyl. In some embodiments, W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R7)CO—, or —CONR7—, wherein R7 is H or C1-C3 alkyl. In one embodiment, W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —NHCO—, —N(C1-C3 alkyl)CO—, —CONH—, or —CON(C1-C3 alkyl)-. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(E-VI), W is a bond, —CH2—, or —C(CH3)H—. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), W is a —CH2— or —C(CH3)H—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), —Y—W— is a bond, —OCH2—, —OCH2CH2—, —OCH(CH3)—, —NH—, —NHCH2—, —NHC(═O)—, or —C(═O)NH—. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), —Y—W— is —OCH2—, —OCH2CH2—, or —OCH(CH3)—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C),
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C),
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), —Z—V-L is —Z—CH2CH2Cl, —Z—CH2CH2CH2Cl, —Z—CH2CH2NH2, or —Z—CH2CH2CH2NH2, wherein Z is a bond, —O—, —NH—, or —N(COCH3)—. In one embodiment, —Z—V-L is —OCH3.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), —Z—V-L is —O—CH2CH2Cl or —O—CH2CH2CH2Cl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), —V-L is —CH2CH2Cl, —CH2CH2CH2Cl, —CH2CH2NH2, or —CH2CH2CH2NH2. In one embodiment, —V-L is —CH3.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), X is a bond, —(CR5R6)t—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—. In one embodiment, X is a bond, —(CR5R6)t—, —O—, —C(═O)—, —S—, —S(═O)—, —SO2—, or —NR7—, wherein R7 is H or C1-C6 alkyl. In some embodiments, X is a bond, —(CR5R6)t—, or —NR7—. In some embodiments, X is a bond or —(CR5R6)t—. In some embodiments, X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, —CH2CH2—, —NH—, or —N(C1-C6 alkyl)-. In some embodiments, X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, —CH2CH2—, —NH—, —N(CH3)—, —N(CH2CH3)—, —N(iPr)-, or —N(tBu)-. In some embodiments, X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, or —CH2CH2—.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), X is —CH2—, —C(CH3)H—, or —C(CH3)2—. In one embodiment, X is —C(CH3)2—.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R1 and R2 are each independently halogen, —CN, —CF3, —OH, C1-C3 alkyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2R16, —(C1-C3 alkyl)-SO2R16, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, or optionally substituted —(C1-C6 alkyl)-SO2R16. In one embodiment, R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C3 alkyl, C1-C3 alkoxy, optionally substituted —(C1-C3 alkyl)-(C1-C3 alkoxy), optionally substituted —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C3 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C3 alkyl)-SO2NR14R15, —SO2R16, or optionally substituted —(C1-C3 alkyl)-SO2R16. In one embodiment, R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, C1-C3 alkyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2R16, or —(C1-C3 alkyl)-SO2R16.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, C1-C3 alkyl, or —CONR14R15. In some embodiments, R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, methyl, methoxy, or —CONH2. In one embodiment, R1 and R2 are each independently hydrogen, Cl, —CN, —CF3, —OH, methyl, methoxy, or —CONH2. In one embodiment, R1 and R2 are each independently hydrogen, halogen, —CN, —CF3, —OH, or methyl. In one embodiment, R1 and R2 are each independently Cl, —CN, —CF3, —OH, methyl, methoxy, or —CONH2. In one embodiment of the PTCs of formula (I)-(VI), R1 and R2 are each independently halogen, —CN, —CF3, —OH, or methyl.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(E-I), R1 and R2 are each halogen, methyl, —CF3, or —CN. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(F), R1 and R2 are each halogen or —CN. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), at least one of R1 and R2 is Cl or —CN. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), at least two of R1 and R2 are each independently Cl or —CN. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), R1 and R2 are each Cl or —CN.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R1 and R2 are each independently optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R1 and R2 are each independently 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R1 have one of the connectivity as shown below with respect to X and Y:
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R2 have one of the connectivity as shown below with respect to X and Z:
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), n1 is 0, 1, or 2. In some embodiments, n1 is 0 or 1. In other embodiments, n1 is 0. In some embodiments, n1 is 1. In one embodiment, the sum of n1 and n2 is 0, 1, 2, 3, or 4. In some embodiments, the sum of n1 and n2 is 1, 2, 3, or 4. In one embodiment, the sum of n1 and n2 is 2.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), n2 is 0, 1, or 2. In some embodiments, n2 is 1 or 2. In other embodiments, n2 is 0. In some embodiments, n2 is 1. In some embodiments, n2 is 2.
In some embodiments of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), n3 is 1, 2, 3, 4, or 5. In some embodiments, n3 is 1, 2, 3, or 4. In one embodiment, n3 is 1, 2, or 3. In one embodiment, n3 is 1 or 2.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, optionally substituted —(C1-C6 alkyl)-SO2R16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, or optionally substituted —(C1-C6 alkyl)-SO2R16. In another embodiment, R3 is hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —SR16, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted C1-C3 alkoxy, optionally substituted —(C1-C3 alkyl)-(C1-C3 alkoxy), optionally substituted —(C1-C3 alkyl)-OH, —NR13R14, optionally substituted —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C3 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C3 alkyl)-SO2NR14R15, optionally substituted —SO2R16, or optionally substituted —(C1-C3 alkyl)-SO2R16.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R3 is selected from —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, or optionally substituted —SO2R16; wherein R16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalkyl, or phenyl. In one embodiment, R3 is selected from —NR14SO2R16, —(C1-C6 alkyl)NR14SO2R16, or —SO2R16; wherein R16 is hydrogen, C1-C3 alkyl, —(C1-C3 alkyl)-NH2, C3-C6 cycloalkyl, or phenyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R3 is selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl). In some embodiments, R3 is selected from hydrogen, F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl). In some embodiments, R3 is selected from hydrogen, F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl). In one embodiment, R3 is selected from hydrogen, F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, methyl, —SCH3, —SO2CH3, —NHSO2CH3, —NHSO2CH2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3. In one embodiment, R3 is selected from hydrogen, F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, methyl, —SCH3, —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3. In some embodiments, R3 is selected from F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl). In some embodiments, R3 is selected from F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl). In one embodiment, R3 is selected from F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, methyl, —SCH3, —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3. In another embodiment, R3 is —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3. In one embodiment, R3 is oxo, ═S, ═NR16, C1-C3 alkyl, —SO2(C1-C3 alkyl), or —NHSO2(C1-C3 alkyl). In one embodiment, at least one of R3 is oxo, ═S, or ═NR16. In one embodiment, at least one of R3 is oxo, ═S, or ═NR16, wherein R16 is H or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(E-VII), R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl). In one embodiment of the PTCs of formula (I)-(VI) and (A)-(E-VII), R3 is selected from hydrogen, F, Cl, Br, I, oxo, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl).
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R3 on a sp3 carbon is each selected from hydrogen, halogen, oxo, ═S, ═NR16, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl). When R3 on a sp3 carbon is oxo, ═S, or ═NR16, the carbon becomes sp2.
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R3 on a sp2 carbon is each selected from hydrogen, halogen, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl).
In one embodiment of the PTCs of formula (I)-(VI), (A), (A-I), (B), and (C), R3 on a nitrogen atom is each selected from C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —(C1-C3 alkyl)-NR13R14, —(C1-C3 alkyl)NR14SO2R16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —(C1-C3 alkyl)-SO2NR14R15, or —(C1-C6 alkyl)-SO2(C1-C3 alkyl).
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(G-II), at least one R3 is selected from —CN, C1-C3 alkoxy, —CONH2, —NHSO2CH3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, or —SO2CH3 and the other R3, if present, is selected from —CN, —CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —(C1-C3 alkyl)NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl). In one embodiment, at least one R3 is selected from —NHSO2CH3, —NHSO2CH2CH3, or —SO2CH3 and the other R3, if present, is selected from —CN, C1-C3 alkyl, C1-C3 alkoxy, —SO2(C1-C3 alkyl), —NH2, —(C1-C3 alkyl)NH2, —NHSO2CH3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl).
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(E-II), R3 is not hydrogen.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(G-II), at least one R3 is —SO2CH3, —NHSO2CH3, —NCH3SO2CH3, —NHSO2CH2CH3, or —N(CH3)SO2CH2CH3. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(G-II), at least one R3 is —SO2CH3, —NHSO2CH3, or —NCH3SO2CH3.
In one embodiment the compounds of formula (I), (IA), (IB), or (IC), R3 is heterocyclyl. In one embodiment, R3 is heterocyclyl selected from
In one embodiment of the PTCs of formula (IB), (IC), (IIA), or (IIB), R3 is —NR14SO2R16, wherein R14 and R16 together form a 5 or 6 membered ring including the nitrogen and sulfur atoms.
In one embodiment of the PTCs of formula (I), (IA), (IB), or (IC), R3 is —NR14SO2R16, wherein R16 is optionally substituted C1-C6 alkyl. In one embodiment, R3 is —NR14SO2R16, wherein R16 is C1-C6 alkyl optionally substituted with one or more groups selected from halogen, —CN, —CF3, —OH, C1-C3 alkyl, C1-C3 alkoxy, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —SCH3. In one embodiment, R3 is —NR14SO2R16, wherein R16 is C1-C3 alkyl substituted with —NH2.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R5 and R6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy; or R5 and R6 taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl. In some embodiments, R5 and R6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl. In one embodiment, R5 and R6 are hydrogen, halogen, —OH, or C1-C3 alkyl. In one embodiment, R5 and R6 are each independently hydrogen, F, —OH, or C1-C3 alkyl. In one embodiment, R5 and R6 are each independently, hydrogen, F, —OH, or methyl. In one embodiment, R5 and R6 are each H. In one embodiment, R5 and R6 are each methyl. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), R5 and R6 are each H or methyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R7 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R7 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R7 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments, R7 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl. In some embodiments, R7 is hydrogen or C1-C6 alkyl. In some embodiments, R7 is hydrogen or C1-C4 alkyl. In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), R7 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R8a and R9a are each independently hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R8a and R9a taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl. In some embodiments, R8a and R8b are each independently hydrogen, —OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15; or R8a and R8b taken together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl. In one embodiment, R8a and R9a are each independently hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C3 alkyl)-CONR14R15. In one embodiment of the PTCs of formula (IB), (IC), (III), or (IIIA), R8a and R9a are not —OH. In one embodiment, R8a and R9a are not —OH.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R7 and R8a taken together form an optionally substituted heterocyclyl. In one embodiment, R7 and R8a taken together form an optionally substituted 3- to 7-membered heterocycle.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R8 and R9 are each independently hydrogen, halogen, or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(IIB), R10 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R10 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R10 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R10 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl. In some embodiments, R10 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(IIB), R11 and R12 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R11 and R12 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. In some embodiments. R11 and R12 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments. R11 and R12 are each independently hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(IIB), R11 and R12 taken together form an optionally substituted heterocyclyl. In one embodiment, R11 and R12 taken together form an optionally substituted 3- to 7-membered heterocyclyl. In other embodiments, R11 and R12 taken together form 3- to 7-membered heterocyclyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R13 and R14 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R13 and R14 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. In some embodiments R13 and R14 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments R13 and R14 are each independently hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R15 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R15 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. In some embodiments, R15 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments, R15 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R14 and R15 taken together form an optionally substituted heterocyclyl. In one embodiment, R14 and R15 taken together form an optionally substituted 3- to 7-membered heterocyclyl. In other embodiments, R14 and R15 taken together form 3- to 7-membered heterocyclyl.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), R16 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. In some embodiments, R16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl. In some embodiments, R16 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (I)-(IIIA), m is 1 or 2.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(F), t is 1 or 2. In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), t is 1.
In one embodiment of the PTCs of formula (I)-(VI), (A), (B), and (C), optional substituent is selected from halogen, —CN, —CF3, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C6 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl). In another embodiment, the optional substituent is selected from halogen, —CN, —CF3, —OH, C1-C3 alkyl, C1-C3 alkoxy, —NH2, —SCH3, —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3.
In one embodiment of the PTCs of formula (I)-(VI), A and B are each monocyclic ring.
In one embodiment of the PTCs of formula (I)-(VI), B is phenyl, pyridyl, or pyrimidyl.
In one embodiment of the PTCs of formula (I)-(IIIA), Z and V are not both a bond.
In one embodiment of the PTCs of formula (I)-(VI), (A)-(C), Y and W are not both a bond.
In one embodiment of the PTCs of formula (I)-(VI), C is a 4- to 10-membered ring.
In one embodiment of the PTCs of formula (D)-(H-I), X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, or —CH2CH2—. In one embodiment, X is —CH2—, —C(CH3)H—, or —C(CH3)2—. In some embodiments, X is —C(CH3)2—.
In one embodiment of the PTCs of formula (D)-(H), X is —NR7—. In one embodiment, X is —NH—, —N(CH3)—, —N(CH2CH3)—, —N(iPr)-, or —N(tBu)-.
In one embodiment of the PTCs of formula (D)-(H-I), Y is —O—. In one embodiment of the PTCs of formula (D)-(H-I), Z is —O—. In one embodiment of the PTCs of formula (D)-(H-I), Y and Z are both —O—.
In one embodiment of the PTCs of formula (D)-(H-I), —V-L is CH2CH2Cl, —CH2CH2CH2Cl, or —CH3. In some embodiments, —V-L is CH2CH2Cl or —CH2CH2CH2Cl.
In one embodiment of the PTCs of formula (D)-(H-I), n1 is 0.
In one embodiment of the PTCs of formula (D)-(H-I), n2 is 0, 1, or 2. In some embodiments, n2 is 2. In some embodiments, n2 is 2 and R2 are each ortho to Z. In other embodiments, n2 is 2 and R2 are each ortho to Z, wherein R2 is halogen or —CN.
In one embodiment of the PTCs of formula (I)-(VI) and (A)-(H-I), the compound can be a stereoisomer. For example, if X is —(CR5R6)— and R5 and R6 are different, the carbon attached to R5 and R6 can be in an S configuration or an R configuration.
In some embodiments of the PTCs of formula (I)-(VI) and (A)-(H-I), a hydrogen atom can be replaced with a deuterium atom.
In one embodiment of the PTCs of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from Table A below, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), or (D)-(H-I), the PTC is selected from PTC A3, A5, A7, A13, A17, A18, A22, A23, A24, A25, A28, A30, A31, A32, A34, A35, A38, A40, A41, A42, A45, A49, A52, A53, A54, A56, A57, A58, A62, A63, A64, A65, A68, A73, A74, A75, or A76, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTC A1, A2, A4, A6, A8, A9, A10, A11, A12, A14, A15, A16, A19, A20, A21, A26, A27, A29, A33, A36, A37, A39, A43, A44, A46, A47, A48, A50, A51, A55, A59, A60, A61, A66, A67, A69, A70, A71, A72, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, or A97, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTCs A98-A186, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTCs A187-A211, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTCs A1-A211, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTCs A212-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTCs A1-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from PTCs A1-A96, A98-A116, A118-A159, A161-A175, and A177-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In one embodiment of the PTC of formula (I)-(VA), (A), (A-I), or (D)-(H-I), the PTC is selected from A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and/or A204, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In one embodiment, PTC in formula Q is a compound of formula (I)-(VA), (A), (A-I), or (D)-(H-I), minus any functional group that was involved in making the PTC-LI bond.
In one embodiment of the PTC of formula (I)-(IV), (VI), (B) or (C), the PTC is selected from Table B below, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(IV), (VI), (B) or (C), the PTC is selected from PTCs B1, B2, B3, or B6 or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(IV), (VI), (B) or (C), the PTC is selected from PTCs B4, B5, B7, B8, B9, B10, or B11 or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the PTC of formula (I)-(IV), (VI), (B) or (C), the PTC is selected from PTCs B1-B11 or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In some embodiments, the the PTC is selected from:
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In one embodiment, the present disclosure provides PTCs comprising the structure of formula (i):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
In one embodiment of the PTCs of formula (i), the compound has the structure of formula (ii):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
In one embodiment of the compounds of formula (i), the compound has the structure of formula (iii):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
In one embodiment of the PTCs of formula (i), the compound has the structure of formula (iv):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
In one embodiment of the PTCs of formula (i), R is W.
In one embodiment of the PTCs of formula (i), W is hydrogen, halogen, optionally substituted alkylsulfonate, optionally substituted arylsufonate, —CF3, or —NR13R14. In one embodiment of the compounds of formula (i), W is halogen, optionally substituted alkylsulfonate, or optionally substituted arylsufonate. In one embodiment of the compounds of formula (i), W is halogen, mesylate, or tosylate.
In one embodiment of the PTCs of formula (i), W is hydrogen, halogen, —CF3, or —NR13R14. In one embodiment, W is hydrogen, halogen, —CF3, or —NH2. In some embodiments, W is aryl, optionally substituted with halogen, C1-C3 alkyl, —CN, —CF3, —OH, C1-C3 alkoxy, —NR13R14, or —SO2R16. In another embodiment, W is a phenyl, optionally substituted with halogen, C1-C3 alkyl, —CN, —CF3, —OH, or C1-C3 alkoxy.
In one embodiment of the PTCs of formula (i)-(iii), W is hydrogen, halogen, —CF3, or —NH2. In one embodiment, W is a halogen. In one embodiment, W is Cl, Br, I, or F. In other embodiments, W is Cl.
In one embodiment of the PTCs of formula (i)-(iii), W is halogen, optionally substituted alkylsufonate, or optionally substituted arylsulfonate.
In one embodiment of the PTCs of formula (i), L is -E-R3.
In one embodiment of the PTCs of formula (i)-(iv), R3 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted —OR15, optionally substituted —SR18, optionally substituted C1-C6 alkoxy, —NR16R17, —NR16SR18, —NR16SOR18, —NR16SO2R18, —NR16COR18, —CONR14R15, —SONR14R15, —SO2NR14R15, optionally substituted —SOR18, or optionally substituted —SO2R18. In one embodiment, R3 is selected from hydrogen, —C1-C3 alkyl, —NR16SO(C1-C3 alkyl), —NR16SO2(C1-C3 alkyl), —SONR14R15, —SO2NR14R15, —SOR18, or —SO2R18. In other embodiments, R3 is selected from —NHSO2(C1-C3 alkyl), —NCH3SO2(C1-C3 alkyl), or —SO2(C1-C3 alkyl).
In one embodiment of the PTCs of formula (i)-(iv), R3 is —NR16R17, —NR16COR18, —NR16S(O)pR18, —S(O)pR18, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In other embodiments, R3 is —NR16R17. In one embodiment, R3 is —NR16S(O)pR18 or —S(O)pR18.
In one embodiment of the PTCs of formula (i)-(iv), R3 is hydrogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —OR15, optionally substituted C1-C6 alkoxy, —NH2, —NR16R17, —NR16COR18, —NR16S(O)pR18, —CONR14R15, —SONR14R15, —SO2NR14R15, optionally substituted —S(O)pR18, —N3, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R3 is hydrogen, —CN, —CF3, —OH, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted —OR15, optionally substituted C1-C3 alkoxy, —NH2, —NR16R17, —NR16COR18, —NR16S(O)pR18, —CONR14R15, —SONR14R15, —SO2NR14R15, optionally substituted —S(O)pR18, —N3, optionally substituted 3- to 7-membered carbocyclyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted 6- to 12-membered aryl, or optionally substituted 5- to 12-membered heteroaryl. In other embodiments, R3 is hydrogen, —CN, —CF3, —OH, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted —OR15, optionally substituted C1-C3 alkoxy, —NH2, —NR16R17, —NR16COR18, —NR16S(O)pR18, —CONR14R15, —SONR14R15, —SO2NR14R15, optionally substituted —S(O)pR18, or -N3. In one embodiment, R3 is optionally substituted 3- to 7-membered carbocyclyl, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted 6-membered aryl, or optionally substituted 5- to 6-membered heteroaryl.
In one embodiment of the PTCs of formula (i)-(iv), R3 is selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, —NHSO2(C1-C6 alkyl), —NCH3SO2(C1-C6 alkyl), —SO2(C1-C6 alkyl), —NHCO(C1-C6 alkyl), or —N(C1-C6 alkyl)CO(C1-C6 alkyl). In another embodiment, R3 is hydrogen, C1-C3 alkyl, C1-C3 alkoxy, —NHSO2(C1-C3 alkyl), —NCH3SO2(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(C1-C3 alkyl)CO(C1-C3 alkyl). In other embodiments, R3 is selected from —NHSO2(C1-C3 alkyl), —NCH3SO2(C1-C3 alkyl), or —SO2(C1-C3 alkyl). In one embodiment, R3 is selected from hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl). In one embodiment, R3 is selected from hydrogen, methyl, ethyl, propyl, isopropyl, methoxy, —SO2CH3, —NHSO2CH3, or —N(CH3)SO2CH3. In one embodiment, R3 is selected from —SO2CH3, —NHSO2CH3, or —N(CH3)SO2CH3.
In one embodiment of the PTCs of formula (i)-(iv), R3 is C1-C6 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R3 is —NR16R17, wherein R16 and R17 are taken together to form an 3- to 7-membered optionally substituted heterocyclyl. In one embodiment, R3 is —NR16R17, wherein R16 and R17 are taken together to form a 6-membered optionally substituted heterocycle. In one embodiment, R3 is —NR16R17, wherein R16 and R17 are taken together to form a 6-membered optionally substituted heterocycle. In one embodiment, R3 is —NR16R17, wherein R16 and R17 are taken together to form an optionally substituted piperizine. In one embodiment, R3 is —NR16R17, wherein R16 and R17 are taken together to form a piperizine, optionally substituted with —SO2CH3, —NHSO2CH3, or —N(CH3)SO2CH3. In one embodiment, R3 is
In one embodiment of the PTCs of formula (i)-(iv), X is a bond, —NR10—, or —(CR8aR9a)t—. In one embodiment, X is a bond. In other embodiments, X is —(CR8R9)t— or —NR10—. In another embodiment, X is —NR10—.
In one embodiment of the PTCs of formula (i)-(iv), X is —NR10—, wherein R10 is hydrogen or optionally substituted C1-C6 alkyl. In another embodiment, R10 is hydrogen. In some embodiments, X is —NR10—, wherein R10 is methyl. In one embodiment, X is —NR10—, wherein R10 is H, C1-C6 alkyl, or —CO(C1-C6 alkyl). In one embodiment, X is —NR10—, wherein R10 is H, C1-C6 alkyl, or —CO(C1-C6 alkyl). In one embodiment, X is —NR10—, wherein R10 is H, C1-C3 alkyl, or —CO(C1-C3 alkyl).
In one embodiment of the PTCs of formula (i)-(iv), X is —(CR8R9)t—. In one embodiment, X is —(CR8R9)—, wherein R8 and R9 are each selected from H, halogen, —OH, or C1-C6 alkyl. In one embodiment, X is a bond or —(CR8aR9a)t—, wherein R8a and R9a are each selected from H, halogen, —OH, or C1-C6 alkyl and t is 1, or 2. In some embodiments, X is —(CR8R9)t—, wherein each R8 and R9 are independently hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, X is —(CR8R9)t—, wherein each R8 and R9 are hydrogen. In some embodiments, X is —(CR8R9)t—, wherein each R8 and R9 are methyl. In some embodiments, X is —(CR8R9)t—, wherein each R8 and R9 are H, C1-C6 alkyl, —OH, or —NH2.
In one embodiment of the PTCs of formula (i)-(iv), X is a bond or —(CR8aR9a)t—, wherein t is 1, or 2.
In one embodiment of the PTCs of formula (i)-(iv), the instance of t when X is —(CR8R9)t— is 1. In other embodiments, the instance of t when X is —(CR8R9)t-t is 2.
In one embodiment of the PTCs of formula (i)-(iv), X—(CR8aR9a)t—, wherein R8a and R9a taken together form an optionally substituted carbocyclyl or optionally substituted heterocyclyl. In one embodiment, X—(CR8aR9a)t—, wherein R8a and R9a taken together form an optionally substituted 3- to 6-membered carbocyclyl or an optionally substituted 3- to 6-membered heterocyclyl containing one heteroatom selected from O, S, or N. In one embodiment, X—(CR8aR9a)t—, wherein R8a and R9a taken together form a 3- to 6-membered carbocyclyl or a 3- to 6-membered heterocyclyl containing one heteroatom selected from O, S, or N. In one embodiment, X—(CR8aR9a)t—, wherein R8a and R9a taken together form a 4-membered heterocyclyl containing one O.
In one embodiment of the PTCs of formula (i)-(iv), X is a bond, —NR10—, or —(CR8aR9a)t—. In one embodiment, X is a bond, —CH2—, —C(CH3)2—, —CH2CH2—, —NH—, —N(CH3)—, —N(iPr)-, or —N(COCH3)—. In other embodiments, X is a bond, —NH—, —CH2—, —C(CH3)2—, or —CH2CH2—. In other embodiments, X is a bond, —NH—, —N(COCH3)—, —N(C1-C3 alkyl)-, —CH2—, —CH(CH3)—, —C(CH3)2—, —CH2CH2—, —CH(OH)—, —CHF—, or —CHF2—. In other embodiments, X is a bond, —CH2—, —C(CH3)2—, —CH2CH2—, —NH—, —N(CH3)—, —N(iPr)-, or —N(COCH3)—.
In one embodiment of the PTCs of formula (i)-(iii), X is —(CR8aOH)— or (CR8aNH2)—.
In one embodiment of the PTCs of formula (i), Y is —(CR8R9)t—, —O—, or —NR10—. In other embodiments, Y is —O—. In another embodiment, Y is —(CR8R9)t—. In another embodiment, Y is —(CR8R9)t—, wherein each R8 and R9 are hydrogen.
In one embodiment of the PTCs of formula (i), the instance of t when Y is —(CR8R9)t— is 1.
In one embodiment of the PTCs of formula (i), Y is —NR10—. In another embodiment, Y is —NR10—, wherein R10 is hydrogen or optionally substituted C1-C6 alkyl. In another embodiment, Y is —NR10—, R10 is hydrogen. In another embodiment, Y is —NR10—, R10 is methyl.
In one embodiment of the compounds of formula (i)-(iv), Y is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In one embodiment, Y is a —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In one embodiment, Y is —CH2—, —O—, —NH—, or —NCH3—. In some embodiments, Y is a bond, —CH2—, —O—, or —NCH3—. In some embodiments, Y is a bond, —CH2—, —O—, or —NH—. In some embodiments, Y is —O—.
In one embodiment of the PTCs of formula (i), Z is —(CR8R9)t—, O, or NR10. In one embodiment, Z is O. In some embodiments, Z is —(CR8R9)t—. In another embodiment, Z is —(CR8R9)t—, wherein each R8 and R9 are hydrogen.
In one embodiment of the PTCs of formula (i), the instance of t when Z is —(CR8R9)t— is 1.
In one embodiment of the PTCs of formula (i), Z is —NR10—. In some embodiments, Z is —NR10—, wherein R10 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, Z is —NR10—, wherein R10 is hydrogen. In some embodiments, Z is —NR10—, wherein R10 is methyl.
In one embodiment of the PTCs of formula (i)-(iii), Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In one embodiment, Z is —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—. In one embodiment, Z is —CH2—, —O—, —NH—, —NCH3—, or —N(COCH3)—. In some embodiments, Z is a bond, —CH2—, —O—, or —NCH3—. In some embodiments, Z is a bond, —CH2—, —O—, or —NH—. In some embodiments, Z is —O—.
In one embodiment of the PTCs of formula (i), V is a bond, —(CR11R12)m—, —C(═O)—, —N(R10)CO—, —CONR10—, or —NSO2R10—. In one embodiment, V is a bond. In other embodiments, V is optionally substituted —C(R11R12)m—. In one embodiment, is optionally substituted —C(R11R12)m—, wherein each R11 and R12 are hydrogen. In some embodiments, V is —(CR11R12)m—.
In one embodiment of the compounds of formula (i), V is —(CR11R12)m—, wherein m is 1, 2, or 3. In some embodiments, V is —(CR11R12)m—, wherein R11 and R12 are each selected from H, halogen, —OH, or C1-C6 alkyl. In some embodiments, V is —(CR11R12)m—, wherein m is 1, 2, or 3. In some embodiments, V is —(CR11R12)m—, wherein R11 and R12 are each selected from H, halogen, —OH, or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), V is —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH(CH3)CH2—, —CH2CH(OH)CH2—, or —CH2C(OH)(CH3)CH2—.
In one embodiment of the PTCs of formula (i), Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—; and V is —(CR11R12)m—.
In one embodiment of the PTCs of formula (i)-(iv), Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—; V is —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH(CH3)CH2—, —CH2CH(OH)CH2—, or —CH2C(OH)(CH3)CH2—; and W is halogen, —NH2, or —CF3.
In one embodiment of the PTCs of formula (i)-(iv), Z is a bond, —CH2—, —C(CH3)H—, —O—, —S—, —NH—, —NCH3—, or —N(COCH3)—; V is —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH(CH3)CH2—, —CH2CH(OH)CH2—, or —CH2C(OH)(CH3)CH2—; and W is halogen, —NH2, or —CF3.
In one embodiment of the PTCs of formula (i), m is 1 or 2. In some embodiments, m is 1.
In one embodiment of the PTCs of formula (i), each R8 and R9 are independently hydrogen or optionally substituted C1-C6 alkyl. In one embodiment, each R8 and R9 are H, C1-C6 alkyl, —OH, or —NH2.
In one embodiment of the PTCs of formula (i), R1a and R1b are each hydrogen or optionally substituted C1-6 alkyl. In other embodiments, R1a and R1b are each hydrogen.
In one embodiment of the PTCs of formula (i), R2a and R2b are each hydrogen or optionally substituted C1-6 alkyl. In other embodiments, R2a and R2b are each hydrogen.
In one embodiment of the PTCs of formula (i)-(iv), R16 and R17 are taken together with the intervening atom to form an optionally substituted heterocyclyl, or optionally substituted heteroaryl. In some embodiments, R16 and R17 are taken together to form an optionally substituted heterocyclyl. In some embodiments, R16 and R17 are taken together to form an 3- to 7-membered optionally substituted heterocyclyl. In some embodiments, R16 and R17 are taken together to form an 3- to 7-membered optionally substituted heterocyclyl, comprising one or more heteroatoms selected from N, O, or S.
In one embodiment of the PTCs of formula (i)-(iv), R16 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R16 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, R16 is hydrogen or C1-C6 alkyl. In some embodiments, R16 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R17 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R17 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, R17 is hydrogen or C1-C6 alkyl. In some embodiments, R17 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R18 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R18 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, R18 is hydrogen or C1-C6 alkyl. In some embodiments, R18 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i), R18 is C1-C6 alkyl; and p is 2.
In one embodiment of the PTCs of formula (i), R2a, R2b and R3 taken together with the intervening atom are optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In other embodiments, R2a, R2b and R3 taken together with the intervening atom are optionally substituted heteroaryl. In some embodiments, R2a, R2b and R3 taken together with the intervening atom are optionally substituted tetrazolyl, imidazolyl, 1,2,3-triazolyl, oxazole, pyrazinyl, pyrimidinyl, or 1,3,5-triazinyl.
In one embodiment of the PTCs of formula (i), R4a is hydrogen, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy. In some embodiments, R4a is optionally substituted C1-6 alkyl or hydrogen. In other embodiments, R4a is hydroxy.
In one embodiment of the PTCs of formula (i), R4b is hydrogen, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy. In some embodiments, R4b is hydrogen.
In one embodiment of the PTCs of formula (i), R5a is hydrogen, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy. In one embodiment, R5a is hydrogen.
In one embodiment of the PTCs of formula (i), R5b is hydrogen, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy. In one embodiment, R5b is hydrogen.
In one embodiment of the PTCs of formula (i), n is 1. In other embodiments, n is 2.
In one embodiment of the PTCs of formula (i), each occurrence of R6 and R7 is independently H, methyl, methoxy, CN, halogen, —OH, —NH2, —COOH, or —CONH2. In one embodiment of the PTCs of formula (i), each occurrence of R6 and R7 is independently H, methyl, methoxy, CN, F, Cl, Br, or I. In other embodiments, each occurrence of R6 and R7 is F, Cl, Br, or I. In one embodiment, each occurrence of R6 and R7 is Cl.
In one embodiment of the PTCs of formula (i), A and B are each independently 5- or 6-membered aryl or heteroaryl. In other embodiments, A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene. In one embodiment, A and B are each phenyl.
In one embodiment of the PTCs of formula (i), A has a meta or para connectivity with X and Y. In one embodiment of the PTCs of formula (i), B has a meta or para connectivity with X and Z.
In one embodiment of the PTCs of formula (i)-(iv), D is —CH2—, —CH(CH3)—, —C(CH3)2—, or —CH2CH2—. In one embodiment, D is —(CH2)2—.
In one embodiment of the PTCs of formula (i), D is —(CR1aR1b)q—; E is —O—, —NR10—, or —NR1—(CR2aR2b)g—; and q is 1 or 2.
In one embodiment of the PTCs of formula (i), D is —O— or —NR10—; E is —(CR2aR2b)g—; and g is 1, 2, 3, or 4.
In one embodiment of the PTCs of formula (i), D is —O— or —NR10—; and E is —O—, —NR10— or —NR10—(CR2aR2b)g—.
In one embodiment of the PTCs of formula (i), R6 and R7 are each independently halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C6 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C6 alkyl)-SO2NR14R15, optionally substituted —SO2R16, or optionally substituted —(C1-C6 alkyl)-SO2R16. In one embodiment, R6 and R7 are each independently halogen, —CN, —CF3, —OH, optionally substituted C1-C3 alkyl, C1-C3 alkoxy, optionally substituted —(C1-C3 alkyl)-(C1-C3 alkoxy), optionally substituted —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, optionally substituted —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, optionally substituted —(C1-C3 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, optionally substituted —(C1-C3 alkyl)-SO2NR14R15, —SO2R16, or optionally substituted —(C1-C3 alkyl)-SO2R16. In one embodiment, R6 and R7 are each independently halogen, —CN, —CF3, —OH, C1-C3 alkyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14SO2R16, —(C1-C3 alkyl)NR14SO2R16, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, —(C1-C3 alkyl)-CONR14R15, —SO2NR14R15, —(C1-C3 alkyl)-SO2NR14R15, —SO2R16, or —(C1-C3 alkyl)-SO2R16. In one embodiment, R6 and R7 are each independently halogen, —CN, —CF3, —OH, C1-C3 alkyl, or —CONR14R15. In some embodiments, R6 and R7 are each independently halogen, —CN, —CF3, —OH, methyl, methoxy, or —CONH2. In one embodiment, R6 and R7 are each independently Cl, —CN, —CF3, —OH, methyl, methoxy, or —CONH2. In one embodiment, R6 and R7 are each independently independently hydrogen, halogen, —OH, —NH2, —CN, —CF3, methyl, —COOH, or —CONH2.
In one embodiment of the PTCs of formula (i), R6 and R7 are each independently optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R6 and R7 are each independently 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl.
In one embodiment of the PTCs of formula (i)-(iv), R6 and R7 are each independently hydrogen, halogen, —OH, —NH2, —CN, —CF3, methyl, —COOH, or —CONH2. In one embodiment, R6 and R7 is each independently halogen, —CN, —CF3, —OH, methyl, or methoxy. In one embodiment, R6 and R7 are each independently halogen, —CN, —CF3, —OH, or methyl. In one embodiment, R6 and R7 are each independently H, halogen, —CN, or methyl. In another embodiment, R6 and R7 is each independently Cl, —CN, —CF3, —OH, methyl, or methoxy. In one embodiment, R6 and R7 is independently H, methyl, methoxy, CN, F, Cl, Br, or I. In one embodiment of the compounds of formula (i)-(iv), R6 and R7 is independently H, methyl, methoxy, CN, F, Cl, Br, I, 123I or CF3. In other embodiments, R6 and R7 is F, Cl, Br, or I. In one embodiment, each occurrence of R6 and R7 is Cl.
In one embodiment of the PTCs of formula (i)-(iv), R6 have one of the connectivity as shown below with respect to X and Y:
In one embodiment of the PTCs of formula (i)-(iv), R have one of the connectivity as shown below with respect to X and Z:
In one embodiment of the PTCs of formula (i)-(iv), n in —(R6)n is 0, 1, or 2. In some embodiments, n is 0 or 1. In other embodiments, n is 0. In some embodiments, n is 1.
In one embodiment of the PTCs of formula (i)-(iv), n in —(R7)n is 0, 1, or 2. In some embodiments, n is 0 or 1. In other embodiments, n is 0. In some embodiments, n is 1.
In one embodiment of the PTCs of formula (i)-(iv), the sum of n in —(R6)n and —(R7)n is 0, 1, 2, 3, or 4. In some embodiments, the sum of n in —(R6)n and —(R7)n is v 1, 2, 3, or 4. In some embodiments, the sum of n in —(R6)n and —(R7)n is 2 or 4. In some embodiments, the sum of n in —(R6)n and —(R7)n is 2.
In one embodiment of the PTCs of formula (i), R8b and R9b are each independently hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R11 and R12 are not —OH.
In one embodiment of the PTCs of formula (i), R11 and R12 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i), g is independently 0, 1, 2, or 3.
In one embodiment of the PTCs of formula (i), R1a, R1b, R2a, and R2b are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —OCO(C1-C3 alkyl), —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C6 alkyl)-CONR14R15; or (R1a and Rib) or (R2a and R2b) taken together form an oxo (═O), an optionally substituted carbocyclyl, or an optionally substituted heterocyclyl.
In one embodiment of the PTCs of formula (i)-(iii), q is 0.
In one embodiment of the PTCs of formula (i)-(iii), E is —CH2—, —CH(CH3)—, —C(CH3)2—, —CH2CH2—, or —CH2CH2CH2—.
In one embodiment of the PTCs of formula (i)-(iii), g is 0.
In one embodiment of the PTCs of formula (i)-(iii), at least one of Z and Y is —O—.
In one embodiment of the PTCs of formula (i) or (iv), Y is —O—, D is —(CR1aR1b)q—, L is —(CR2aR2b)—R3, and R3 is —NR16S(O)pR18. In one embodiment, Y is —O—, D is —(CR1aR1b)—, L is —(CR2aR2b)—R3, and R3 is —NR16S(O)2(C1-C3 alkyl). In one embodiment, Y is —O—, D is —CH2—, —CH(CH3)—, or —C(CH3)2—, L is —CH2—R3, and R3 is —NHS(O)2CH3.
In one embodiment of the compounds of formula (i)-(iii), when E is —O—, R3 is hydrogen, —CF3, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In other embodiments, when E is —O—, R3 is hydrogen, —CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.
In one embodiment of the PTCs of formula (i)-(iv), at least one of Z and Y is —O—.
In one embodiment of the PTCs of formula (i)-(iv), -D-C(O)-E-R3 is
or its tautomeric form
In one embodiment of the PTCs of formula (i)-(iv), —Y-D-C(O)-E-R3 is
or its tautomeric form
In one embodiment of the PTCs of formula (i), -D-C(O)-E-R3 is
In one embodiment of the PTCs of formula (i)-(iv), R1a, and R1b are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —OCO(C1-C3 alkyl), —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, —(C1-C6 alkyl)-CONR14R15; or R1a and R1b taken together form an oxo (═O), an optionally substituted carbocyclyl, or an optionally substituted heterocyclyl. In some embodiments, R1a, and R1b are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —OCO(C1-C3 alkyl), —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C6 alkyl)-CONR14R5. In one embodiment, R1a and R1b are each hydrogen or R1a and R1b taken together form an oxo (═O).
In one embodiment of the PTCs of formula (i)-(iv), R2a and R2b are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —OCO(C1-C3 alkyl), —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C6 alkyl)-CONR14R15; or R2a and R2b taken together form an oxo (═O), an optionally substituted carbocyclyl, or an optionally substituted heterocyclyl. In some embodiments, R2a and R2b are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —OCO(C1-C3 alkyl), —NR13R14, —(C1-C3 alkyl)-NR13R14, —NR14COR16, —(C1-C3 alkyl)-NR14COR16, —CONR14R15, or —(C1-C6 alkyl)-CONR14R15. In one embodiment, R2a and R2b are each hydrogen or R2a and R2b taken together form an oxo (═O).
In one embodiment of the PTCs of formula (ii)-(iii) R8a and R9a are each independently hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, optionally substituted —(C1-C6 alkyl)-CONR14R15, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R8a and R9a are each independently hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR13R14, optionally substituted —(C1-C6 alkyl)-NR13R14, —NR14COR16, optionally substituted —(C1-C6 alkyl)-NR14COR16, —CONR14R15, or optionally substituted —(C1-C6 alkyl)-CONR14R15. In one embodiment, R8a and R9a hydrogen, halogen, —OH, or C1-C3 alkyl. In one embodiment, R8a and R9a hydrogen, halogen, —OH, or methyl. In one embodiment, R8a and R9a hydrogen, F, —OH, or methyl.
In one embodiment of the PTCs of formula (i)-(iv), R10 is hydrogen, halogen, optinally substituted C1-C6 alkyl, or optionally substituted C1-C6 alkoxy. In some embodiments, R10 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxy. In some embodiments, R10 is hydrogen, C1-C3 alkyl, or C1-C3 alkoxy.
In one embodiment of the PTCs of formula (i), R2a and R10 taken together form an optionally substituted heterocyclyl. In one embodiment, 2a and R10 taken together form an optionally substituted 5- or 6-membered heterocyclyl.
In one embodiment of the PTCs of formula (i)-(iv), R13 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R13 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, R13 is hydrogen or C1-C6 alkyl. In some embodiments, R13 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R14 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R14 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, R14 is hydrogen or C1-C6 alkyl. In some embodiments, R14 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R15 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, R15 is hydrogen or optionally substituted C1-C6 alkyl. In some embodiments, R15 is hydrogen or C1-C6 alkyl. In some embodiments, R15 is hydrogen or C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R14 and R15 are taken together to form an optionally substituted heterocyclyl, or optionally substituted heteroaryl. In some embodiments, R14 and R15 are taken together to form an optionally substituted heterocyclyl. In some embodiments, R14 and R15 are taken together to form an 3- to 7-membered optionally substituted heterocyclyl. In some embodiments, R14 and R15 are taken together to form an 3- to 7-membered optionally substituted heterocyclyl, comprising one or more heteroatoms selected from N, O, or S.
In one embodiment of the PTCs of formula (i)-(iv), R11 and R12 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl. In one embodiment, R11 and R12 are each independently hydrogen, halogen, or C1-C3 alkyl. In one embodiment, R11 and R12 are not —OH.
In one embodiment of the PTCs of formula (i)-(iv), g is independently 0, 1, 2, or 3. In one embodiment, g is 0. In another embodiment, g is 1, 2, or 3. In some embodiments, g is 1 or 2.
In one embodiment of the PTCs of formula (i), n is S(O)n is 2. In another embodiment, n is 1 or 2. In some embodiments, n is 0.
In one embodiment of the PTCs of formula (i)-(iv), p is 2. In another embodiment, p is 1 or 2. In some embodiments, p is 0.
In one embodiment of the PTCs of formula (i)-(iv), q is 0. In another embodiment, q is 1. In one embodiment, q is 2.
In one embodiment of the PTCs of formula (i)-(iv), t is 1. In one embodiment, t is 2.
In one embodiment of the PTCs of formula (iii), gg is 1, 2, or 3. In some embodiments, gg is 1 or 2.
In one embodiment of the PTCs of formula (i)-(iii), Z and V are not both a bond or absent (e.g., m is 0 in —(CR11R12)m—).
In one embodiment of the PTCs of formula (i)-(iv), W can be halogen, optionally substituted alkyl sulfonate or optionally substituted aryl sulfonate. In one embodiment, W is halogen, tosylate or mesylate.
In one embodiment of the PTCs of formula (i)-(iv), X is —(CR8R9)— or —(CR8aR9a)—, wherein R8, R9, R8a and R9a are each independently hydrogen, halogen, —OH, —NH2, or —C1-C3 alkyl.
In one embodiment of the PTCs of formula (i)-(iv), R6 and R7 are each independently hydrogen, halogen, —OH, —NH2, —CN, —CF3, methyl, —COOH, or —CONH2.
In one embodiment, the present disclosure provides PTCs as disclosed in Table C or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment, the present disclosure provides a compound selected from Compounds AA1-AA98, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In one embodiment of the PTCs of formula (i)-(iv), the PTC is connected to the linker LI through R3, R6, R7, R10, R13, R14, R15, R16, or R17. In one embodiment of the PTCs of formula (i)-(iv), the PTC forms a covalent bond with the linker LI through standard organic chemistry protocols, such as substitution reactions and amino acid coupling reactions.
In one embodiment of the PTCs of formula (i)-(iv), a hydrogen (e.g., C—H, N—H, O—H, S—H), halogen, sulfonates (e.g., tosylate, mesylate), or any chemical group as defined in the formula (i)-(iv) is used to form the covalent bond between PTC and the linker LI. Thus, it can be understood that PTCs as disclosed herein as a neutral molecule is intended to be covalently bonded to the linker LI to form the protac molecule of formula (Q) by at least displacing one atom or one chemical group (e.g., H, halogen, OH, NH2, OTs, OMs, etc) from the PTCs of formula (i)-(iv) to form the covalent bond with LI.
In one embodiment, PTC in formula Q is a compound of formula (i)-(iv), minus any functional group that was involved in making the PTC-LI bond.
The compounds disclosed in WO 2019/226991 can be useful PTCs for the present invention. The disclosure of WO 2019/226991 is incorporated by reference in its entirety for all purposes.
In one embodiment, the present invention is directed to a compound having a structure of Formula (a):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
In one embodiment of the PTCs of formula (a), X is —C(R8R9)—. In one embodiment X is —C(R8R9)—, wherein R8 and R9 are each independently H or C1-C3 alkyl. In another embodiment, X is —C(R8R9)—, wherein R8 and R9 are each C1 alkyl. In some embodiments, X is —S(O)2— or —C(CH3)2—. In one embodiment, R8 and R9 is each hydrogen, halogen, —OH, —NH2, or —C1-C3 alkyl.
In one embodiment of the PTCs of formula (a), L is halogen, mesylate, or tosylate.
In one embodiment of the PTCs of formula (a), R1 is —OH. In another embodiment, R1 is —OC(═O)R13. In some embodiments, R1 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R1 is —OC(═O)R13, wherein R13 is methyl. In one embodiment, R1 is H.
In one embodiment of the PTCs of formula (a), R2 is —OH. In another embodiment, R2 is —OC(═O)R13. In some embodiments, R2 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In other embodiments, R2 is —OC(═O)R13, wherein R13 is methyl.
In one embodiment of the PTCs of formula (a), at least one of R1, R2, or R3 is —OH. In some embodiments, at least two of R1, R2, or R3 are each —OH. In other embodiments, R1 and R2 are each —OH.
In one embodiment of the PTCs of formula (a), at least one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, at least one of R1, R2, or R3 is —OC(═O)R13, wherein R13 is methyl. In some embodiments, at least two of R1, R2, or R3 are each —OC(═O)R13, wherein R13 is C1-C4 alkyl. In another embodiment, at least two of R1, R2 or R3 are each —OC(═O)R13, wherein R13 is methyl. In other embodiments, R1 and R2 are each —OC(═O)R13, wherein R13 is methyl.
In one embodiment of the PTCs of formula (a), R3 is —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), or —N(C1-C6 alkyl)(S(O)nR5). In one embodiment, R3 is a —NH2. In one embodiment, R3 is a —NHC(═O)R13. In one embodiment, R3 is a —N(C(═O)R13)2. In another embodiment, R3 is a —NHS(O)nR5. In some embodiments, R3 is a —NHS(O)2R5. In other embodiments, R3 is a —NHS(O)2R5, wherein R is C1-C3 alkyl. In one embodiment, R3 is a —NHS(O)2R5, wherein R5 is C1 alkyl. In one embodiment, R3 is a —N(C(═O)R13)(S(O)nR). In one embodiment, R3 is a —N(C1-C6 alkyl)(S(O)nR5). In one embodiment, R3 is a —NHS(O)2CH3.
In one embodiment of the PTCs of formula (a), R3 is —NH2, —NHC(═O)(C1-C4 alkyl), —N[(C(═O)(C1-C4 alkyl)]2, —NHS(O)n(C1-C3 alkyl), —N[C(═O)(C1-C4 alkyl)][(S(O)n(C1-C3 alkyl)], or —N[C1-C6 alkyl][S(O)n(C1-C3 alkyl)]. In some embodiments, R3 is —NH(C(═O)CH3) or —N(C(═O)CH3)2. In other embodiments, R3 is —NHS(O)2CH3. In other embodiments, R3 is —N(C(═O)CH3) (S(O)2CH3).
In one embodiment of the PTCs of formula (a), R3 is a —S(O)nR5. In one embodiment, R3 is a —S(O)2R5. In another embodiment, R3 is a —S(O)2(C1-C3 alkyl). In other embodiments, R3 is a —S(O)2CH3. In other embodiments, R3 is a —S(O)2CH2CH3.
In one embodiment of the PTCs of formula (a), R3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom in the ring. In one embodiment, R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine. In a certain embodiment, R3 is
In one embodiment of the PTCs of formula (a), R3 is —OR4. In one embodiment, R3 is —OR4, wherein R4 is C1-C6 alkyl. In another embodiment, R3 is —OR4, wherein R4 is C1-C3 alkyl. In one embodiment, R3 is —OR4, wherein R4 is methyl, ethyl, n-propyl, or i-propyl. In one embodiment, R3 is —OR4, wherein R4 is methyl. In another embodiment, R3 is —OR4, wherein R4 is i-propyl.
In one embodiment of the PTCs of formula (a), R3 is a halogen. In other embodiments, R3 is F, Cl, Br, or I. In one embodiment, R3 is F.
In one embodiment of the PTCs of formula (a), at least one of R11a, R11b, R11c and R11d is Cl. In another embodiment, at least one of R11a, R11b, R11c and R11d is Br. In some embodiments, at least one of R11, R11b, R11c and R11d is methyl.
In one embodiment of the PTCs of formula (a), at least two of R11a, R11b, R11c and R11d are methyl, F, Cl, Br, I, or 123I. In another embodiment, exactly two of R11a, R11b, R11c and R11d are methyl, F, Cl, Br, I, or 123I.
In one embodiment of the PTCs of formula (a), R11a and R11b are each H and R11c and R11d are each independently methyl, F, Cl, Br, I, or 123I. In one embodiment, R11a and R11b are each H, and R11c and R11d are each Cl. In one embodiment, R11a and R11b are each H, and R11c and R11d are each Br. In one embodiment, R11a and R11b are each H, and R11c and R11d are each methyl.
In one embodiment of the PTCs of formula (a), R11a and R11c are each H, and R11b and R11d are each independently methyl, F, Cl, Br, I, or 123I. In one embodiment, R11a and R11c are each H, and R11b and R11d are each Cl. In one embodiment, R11a and R11c are each H, and R11b and R11d are each Br. In one embodiment, R11a and R11c are each H, and R11b and R11d are each methyl.
In one embodiment of the PTCs of formula (a), R11a, R11b, R11c and R11d is, each independently, H, halogen, —OH, —NH2, —CN, —CF3, methyl, —COOH, or —CONH2.
In one embodiment of the PTCs of formula (a), R13 is C1-C3 alkyl. In other embodiments, R13 is methyl, ethyl, or propyl. In one embodiment, R13 is a methyl.
In one embodiment of the PTCs of formula (a), n is 0. In another embodiment n is 1. In some embodiments, n is 2.
In one embodiment of the PTCs of formula (a), the PTCs comprises one or more of F, Cl, Br, I or 123I substitutions for R3. In one embodiment, the PTCs comprises one or more of I or 123I substitutions for R3.
In one embodiment of the PTCs of formula (a), the PTCs comprises at least one R6 substituent on R3, wherein at least one R6 is further substituted with at least one of F, Cl, Br, I or 123I. In another embodiment, R6 substituent on R3 is further substituted with at least one of I or 123I.
In some more specific embodiments of the PTCs of Formula (a), the PTC has one of the following structures from Table D, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. In one embodiment, the PTCs of Formula (a) is selected from Compounds 1, 1a, 1A, 1aA, 5, 5a, 5A, 5aA, 7, 7a, 7A, 7aA, 8, 8a, 8A, 8aA, 9, 9a, 9A, 9aA, 11, 11a, 11A, 11aA, 12, 12a, 13, 13a, 13A, 13aA, 14, 14a, 14A, 14aA, 22, or 22a, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
In one embodiment of the PTCs of formula (a), the PTC is connected to the linker LI through R1, R2, R3, R4, R5, R11a, R11b, R11c, R11d and R13. In one embodiment of the PTCs of formula (a), the PTC forms a covalent bond with the linker LI through standard organic chemistry protocols, such as substitution reactions and amino acid coupling reactions.
In one embodiment of the PTCs of formula (a), a hydrogen (e.g., C—H, N—H, O—H, S—H), halogen, sulfonates (e.g., tosylate, mesylate), or any chemical group as defined in the formula (Ia) is used to form the covalent bond between PTC and the linker LI. Thus, it can be understood that PTCs as disclosed herein as a neutral molecule is intended to be covalently bonded to the linker LI to form the protac molecule of formula (Q) by at least displacing one atom or one chemical group (e.g., H, halogen, OH, NH2, OTs, OMs, etc) from the PTCs of formula (a) to form the covalent bond with LI.
In one embodiment, PTC in formula Q is a compound of formula (a), minus any functional group that was involved in making the PTC-LI bond.
The compounds disclosed in WO 2017/177307 can be useful PTCs for the present invention. The disclosure of WO 2017/177307 is incorporated by reference in its entirety for all purposes.
In one embodiment, any of the PTCs disclosed herein can further comprise a chemical group useful in covalently attaching the PTC to the LI. In one embodiment, any of the PTCs disclosed herein can be derivatized with a chemical group useful in covalently attaching the PTC to the LI. In one embodiment, any of the PTCs disclosed herein can be derivatized with a chemical group useful in covalently attaching the PTC to the LI. In one embodiment, the derivatization may include small linking group that can be covalently attach to LI (e.g., —NH—; —OC(O)NH—; —OC(O)—, etc).
In one embodiment, the PTCs as disclosed herein is an androgen receptor modulator. In one embodiment, the PTCs as disclosed herein binds to androgen receptor. In another embodiment, the PTCs as disclosed herein binds to androgen receptor N-terminal domain.
In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound wherein the PTC is selected from any one of formula (I)-(V) or compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound wherein the PTC is selected from Compounds A1-A186 or B1-B11, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound wherein the PTC is selected from any one of formula (i)-(iv) or compounds of Table C, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound wherein the PTC is selected from Compounds AA1-AA98, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound of wherein the PTC is selected from formula (a) or compounds of Table D, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound wherein the PTC is selected from Compounds 1, 1a, 1A, 1aA, 5, 5a, 5A, 5aA, 7, 7a, 7A, 7aA, 8, 8a, 8A, 8aA, 9, 9a, 9A, 9aA, 11, 11a, 11A, 11aA, 12, 12a, 13, 13a, 13A, 13aA, 14, 14a, 14A, 14aA, 22, or 22a, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a PTC wherein the PTC is selected from a PTC of any one of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (A-I), (B)-(D), (E), (E-I)-(E-VII), (F), (G), (G-I), (G-II), (H), and (H-I) (“formula (I)-(VI) and (A)-(H-I)”) or PTCs of Tables A and B, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
Protein Target Compounds (PTCs) with a Linker (LI) Containing a Functional Group
In one embodiment, the present disclosure includes PTC-LIA compound where the LIA is a linker (LI) with a functional group (FG) useful in reacting with a ligase modulator compound to form a compound of formula (Q).
In one embodiment of PTC-LIA, PTC can be any PTC disclosed herein, for example compounds of formula formula (I)-(VI), (A)-(H-I), (i)-(iv), and (a) or any compounds in Tables A-D.
In one embodiment of PTC-LIA, LIA is any linker (LI) disclosed herein which contains functional group (FG) selected from carboxylic acid, aldehyde, hydroxyl, alkoxyl, aryloxy-, halogen, amine, amide, azide, alkynyl, or sulfonates (e.g., tosylate, mesylate, triflate, etc.).
In one embodiment of PTC-LIA, LIA has the structure -LI-FG. In one embodiment, PTC-LIA has the structure selected from PTC-LI-COOH, PTC-LI-COH, PTC-LI-OH, PTC-LI-O-alkyl, PTC-LI-O-aryl, PTC-LI-I (iodine), PTC-LI-Br, PTC-LI-Cl, PTC-LI-F, PTC-LI-NH2, PTC-LI-NH(alkyl), PTC-LI-NH(aryl), PTC-LI-NHCO(alkyl), PTC-LI-N(alkyl)CO(alkyl), PTC-LI-CONH2, PTC-LI-CONH(alkyl), PTC-LI-CONH(aryl), PTC-LI-N3, PTC-LI-C≡CH, PTC-LI-C≡C(alkyl), PTC-LI-OSO2(alkyl), PTC-LI-OSO2(haloalkyl), or PTC-LI-OSO2(aryl), wherein PTC and LI are as disclosed herein.
In some embodiments, PTC-LIA is a compound of formula (Y-IV), (Y-IVA), (Y-V), (Y-VA), (Y-VI), (Y-VIA), (Y-VII), (Y-VIII), (Y-IX), or (Y-X):
or a pharmaceutically acceptable salt thereof, wherein A, B, C, R1, R2, R3, Z, V, L, Y, W, LI, FG, n1, n2, and n3 are as defined herein.
In some embodiments, PTC-LIA is selected from
or a pharmaceutically acceptable salt thereof, wherein a, b, c, and d are each independently an integer between 1 to 10. In one embodiment, a is 5, b is 3, and c is 1. In one embodiment, a is 2, b is 5, and c is 1. In one embodiment, a is 2, b is 5, c is 1, and d is 3. In one embodiment, a is 5 and c is 1. In one embodiment, a is 5. In one embodiment, a is 3.
Ligase Modulators (PLMs)
In one embodiment, any of the PLMs disclosed herein can be the PLM as covalently attached to the LI. In some embodiments, any of the PLMs disclosed herein can be the ligase modulator moiety before covalently attaching it to the LI. In a non limited example, the PLM can comprise a chemical group (e.g., alcohol, amine, azides, —C≡CH, etc) which can be reacted with another chemical group on or attached to the LI in order to form a covalent bond, e.g., amine bond, ether bond, amide bond, ester bond, triazole (Click chemistry). In one embodiment, a chemical group already present in the PLM as described here can be used to covalently attach the PLM to the LI. The chemistry used to covalently attach the LI to the PLM can be readily understood by one skilled in the art.
In one embodiment, any of the PLMs disclosed herein can further comprise a chemical group useful in covalently attaching the PLM to the LI. In one embodiment, any of the PLMs disclosed herein can be derivatized with a chemical group useful in covalently attaching the PLM to the LI. In one embodiment, any of the PLMs disclosed herein can be derivatized with a chemical group useful in covalently attaching the PLM to the LI. In one embodiment, the derivatization may include small linking group that can be covalently attach to LI (e.g., —NH—; —OC(O)NH—; —OC(O)—, etc).
In one embodiment, the PLMs of the present disclosure are E3 ligases or comprises an E3 ligase recognition domain.
In one embodiment, the PLM is thalidomide, pomalidomide, or lenalidomide, or derivatives thereof. See E. S. Fischer, et al. Nature 2014, 512, 49-53.
In one embodiment, the PLM is a von Hippel Lindau (VHL) ligand, a celeblon, a mouse double minute 2 homolog (MDM2) or an inhibitor of apoptosis (IAP).
In one embodiment, the PLM is a von Hippel Lindau (VHL) ligand which binds to the VHL E3 ubiquitin ligase, including but not limited to those disclosed in C. M. Crews, et al. Oncogene 2008, 27, 7201; C. M. Crews, et al. Angew. Chem. Int. Ed. 2012, 51, 11463; WO 2013/106646, WO 2016/118666, WO 2016/149668, WO 2017/011590, and/or WO 2019/023553, each disclosure are hereby incorporated by reference in their entireties for all purposes.
In one embodiment, the PLM is a moiety specific for an E3 ubiquitin ligase. In one embodiment, the PLM is an E3 ligase substrate receptor cereblon (CRBN). Examples of celeblon ligands are disclosed in U.S. Pat. No. 9,750,816 and Wustrow, D.; Zhou, H.-J.; Rolfe, M., Annu. Rep. Med. Chem. 2013, 48, 205-225, the disclosures of which are hereby incorporated by reference in their entireties for all purposes.
In one embodiment, the PLM is a mouse double minute 2 homolog (MDM2). In cancer patients, about 50% were found with p53 mutation (M. Hollstein, et al. Science (1991), 233, 49-53), while patients with wild type p53 were often found p53 down regulation by MDM2 through the protein-protein interaction of p53 and MDM2 (P. Chene, et al. Nat. Rev. Cancer (2003), 3, 102-109). Under normal cell condition without oncogenic stress signal, MDM2 keeps p53 at low concentration. In response to DNA damage or cellular stress, p53 level increases, and that also causes increase in MDM2 due to the feedback loop from p53/MDM2 auto regulatory system. In other words, p53 regulates MDM2 at the transcription level, and MDM2 regulates p53 at its activity level (A. J. Levine, et al. Genes Dev. (1993) 7, 1126-1132). Several mechanisms can explain p53 down regulation by MDM2. First, MDM2 binds to N-terminal domain of p53 and blocks expression of p53-responsive genes (J. Momand, et al. Cell (1992), 69, 1237-1245). Second, MDM2 shuttles p53 from nucleus to cytoplasm to facilitate proteolytic degradation (J. Roth, et al. EMBO J. (1998), 17, 554-564). Lastly, MDM2 carries intrinsic E3 ligase activity of conjugating ubiquitin to p53 for degradation through ubiquitin-dependent 26s proteasome system (UPS) (Y. Haupt, et al. Nature (1997) 387, 296-299). Therefore, disrupting p53/MDM2 auto regulation can restore p53 activity and could bring a new approach in the treatment of cancer. See WO 2017/011371 and Wustrow, D. et al., Annu. Rep. Med. Chem. 2013, 48, 205-225, which are hereby incorporated by reference in their entirety.
In one embodiment, the PLM is a human double minute 2 homolog (HDM2). See Wustrow, D. et al., Annu. Rep. Med. Chem. 2013, 48, 205-225, which are hereby incorporated by reference in their entirety.
In one embodiment, the PLM is an inhibitor of apoptosis (IAP). IAPs are a protein family involved in suppressing apoptosis, i.e. cell death. The human IAP family includes 8 members, and numerous other organisms contain IAP homologs. IAPs contain an E3 ligase specific domain and baculoviral IAP repeat (BIR) domains that recognize substrates, and promote their ubiquitination. IAPs promote ubiquitination and can directly bind and inhibit caspases. Caspases are proteases (e.g. caspase-3, caspase-7 and caspace-9) that implement apoptosis. As such, through the binding of caspases, IAPs inhibit cell death.
In one embodiment, the PLM has the structure of formula (E3A):
wherein:
V1, V2 are each independently a bond, O, NRa, CR8aRb, C═O, C═S, SO, SO2;
Ra and Rb are each independently H, linear or branched C1-6 alkyl, optionally substituted by 1 or more halo, or C1-6 alkoxyl optionally substituted with 0 to 3 R;
R is 0, 1, 2, or 3, groups, each independently selected from H, halo, —OH, C1-3 alkyl, or C═O;
G1 is an optionally substituted -T-N(R1aR1b), -T-aryl, an optionally substituted -T-heteroaryl, an optionally substituted -T-heterocycle, an optionally substituted —NR1-T-aryl, an optionally substituted —NR1-T-heteroaryl or an optionally substituted —NR1-T-heterocycle, where T is covalently bonded to V1;
each R1, R1a and R1b is independently H, a C1-C6 alkyl group (linear, branched, optionally substituted by 1 or more halo, —OH), RaC═O, RaC═S, RaSO, RaSO2, N(RaRb)C═O, N(RaRb)C═S, N(RaRb)SO, N(RaRb)SO2;
V2 is an optionally substituted —NR1-T-aryl, an optionally substituted —NR1-T-heteroaryl group or an optionally substituted —NR1-T-heterocycle, wherein —NR1 is covalently bonded to X2; R1 is H or CH3, preferably H; and
T is an optionally substituted —(CH2)n— group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a C1-C6 alkyl group (linear, branched, optionally substituted by 1 or more halogen, —OH) or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6; wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In one embodiment, the PLM has the structure of formula (E3B):
wherein, G1 is optionally substituted aryl, optionally substituted heteroaryl, or —CR9R10R11;
each R9 and R10 is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl; or R9 and R10 and the carbon atom to which they are attached form an optionally substituted cycloalkyl;
R11 is optionally substituted heterocyclic, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl, or —NR12R13,
R12 is H or optionally substituted alkyl;
R13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;
Rc and Rd is each independently H, haloalkyl, or optionally substituted alkyl;
G2 is a phenyl or a 5-10 membered heteroaryl,
Re is H, halogen, CN, OH, NO2, NRcRd, ORcR, CONRcRd, NRcCORd, SO2NRcRd, NRcSO2Rd, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted cycloalkyl; optionally substituted cycloheteroalkyl;
each Rf is independently halo, optionally substituted alkyl, haloalkyl, hydroxy, optionally substituted alkoxy, or haloalkoxy;
Rg is H, C1-6alkyl, —C(O)R19; —C(O)OR19; or —C(O)NR19R19;
p is 0, 1, 2, 3, or 4;
each R18 is independently halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker;
each R19 is independently H, optionally substituted alkyl, or optionally substituted aryl;
q is 0, 1, 2, 3, or 4; and
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In one embodiment, the PLM has the structure of formula (E3C):
wherein, R9 is H;
R10 is isopropyl, tert-butyl, sec-butyl, cyclopentyl, or cyclohexyl;
R11 is —NR12R13;
R12 is H;
R13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;
Rc is H, haloalkyl, methyl, ethyl, isopropyl, cyclopropyl, or C1-C6 alkyl (linear, branched, optionally substituted), each optionally substituted with 1 or more halo, hydroxyl, nitro, CN, C1-C6 alkyl (linear, branched, optionally substituted), or C1-C6 alkoxyl (linear, branched, optionally substituted);
Re is
wherein R17 is H, halo, optionally substituted C3-6cycloalkyl, optionally substituted C1-6alkyl, optionally substituted C1-6alkenyl, or C1-6haloalkyl; and Xa is S or O; and wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In one embodiment, the PLM has the structure of formula (E3D):
wherein, R9 is H;
R10 is C1-6 alkyl;
R11 is —NR12R13;
R12 is H;
R13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;
Rc is H, haloalkyl, methyl, ethyl, isopropyl, cyclopropyl, or C1-C6 alkyl (linear, branched, optionally substituted), each optionally substituted with 1 or more halo, hydroxyl, nitro, CN, C1-C6 alkyl (linear, branched, optionally substituted), or C1-C6 alkoxyl (linear, branched, optionally substituted); and
Re is
wherein R17 is H, halo, optionally substituted C3-6cycloalkyl, optionally substituted C1-6alkyl, optionally substituted C1-6alkenyl, or C1-6haloalkyl; and Xa is S or O;
R9 is H, C1-6 alkyl, —C(O)R19; —C(O)OR19; or —C(O)NR19R19;
R19 is independently H, optionally substituted alkyl, or optionally substituted aryl; and
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In one embodiment of the PLMs of formula (E3A)-(E3D), the connectivity to the linker LI is at R13.
In some embodiments of the compound of formula (Q), the PLM is represented by formula (W-II):
wherein the PLM is covalently bound to the LI via
In one embodiment, the PLM is selected from
wherein
indicates where the PLM attaches to the Linker LI.
In some embodiments of the compound of formula (Q), the the PLM is selected from:
wherein
indicates where the PLM attaches to the Linker LI.
In some embodiments of the compound of formula (Q), the the PLM is selected from
wherein the PLM is covalently bound to the LI via
In one embodiment, the PLM has the structure of formula (E3D2)
wherein Xa is O or S
Rc is H, methyl or ethyl
R17 is H, methyl, ethyl, hydoxymethyl or cyclopropyl;
M is optionally substituted heteroaryl, optionally substituted aryl or —CR9R10R11;
R9 is H;
R10 is H, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted hydroxyalkyl, optionally substituted thioalkyl or cycloalkyl;
R11 is optionally substituted heteroaromatic, optionally substituted heterocyclic, optionally substituted aryl or —NR12R13;
R12 is H or optionally substituted alkyl;
R13 is H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl; optionally substituted (oxoalkyl)carbamate; and wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI.
In some embodiments, any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H, O—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H, O—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In some embodiments of the compound of formula (Q), the PLM is represented by formula (W-IIIA):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
In some embodiments of the compound of formula (Q), the PLM is represented by formula (W-IIIB):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
represent a bond to the LI;
In some embodiments of the PLM of formula (W-IIIA) or formula (W-IIIB), X is —C(C1-3 alkyl)2.
In some embodiments of the compound of formula (Q), the PLM is selected from the group consisting of:
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
In some embodiments of the compound of formula (Q), the PLM is:
In one embodiment, the PLM is selected from
wherein R is a functional group or an atom, and optionally one of which can be modified to be covalently joined to a Linker LI and n is 1, 2, 3, or 4.
In one embodiment, the PLM has the structure of formula (E3Ga)-(E3Gd):
wherein R1′ and R2′ are independently selected from the group consisting of F, Cl, Br, I, acetylene, CN, CF3 and NO2;
R3′ is selected from the group consisting of —OCH3, —OCH2CH3, —OCH2CH2F, —OCH2CH2OCH3, and —OCH(CH3)2;
R4′ is selected from the group consisting of H, halogen, —CH3, —CF3, —OCH3, —C(CH3)3, —CH(CH3)2, -cyclopropyl, —CN, —C(CH3)2OH, —C(CH3)2OCH2CH3, —C(CH3)2CH2OH, —C(CH3)2CH2OCH2CH3, —C(CH3)2CH2OCH2CH2OH, —C(CH3)2CH2OCH2CH3, —C(CH3)2CN, —C(CH3)2C(O)CH3, —C(CH3)2C(O)NHCH3, —C(CH3)2C(O)N(CH3)2, —SCH3, —SCH2CH3, —S(O)2CH3, —S(O2)CH2CH3, ˜NHC(CH3)3, —N(CH3)2, pyrrolidinyl, and 4-morpholinyl;
R5′ is selected from the group consisting of halogen, -cyclopropyl, —S(O)2CH3, —S(O)2CH2CH3, 1-pyrrodinyl, —NH2, —N(CH3)2, and —NHC(CH3)3; and
R6′ is selected from the structures presented below where the linker LI connection point is indicated by *
In one embodiment of the PLM has the structure of formula (E3Ga)-(E3Gd), beside R6′ as the point for linker attachment, R4′ can also serve as the linker attachment position. In the case that R4′ is the linker connection site, the linker will be connected to the terminal atom of R4′ groups.
In one embodiment, the PLM is selected from
and wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H, O—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H, O—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI. In some embodiments of the compound of formula (Q), the PLM is
In one embodiment, the PLM comprises an alanine-valine-proline-isoleucine tetrapeptide fragment or an unnatural mimetic thereof.
In one embodiment, the PLM is selected from
wherein R is H or methyl; wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H, O—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
In one embodiment, the PLM is selected from
wherein one atom or one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one atom in the PLM is replaced to form a covalent bond to the LI. In some embodiments, one chemical group in the PLM is replaced to form a covalent bond to the LI. In some embodiments, a hydrogen (e.g., C—H, N—H), or halogen is used to form the covalent bond between PLM and the linker LI. In some embodiments, the hydrogen from a N—H group is replaced to form the covalent bond between PLM and the linker LI.
The present compounds find use in any number of methods. For example, in some embodiments the compounds are useful in methods for modulating androgen receptor (AR). Accordingly, in one embodiment, the present disclosure provides the use of compounds of formula (Q) wherein the PTC has the structure of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (A-I), (B)-(D), (E), (E-I)-(E-VII), (F), (G), (G-I), (G-II), (H), and (H-I) (“formula (I)-(VI) and (A)-(H-I)”), (i)-(iv) or (a), or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, for modulating androgen receptor (AR) activity. For example in some embodiments, modulating androgen receptor (AR) activity is in a mammalian cell. Modulating androgen receptor (AR) can be in a subject in need thereof (e.g., a mammalian subject) and for treatment of any of the described conditions or diseases.
In one embodiment, the modulating AR is binding to AR. In other embodiments, the modulating AR is inhibiting AR.
In one embodiment, the modulating AR is modulating AR N-terminal domain (NTD). In one embodiment, the modulating AR is binding to AR NTD. In other embodiments, the modulating AR is inhibiting AR NTD. In one embodiment, the modulating AR is modulating AR N-terminal domain (NTD). In some embodiments, modulating the AR is inhibiting transactivation of androgen receptor N-terminal domain (NTD).
In other embodiments, modulating androgen receptor (AR) activity is for treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, age related macular degeneration, and combinations thereof. For example in some embodiments, the indication is prostate cancer. In other embodiments, the prostate cancer is primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. While in other embodiments, the prostate cancer is androgen dependent prostate cancer. In other embodiments, the spinal and bulbar muscular atrophy is Kennedy's disease.
In one embodiment of the present disclosure, a method of treating a condition associated with cell proliferation in a patient in need thereof is provided, comprising administering a compound of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, to a subject in need thereof. In one embodiment, the present invention provides a method of treating cancer or tumors. In another embodiment, the present invention provides a method of treating prostate cancer or breast cancer.
In another embodiment, the present invention provides a method of treating prostate cancer. In one embodiment, prostate cancer is metastatic castration-resistant prostate cancer.
In another embodiment, the present invention provides a method of treating breast cancer. In one embodiment, breast cancer is triple negative breast cancer.
In one embodiment of the present disclosure, a method of reducing, inhibiting, or ameliorating proliferation, comprising administering a therapeutically effective amount of a compound of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof is provided. In one embodiment, the reducing, inhibiting, or ameliorating in the method disclosed herein, is in vivo. In another embodiment, the reducing, inhibiting, or ameliorating is in vitro.
In one embodiment, the cells in the method disclosed herein, are a cancer cells. In one embodiment, the cancer cells are a prostate cancer cells. In one embodiment, the prostate cancer cells are cells of primary/localized prostate cancer (newly diagnosed or early stage), locally advanced prostate cancer, recurrent prostate cancer (e.g., prostate cancer which was not responsive to primary therapy), metastatic prostate cancer, advanced prostate cancer (e.g., after castration for recurrent prostate cancer), metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In another embodiment, the prostate cancer cells are cells of a metastatic castration-resistant prostate cancer. In other embodiments, the prostate cancer cells are an androgen-dependent prostate cancer cells or an androgen-independent prostate cancer cells. In one embodiment, the cancer cells are breast cancer cells.
In one embodiment, the condition or disease associated with cell proliferation is cancer. In one embodiment of any one of the methods disclosed herein, the cancer is selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration. In one embodiment, the condition or disease is prostate cancer. In one embodiment, prostate cancer is selected from primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In another embodiment, the prostate cancer is a metastatic castration-resistant prostate cancer. In some embodiments, the prostate cancer is an androgen-dependent prostate cancer cells or an androgen-independent prostate cancer. In one embodiment, the condition or disease is breast cancer.
In another embodiment of the present disclosure, a method for reducing or preventing tumor growth, comprising contacting tumor cells with a therapeutically effective amount of a compound of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof is provided.
In one embodiment, reducing or preventing tumor growth includes reduction in tumor volume. In one embodiment, reducing or preventing tumor growth includes complete elimination of tumors. In one embodiment, reducing or preventing tumor growth includes stopping or halting the existing tumor to grow. In one embodiment, reducing or preventing tumor growth includes reduction in the rate of tumor growth. In one embodiment, reducing or preventing tumor growth includes reduction in the rate of tumor growth such that the rate of tumor growth before treating a patient with the methods disclosed herein (r1) is faster than the rate of tumor growth after said treatment (r2) such that r1>r2.
In one embodiment, the reducing or preventing in the method disclosed herein is in vivo. In another embodiment, the treating is in vitro.
In one embodiment, the tumor cell in the method disclosed herein is selected from prostate cancer, breast cancer, ovarian cancer, endometrial cancer, or salivary gland carcinoma. In one embodiment, the tumor cells are prostate cancer tumor cells. In one embodiment, the prostate cancer tumor cells are tumor cells of primary/localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In other embodiments, the prostate cancer is a metastatic castration-resistant prostate cancer. In some embodiments, the prostate cancer is androgen-dependent prostate cancer or androgen-independent prostate cancer. In another embodiment, the tumor cells are is breast cancer tumor cells.
The present disclosure also includes pharmaceutical compositions for modulating androgen receptor (AR) in a subject. In one embodiment, a pharmaceutical composition comprises one or more compounds of formula (Q) wherein the PTC has the structure of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (A-I), (B)-(D), (E), (E-I)-(E-VII), (F), (G), (G-I), (G-II), (H), and (H-I) (“formula (I)-(VI) and (A)-(H-I)”), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof.
In one embodiment of the present disclosure, a pharmaceutical composition comprises a therapeutically effective amounts of one or more compounds of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof.
In a specific embodiment, a pharmaceutical composition, as described herein, comprises one or more compounds of formula (Q) wherein the PTC is selected from Table A, or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, a pharmaceutical composition as described herein comprise one or more compounds of formula (Q) wherein the PTC has the structure selected from Table B, or a pharmaceutically acceptable salt or solvate thereof.
In a specific embodiment, a pharmaceutical composition, as described herein, comprises one or more compounds of formula (Q) wherein the PTC has the structure selected from A1-A234 or B1-B11, or a pharmaceutically acceptable salt or solvate thereof.
In one embodiment, a pharmaceutical composition, as described herein, comprising one or more compounds of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof, further comprises one or more additional therapeutically active agents. In one embodiment, one or more additional therapeutically active agents are selected from therapeutics useful for treating cancer, neurological disease, a disorder characterized by abnormal accumulation of α-synuclein, a disorder of an aging process, cardiovascular disease, bacterial infection, viral infection, mitochondrial related disease, mental retardation, deafness, blindness, diabetes, obesity, autoimmune disease, glaucoma, Leber's Hereditary Optic Neuropathy, and rheumatoid arthritis.
In some embodiments, the one or more additional therapeutic agents is a a poly (ADP-ribose) polymerase (PARP) inhibitor including but not limited to olaparib, niraparib, rucaparib, talazoparib; an androgen receptor ligand binding domain inhibitor including but not limited to enzalutamide, apalutamide, darolutamide, bicalutamide, nilutamide, flutamide, ODM-204, TAS3681; an inhibitor of CYP17 including but not limited to galeterone, abiraterone, abiraterone acetate; a microtubule inhibitor including but not limited to docetaxel, paclitaxel, cabazitaxel (XRP-6258); a modulator of PD-1 or PD-L1 including but not limited to pembrolizumab, durvalumab, nivolumab, atezolizumab; a gonadotropin releasing hormone agonist including but not limited to cyproterone acetate, leuprolide, a 5-alpha reductase inhibitor including but not limited to finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111; a vascular endothelial growth factor inhibitor including but not limited to bevacizumab (Avastin); a histone deacetylase inhibitor including but not limited to OSU-HDAC42; an integrin alpha-v-beta-3 inhibitor including but not limited to VITAXIN; a receptor tyrosine kinase including but not limited to sunitumib; a phosphoinositide 3-kinase inhibitor including but not limited to alpelisib, buparlisib, idealisib; an anaplastic lymphoma kinase (ALK) inhibitor including but not limited to crizotinib, alectinib; an endothelin receptor A antagonist including but not limited to ZD-4054; an anti-CTLA4 inhibitor including but not limited to MDX-010 (ipilimumab); an heat shock protein 27 (HSP27) inhibitor including but not limited to OGX 427; an androgen receptor degrader including but not limited to ARV-330, ARV-110; a androgen receptor DNA-binding domain inhibitor including but not limited to VPC-14449; a bromodomain and extra-terminal motif (BET) inhibitor including but not limited to BI-894999, GSK25762, GS-5829; an N-terminal domain inhibitor including but not limited to a sintokamide; an alpha-particle emitting radioactive therapeutic agent including but not limited to radium 233 or a salt thereof; niclosamide; or related compounds thereof; a selective estrogen receptor modulator (SERM) including but not limited to tamoxifen, raloxifene, toremifene, arzoxifene, bazedoxifene, pipindoxifene, lasofoxifene, enclomiphene; a selective estrogen receptor degrader (SERD) including but not limited to fulvestrant, ZB716, OP-1074, elacestrant, AZD9496, GDC0810, GDC0927, GW5638, GW7604; an aromitase inhibitor including but not limited to anastrazole, exemestane, letrozole; selective progesterone receptor modulators (SPRM) including but not limited to mifepristone, lonaprison, onapristone, asoprisnil, lonaprisnil, ulipristal, telapristone; a glucocorticoid receptor inhibitor including but not limited to mifepristone, COR108297, COR125281, ORIC-101, PT150; CDK4/6 inhibitors including palbociclib, abemaciclib, ribociclib; HER2 receptor antagonist including but not limited to trastuzumab, neratinib; a mammalian target of rapamycin (mTOR) inhibitor including but not limited to everolimus, temsirolimus.
In a further embodiment of the present disclosure, a pharmaceutical composition comprising one or more compounds of formula (Q) wherein the PTC has the structure of formula I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient or adjuvant is provided. The pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes. In another embodiment, a pharmaceutical composition comprising one or more compounds of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof, further comprises a pharmaceutically acceptable carrier. In one embodiment, a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent. In one embodiment, suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone.
In certain embodiments, the pharmaceutical compositions of the present disclosure may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the pharmaceutical compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the oligonucleotide(s) of the formulation.
For the purposes of this disclosure, the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. Intraarterial and intravenous injection as used herein includes administration through catheters.
The compounds disclosed herein can be formulated in accordance with the routine procedures adapted for desired administration route. Accordingly, the compounds disclosed herein can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The compounds disclosed herein can also be formulated as a preparation for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt). Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. Suitable formulations for each of these methods of administration can be found, for example, in Remington: The Science and Practice of Pharmacy, A. Gennaro, ed., 20th edition, Lippincott, Williams & Wilkins, Philadelphia, Pa.
In certain embodiments, a pharmaceutical composition of the present disclosure is prepared using known techniques, including, but not limited to mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes.
In one embodiment, the present disclosure provides a pharmaceutical composition comprising a compound of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof, as disclosed herein, combined with a pharmaceutically acceptable carrier. In one embodiment, suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions. Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, from about 0.01 to about 0.1 M and preferably 0.05M phosphate buffer or 0.8% saline. Such pharmaceutically acceptable carriers can be aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents suitable for use in the present application include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
Aqueous carriers suitable for use in the present application include, but are not limited to, water, ethanol, alcoholic/aqueous solutions, glycerol, emulsions or suspensions, including saline and buffered media. Oral carriers can be elixirs, syrups, capsules, tablets and the like.
Liquid carriers suitable for use in the present application can be used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compounds. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
Liquid carriers suitable for use in the present application include, but are not limited to, water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also include an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form comprising compounds for parenteral administration. The liquid carrier for pressurized compounds disclosed herein can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
Solid carriers suitable for use in the present application include, but are not limited to, inert substances such as lactose, starch, glucose, methyl-cellulose, magnesium stearate, dicalcium phosphate, mannitol and the like. A solid carrier can further include one or more substances acting as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier can be a finely divided solid which is in admixture with the finely divided active compound. In tablets, the active compound is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active compound. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free flowing form such as a powder or granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropyl methylcellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
Parenteral carriers suitable for use in the present application include, but are not limited to, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous carriers include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose and the like. Preservatives and other additives can also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.
Carriers suitable for use in the present application can be mixed as needed with disintegrants, diluents, granulating agents, lubricants, binders and the like using conventional techniques known in the art. The carriers can also be sterilized using methods that do not deleteriously react with the compounds, as is generally known in the art.
Diluents may be added to the formulations of the present invention. Diluents increase the bulk of a solid pharmaceutical composition and/or combination, and may make a pharmaceutical dosage form containing the composition and/or combination easier for the patient and care giver to handle. Diluents for solid compositions and/or combinations include, for example, microcrystalline cellulose (e.g., AVICEL), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., EUDRAGIT®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
Additional embodiments relate to the pharmaceutical formulations wherein the formulation is selected from the group consisting of a solid, powder, liquid and a gel. In certain embodiments, a pharmaceutical composition of the present invention is a solid (e.g., a powder, tablet, a capsule, granulates, and/or aggregates). In certain of such embodiments, a solid pharmaceutical composition comprising one or more ingredients known in the art, including, but not limited to, starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents.
Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions and/or combinations include acacia, alginic acid, carbomer (e.g., carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, gum tragacanth, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g., KLUCEL), hydroxypropyl methyl cellulose (e.g., METHOCEL), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g., KOLLIDON, PLASDONE), pregelatinized starch, sodium alginate, and starch.
The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition and/or combination. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., AC-DI-SOL and PRIMELLOSE), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., KOLLIDON and POLYPLASDONE), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., EXPLOTAB), potato starch, and starch.
Glidants can be added to improve the flowability of a non-compacted solid composition and/or combination and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and dye. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition and/or combination to reduce adhesion and ease the release of the product from the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition and/or combination of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
Solid and liquid compositions may also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
In certain embodiments, a pharmaceutical composition of the present invention is a liquid (e.g., a suspension, elixir and/or solution). In certain of such embodiments, a liquid pharmaceutical composition is prepared using ingredients known in the art, including, but not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
Liquid pharmaceutical compositions can be prepared using compounds of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv) or (a), or a pharmaceutically acceptable salt or solvate thereof, and any other solid excipients where the components are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
For example, formulations for parenteral administration can contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers can be useful excipients to control the release of active compounds. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration contain as excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylene-9-auryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral administration can also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or citric acid for vaginal administration.
Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition and/or combination an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that may be useful in liquid compositions and/or combinations of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
Liquid pharmaceutical compositions can also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum.
Sweetening agents such as aspartame, lactose, sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar may be added to improve the taste.
Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
A liquid composition can also contain a buffer such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
In one embodiment, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also contain suitable stabilizers or agents that increase the solubility of the pharmaceutical agents to allow for the preparation of highly concentrated solutions.
The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables. Formulations for intravenous administration can comprise solutions in sterile isotonic aqueous buffer. Where necessary, the formulations can also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachet indicating the quantity of active agent. Where the compound is to be administered by infusion, it can be dispensed in a formulation with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water. Where the compound is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
Suitable formulations further include aqueous and non-aqueous sterile injection solutions that can contain antioxidants, buffers, bacteriostats, bactericidal antibiotics and solutes that render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents.
In certain embodiments, a pharmaceutical composition of the present invention is formulated as a depot preparation. Certain such depot preparations are typically longer acting than non-depot preparations. In certain embodiments, such preparations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, depot preparations are prepared using suitable polymeric or hydrophobic materials (for example an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
In certain embodiments, a pharmaceutical composition of the present invention comprises a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.
In certain embodiments, a pharmaceutical composition of the present invention comprises a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80 and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
In certain embodiments, a pharmaceutical composition of the present invention comprises a sustained-release system. A non-limiting example of such a sustained-release system is a semi-permeable matrix of solid hydrophobic polymers. In certain embodiments, sustained-release systems may, depending on their chemical nature, release pharmaceutical agents over a period of hours, days, weeks or months.
Appropriate pharmaceutical compositions of the present disclosure can be determined according to any clinically-acceptable route of administration of the composition to the subject. The manner in which the composition is administered is dependent, in part, upon the cause and/or location. One skilled in the art will recognize the advantages of certain routes of administration. The method includes administering an effective amount of the agent or compound (or composition comprising the agent or compound) to achieve a desired biological response, e.g., an amount effective to alleviate, ameliorate, or prevent, in whole or in part, a symptom of a condition to be treated, e.g., oncology and neurology disorders. In various aspects, the route of administration is systemic, e.g., oral or by injection. The agents or compounds, or pharmaceutically acceptable salts or derivatives thereof, are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperintoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, intraportally, and parenterally. Alternatively or in addition, the route of administration is local, e.g., topical, intra-tumor and peri-tumor. In some embodiments, the compound is administered orally.
In certain embodiments, a pharmaceutical composition of the present disclosure is prepared for oral administration. In certain of such embodiments, a pharmaceutical composition is formulated by combining one or more agents and pharmaceutically acceptable carriers. Certain of such carriers enable pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject. Suitable excipients include, but are not limited to, fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certain embodiments, such a mixture is optionally ground and auxiliaries are optionally added. In certain embodiments, pharmaceutical compositions are formed to obtain tablets or dragee cores. In certain embodiments, disintegrating agents (e.g., cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate) are added.
In certain embodiments, dragee cores are provided with coatings. In certain such embodiments, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to tablets or dragee coatings.
In certain embodiments, pharmaceutical compositions for oral administration are push-fit capsules made of gelatin. Certain of such push-fit capsules comprise one or more pharmaceutical agents of the present invention in admixture with one or more filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In certain embodiments, pharmaceutical compositions for oral administration are soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In certain soft capsules, one or more pharmaceutical agents of the present invention are be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
In certain embodiments, pharmaceutical compositions are prepared for buccal administration. Certain of such pharmaceutical compositions are tablets or lozenges formulated in conventional manner.
In certain embodiments, a pharmaceutical composition is prepared for transmucosal administration. In certain of such embodiments penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
In certain embodiments, a pharmaceutical composition is prepared for administration by inhalation. Certain of such pharmaceutical compositions for inhalation are prepared in the form of an aerosol spray in a pressurized pack or a nebulizer. Certain of such pharmaceutical compositions comprise a propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In certain embodiments using a pressurized aerosol, the dosage unit may be determined with a valve that delivers a metered amount. In certain embodiments, capsules and cartridges for use in an inhaler or insufflator may be formulated. Certain of such formulations comprise a powder mixture of a pharmaceutical agent of the invention and a suitable powder base such as lactose or starch.
In other embodiments the compound of the present disclosure are administered by the intravenous route. In further embodiments, the parenteral administration may be provided in a bolus or by infusion.
In certain embodiments, a pharmaceutical composition is prepared for rectal administration, such as a suppository or retention enema. Certain of such pharmaceutical compositions comprise known ingredients, such as cocoa butter and/or other glycerides.
In certain embodiments, a pharmaceutical composition is prepared for topical administration. Certain of such pharmaceutical compositions comprise bland moisturizing bases, such as ointments or creams. Exemplary suitable ointment bases include, but are not limited to, petrolatum, petrolatum plus volatile silicones, and lanolin and water in oil emulsions. Exemplary suitable cream bases include, but are not limited to, cold cream and hydrophilic ointment.
In certain embodiments, the therapeutically effective amount is sufficient to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.
In certain embodiments, one or more compounds of formula (Q) wherein the PTC has the structure of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (A-I), (B)-(D), (E), (E-I)-(E-VII), (F), (G), (G-I), (G-II), (H), and (H-I) (“formula (I)-(VI) and (A)-(H-I)”), or (a), or a pharmaceutically acceptable salt or solvate thereof are formulated as a prodrug. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically more active form. In certain embodiments, prodrugs are useful because they are easier to administer than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., through oral administration) than is the corresponding active form. In certain instances, a prodrug may have improved solubility compared to the corresponding active form. In certain embodiments, prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, a prodrug is an ester. In certain such embodiments, the ester is metabolically hydrolyzed to carboxylic acid upon administration. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is cleaved upon administration to form the corresponding active form.
In certain embodiments, a prodrug is produced by modifying a pharmaceutically active compound such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, e.g., Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392).
In various aspects, the amount of the PTCs of formula (Q) wherein the PTC has the structure of formula (I)-(VI) and (A)-(H-I), (i)-(iv), or (a), or a pharmaceutically acceptable salt or solvate thereof, or compounds disclosed in Tables A and B, or a pharmaceutically acceptable salt or solvate thereof, can be administered at about 0.001 mg/kg to about 100 mg/kg body weight (e.g., about 0.01 mg/kg to about 10 mg/kg or about 0.1 mg/kg to about 5 mg/kg).
The concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. The agent may be administered in a single dose or in repeat doses. The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. Treatments may be administered daily or more frequently depending upon a number of factors, including the overall health of a patient, and the formulation and route of administration of the selected compound(s). An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
The compounds or pharmaceutical compositions of the present disclosure may be manufactured and/or administered in single or multiple unit dose forms.
Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.
The disclosure now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
Synthetic Preparation
The novel compounds of the present invention can be prepared in a variety of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods as hereinafter described below, together with synthetic methods known in the art of synthetic organic chemistry or variations thereon as appreciated by those skilled in the art.
Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene and Wuts, Protective Groups in Organic Synthesis, 44th. Ed., Wiley & Sons, 2006, as well as in Jerry March, Advanced Organic Chemistry, 4th edition, John Wiley & Sons, publisher, New York, 1992 which are incorporated herein by reference in their entirety.
Compounds of the present invention can be prepared by the literature methods cited in the following text. The following schemes depict established, known syntheses of these scaffolds.
The groups and/or the substituents of the compounds of the present invention can be synthesized and attached to these scaffolds by the literature methods cited in the following text. The following schemes depict the known techniques for accomplishing this joinder.
Compounds of the present invention can be synthesized using the following methods. General reaction conditions are given, and reaction products can be purified by general known methods including crystallization, silica gel chromatography using various organic solvents such as hexane, cyclohexane, ethyl acetate, methanol and the like, preparative high pressure liquid chromatography or preparative reverse phase high pressure liquid chromatography.
Representative Synthesis of PTCs
For synthesis of Compounds in Tables A and B, see PCT/US2019/057034 for procedures. The disclosures of PCT/US2019/057034 are hereby incorporated by reference in their entireties.
To a suspension of 4-[1-[3,5-dichloro-4-(3-chloropropoxy)phenyl]-1-methyl-ethyl]phenol (7) (0.135 g, 0.36 mmol) and Cs2CO3 (0.197 g, 0.6 mmol) in DMF (3 mL) was added (4-methylsulfonyloxazol-5-yl)methyl 4-methylbenzenesulfonate (2) (0.1 g, 0.3 mmol) at 25° C. The mixture was stirred at 60° C. for 6 hours. LCMS showed the reaction was completed. The resulting mixture was poured into H2O (8 mL) and extracted with EtOAc (5 mL×3). The combined organic layers were washed with brine (5 mL×2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give 5-[[4-[1-[3,5-dichloro-4-(3-chloropropoxy)phenyl]-1-methyl-ethyl]phenoxy]methyl]-4-methylsulfonyl-oxazole (A1) (37.9 mg, yield: 23.6%) as yellow oil. HPLC purity (220 nm): 96.25%. 1H NMR (400 MHz, CHCl3-d) δ 7.99 (s, 1H), 7.16-7.10 (m, 4H), 6.94 (d, J=8.82 Hz, 2H), 5.42 (s, 2H), 4.15 (t, J=5.73 Hz, 2H), 3.86 (t, J=6.50 Hz, 2H) 3.18 (s, 3H), 2.28 (quin, J=6.17 Hz, 2H), 1.62 (s, 6H). LCMS (M+23) m/z: calcd 533; found 556.
To a mixture of 4-((4-(2-(3,5-dichloro-4-(3-chloropro poxy)phenyl)propan-2-yl)phenoxy)methyl)-1H-imidazole (6) (80 mg, 0.2 mmol) and TEA (0.1 mL, 0.5 mmol) in DCM (2 mL) was added methanesulfonyl chloride (41 mg, 0.4 mmol) dropwise at 0° C., and the mixture was stirred at 25° C. for 2 hours. TLC showed the reaction was completed. The mixture was diluted with water (20 mL), extracted with DCM (5 mL×3), and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (NH4HCO3) to give 4-((4-(2-(3,5-dichloro-4-(3-chloropropoxy)phenyl)propan-2-yl)phenoxy)methyl)-1-(methyl sulfonyl)-imidazole (A5) (16 mg, yield: 16.6%) as colorless oil. 1H NMR (400 MHz, CHCl3-d) δ=7.99 (d, J=1.3 Hz, 1H), 7.40 (s, 1H), 7.15-7.12 (m, 4H), 6.95-6.90 (m, 2H), 5.05 (s, 2H), 4.15 (t, J=5.7 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 3.30 (s, 3H), 2.31-2.26 (m, 2H), 1.63 (s, 6H). LCMS (220 nm): 95.2%. LCMS (M+1) m/z: calcd 530.1; found 531.0.
To a solution of 3-(1-(4-(2-(3,5-dichloro-4-(3-chloropropoxy)phenyl)propan-2-yl)phenoxy)ethyl)-5-(methylthio)-4H-pyrazole (5) (220 mg, 0.49 mmol) in DCM (5 mL) was added m-CPBA (85% purity, 226 mg, 4.03 mmol) at 0° C. The reaction was stirred at 20° C. for 4 hours. LCMS showed the reaction was completed. The mixture was quenched with saturated aqueous Na2S2O3 (5 mL) and saturated aqueous NaHCO3 (5 mL), then extracted with DCM (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (TFA) to give 2-((4-(2-(3,5-Dichloro-4-(3-chloropropoxy)phenyl)propan-2-yl)phenoxy)methyl)-5-(methylsulfonyl)-1,3,4-oxadiazole (A7) (74 mg, yield: 31.6%) as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ ppm 7.14 (d, J=8.9 Hz, 2H), 7.11 (s, 2H), 6.95 (d, J=8.8 Hz, 2H), 5.35 (s, 2H), 4.15 (t, J=5.73 Hz, 2H), 3.86 (t, J=6.39 Hz, 2H), 3.50 (s, 3H), 2.28 (t, J=6.06 Hz, 2H), 1.63 (s, 6H). LCMS (220 nm): 97%. LCMS M+H+) m/z: calcd 532.04, found 533.1.
A solution of 5-(chloromethyl)-4-methylsulfonyl-oxazole (6) (500 mg, 2.56 mmol), 4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]phenol (11) (919 mg, 2.56 mmol) and Cs2CO3 (1.67 g, 5.11 mmol) in DMF (20 mL) was stirred at 25° C. for 2 hours. Then the resulting solution was stirred at 40° C. for 0.5 hr. The reaction was completed detected by TLC. The reaction was quenched with water (50 mL), and the mixture was extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by MPLC to give 5-[[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]phenoxy]methyl]-4-methylsulfonyl-oxazole (528 mg, yield: 39.8%) as white solid. 1H NMR (400 MHz, CHLOROFORM-d) δ=7.92 (s, 1H), 7.09-7.02 (m, 4H), 6.89-6.83 (m, 2H), 5.34 (s, 2H), 4.18 (t, J=6.4 Hz, 2H), 3.79 (t, J=6.4 Hz, 2H), 3.11 (s, 3H), 1.54 (s, 6H). MS(M+H+) m/z: clcd. 517.0; found 518.1, 540.0.
To a solution of [3-[4-[1-[3,5-dichloro-4-(3-chloropropoxy)phenyl]-1-methyl-ethyl]phenyl]isoxazol-5-yl]methanamine (7) (60 mg, 0.13 mmol) in DCM (3 mL) was added TEA (40 mg, 0.40 mmol) and MsCl (18 mg, 0.16 mmol) under N2 atmosphere at 0° C. The reaction was stirred at 20° C. for 5 hrs. TLC showed the reaction was completed. The mixture was poured into H2O (5 mL) and extracted with DCM (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (TFA) to give N-((3-(4-(2-(3,5-dichloro-4-(3-chloropropoxy)phenyl)propan-2-yl)phenyl)isoxazol-5-yl)methyl) methanesulfonamide (A22) (5 mg, yield: 7.11%) as brown oil. LCMS purity (220 nm): 89.4%. 1H NMR (400 MHz, CHCl3-d) δ=7.73 (br d, J=7.9 Hz, 2H), 7.31 (br d, J=8.2 Hz, 2H), 7.14 (s, 2H), 6.60 (s, 1H), 4.89-4.80 (m, 1H), 4.54 (d, J=6.2 Hz, 2H), 4.16 (t, J=5.6 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 2.99 (s, 3H), 2.33-2.25 (m, 2H), 1.68 (s, 6H). LCMS(M+H+) m/z: clcd. 530.0; found 531.0.
To a mixture of 4-[N-tert-butyl-3,5-dichloro-4-(2-chloroethoxy)anilino]phenol (9) (110 mg, 0.283 mmol) and Cs2CO3 (277 mg, 0.85 mmol) in DMF (5 mL) was added 5-(chloromethyl)-4-methylsulfonyl-oxazole (10) (83 mg, 0.42 mmol). Then the resulting mixture was stirred at 40° C. for 2 hours. LCMS showed the reaction was completed. The mixture was cooled down, quenched with water (5 mL) and extracted with EtAOc (5 mL×3). The combined organic layers were washed with brine (5 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by p-HPLC (TFA) to give the N-tert-butyl-3,5-dichloro-4-(2-chloroethoxy)-N-[4-[(4-methylsulfonyl-oxazol-5-yl)-methoxy]-phenyl]aniline (A31) (36.5 mg, yield: 23.5%) as yellow solid. HPLC purity (220 nm): 91.7%. 1H NMR (400 MHz, CHCl3-d) δ 8.01 (s, 1H), 7.06-7.02 (m, 2H), 6.99-6.94 (m, 2H), 6.73 (s, 2H), 5.41 (s, 2H), 4.17 (t, J=6.4 Hz, 2H), 3.82 (t, J=6.4 Hz, 2H), 3.20 (s, 3H), 1.35 (s, 9H). LCMS (M+Na+) m/z: calcd 546.1; found 569.1.
To a suspension of 5-(chloromethyl)-4-(methylsulfonyl)oxazole (5) (200 mg, 0.5 mmol) and Ag2CO3 (564 mg, 0.2 mmol) in DMF (2 mL) was added 4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)aniline (4) (382 mg, 0.1 mmol), and the mixture was stirred at 65° C. for 2 hours. TLC showed the reaction was completed. The resulting mixture was cooled down, poured into H2O (6 mL), extracted with EtOAc (2 mL×2). The combined organic layers were washed with brine (4 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give 4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)-N-((4-(methylsulfonyl)oxazol-5-yl) methyl)aniline hydrochloride (A32) (20 mg, yield: 3.8%) as white solid. 1H NMR (400 MHz, CHCl3-d) δ 7.85 (s, 1H), 7.16-7.09 (m, 4H), 7.04-6.93 (m, 2H), 4.80 (s, 2H), 4.26 (t, J=6.4 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 3.16 (s, 3H), 1.61 (s, 6H). LCMS (M+H+) m/z: calcd: 516.0; found 517.0.
To a mixture of 5-(1-(4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)phenoxy)ethyl)-4-(methylthio)oxazole (8) (50 mg, 0.1 mmol) was added mCPBA (80% purity, 64 mg, 0.3 mmol) in DCM (3 mL) at 25° C., and the mixture was stirred at the same temperature for 16 hours. LCMS showed the reaction was completed. The reaction was quenched with H2O (5 mL), extracted with EtOAc (6 mL×3). The combined organic layers were washed with brine (3 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by p-HPLC (TFA) 5-(1-(4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)phenoxy)ethyl)-4-(methylsulfonyl)oxazole (21.7 mg, yield: 40.8%) as white solid. HPLC purity (220 nm): 98.5%. 1H NMR (400 MHz, CHCl3-d) δ=7.94 (s, 1H), 7.14-7.03 (m, 4H), 6.92 (d, J=8.9 Hz, 2H), 6.10 (q, J=6.5 Hz, 1H), 4.26 (t, J=6.3 Hz, 2H), 3.86 (t, J=6.3 Hz, 2H), 3.06 (s, 3H), 1.74 (d, J=6.7 Hz, 3H), 1.59 (s, 6H). LCMS (M+H+) m/z: calcd: 531.0; found 532.0.
To a solution of 2-chloro-4-[[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]phenoxy]methyl]oxazole (5) (10 mg, 0.02 mmol) in 1,4-dioxane (0.2 mL) was added methanesulfonamide (2.4 mg, 0.02 mmol), Brettphos Pd G3 (2 mg, w20%) and t-BuONa (3 mg, 0.03 mmol). The mixture was stirred at 80° C. for 10 hours under N2 atmosphere. LCMS showed 5% desired MS and 90% starting material. The resulting 20 reaction mixtures were cooled down and combined. The mixture was filtered and the filtrate concentrated under reduced pressure. The residue was purified by prep-HPLC (TFA) to give N-[[5-bromo-4-[4-[1-[3,5-dichloro-4-(3-chloropropoxy)phenyl]-1-methyl-ethyl]phenyl]oxazol-2-yl]methyl]methanesulfonamide (2 mg, yield: 1.8%) as pale yellow solid. LCMS (220 nm): 85.79%. 1H NMR (400 MHz, CHCl3-d) δ 7.16 (d, J=8.8 Hz, 2H), 7.12 (s, 2H), 7.08 (s, 1H), 6.86 (d, J=8.8 Hz, 2H), 4.86 (s, 2H), 4.27 (t, J=6.4 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 3.09 (s, 3H), 1.64 (s, 6H). LCMS (M+H+) m/z: calcd: 532.04; found 533.0.
A solution of N-[3-[[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]phenoxy]methyl]-1-tetrahydropyran-2-yl-pyrazol-4-yl]methanesulfonamide (9) (70 mg, 0.113 mmol) in HCl/EtOAc (4M, 2 mL) was stirred at 20° C. for 2 hours. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (FA) to give N-[3-[[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]phenoxy]methyl]-1H-pyrazol-4-yl]methanesulfonamide(A40) (11.6 mg, yield: 18.2%) as white solid. 1H NMR (400 MHz, CHCl3-d) δ p pm 7.71 (s, 1H), 7.10-7.17 (m, 4H), 6.89-6.94 (m, 2H), 6.22 (s, 1H), 5.21 (s, 2H), 4.26 (t, J=6.39 Hz, 2H), 3.86 (t, J=6.28 Hz, 2H), 2.90 (s, 3H), 1.62 (s, 6H). LCMS (M+Na+) m/z: calcd: 531.06; found 532.1.
A mixture of tert-butyl N-(4-((4-(1-(3,5-dichloror-4-(2-chloroethoxy)phenyl)-1-methyl-ethyl)phenoxy)methyl)pyrimidin-5-yl)-N-methylsulfonyl-carbamate (6) (50 mg, 0.062 mmol) in DCM (5.0 mL) and TFA (0.5 mL) was stirred at 20° C. for 1 hour. LCMS showed the reaction was completed. The resulting mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (TFA) to give N-(4-((4-(1-(3,5-dichloro-4-(2-chloroethoxy)phenyl)-1-methyl-ethyl)phenoxy)methyl)pyrimidin-5-yl) methanesulfonamide (A41) (8 mg, yield: 23.7%) as yellow oil. 1H NMR (400 MHz, CHCl3-d) δ ppm 9.01 (d, J=4.40 Hz, 2H), 7.81 (br s, 1H), 7.16 (d, J=8.93 Hz, 2H), 7.10 (s, 2H), 6.93 (d, J=8.93 Hz, 2H), 5.36 (s, 2H), 4.26 (t, J=6.36 Hz, 2H), 3.86 (t, J=6.36 Hz, 2H), 3.03 (s, 3H), 1.62 (s, 6H). LCMS (M+H+) m/z: 545.05; found 546.0. HPLC purity(220 nm): 84.4%.
To a solution of 2-(methane-sulfonamido)oxazole-4-carboxylic acid (3) (60 mg, 0.3 mmol) in DMF (3 mL) was added 4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]aniline (4) (104 mg, 0.3 mmol), HATU (133 mg, 0.35 mmol) and TEA (0.12 mL, 0.9 mmol) at 25° C. The mixture was stirred at the same temperature for 3 hours. LCMS showed the reaction was completed, the mixture was quenched with H2O (1 mL), and directly purified by prep-HPLC (TFA), to give N-[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]phenyl]-2-(methanesulfonamido)oxazole-4-carboxamide (A49) (23.2 mg, yield: 14.6%) as white solid. 1H NMR (400 MHz, CHCl3-d) δ 8.44 (s, 1H), 7.91 (s, 1H), 7.56 (d, J=8.8 Hz, 2H), 7.21 (d, J=8.8 Hz, 2H), 7.13 (s, 2H), 4.27 (t, J=6.4 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 3.32 (s, 3H), 1.65 (s, 6H). LCMS (M+H+) m/z: clcd 545.03; found 546.0.
To a mixture of 4-[1-[3,5-dichloro-4-(3,3,3-trifluoro propoxy)phenyl]-1-methyl-ethyl]phenol (3) (40 mg, 0.10 mmol) and 5-(chloromethyl)-4-methylsulfonyl-oxazole (4) (24 mg, 0.12 mmol) in DMF (0.5 mL) was added Cs2CO3 (66 mg, 0.20 mmol) and the mixture was stirred at 25° C. for 16 hours. LCMS showed the reaction was completed. The mixture was poured into water (2 mL) and extracted with EtOAc (5 mL×3). The combined organic layers were washed with brine (5 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by p-TLC to give 5-[[4-[1-[3,5-dichloro-4-(3,3,3-trifluoropropoxy)phenyl]-1-methyl-ethyl]phenoxy]methyl]-4-methylsulfonylo-xazole (A54) (18 mg, yield: 29.9%) as yellow oil. LCMS purity: (220 nm): 93.3%. 1H NMR (400 MHz, CHCl3-d) δ 8.00 (s, 1H), 7.16-7.12 (m, 4H), 6.94 (d, J=8.8 Hz, 2H), 5.42 (s, 2H), 4.22 (t, J=6.8 Hz, 2H), 3.19 (s, 3H), 2.78-2.64 (m, 2H), 1.62 (s, 6H). LCMS (M+NH4+) m/z: calcd 551.1; found 569.0.
To a solution of 2-(2-chloroethoxy)-5-(2-(3-cyano-4-hydroxyphenyl)propan-2-yl)benzonitrile (7) (130 mg, 0.38 mmol) in DMF (2 mL) was added 5-(chloromethyl)-4-(methylsulfonyl)oxazole (G) (75 mg, 0.38 mol) and Cs2CO3 (249 mg, 0.76 mmol) under N2 atmosphere. The reaction was stirred at 0° C. for 3 hours. LCMS showed the reaction was completed. The mixture was diluted with EtOAc (5 mL) and poured into H2O (5 mL). The aqueous phase was extracted with EtOAc (5 mL×2). The combined organic layers were washed with brine (5 mL×4), then dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by prep-HPLC(TFA) to give 2-(2-chloroethoxy)-5-(2-(3-cyano-4-((4-(methylsulfonyl)oxazol-5-yl)methoxy)phenyl)propan-2-yl)benzonitrile (A63) (53 mg, yield: 27.8%) as white solid. LCMS purity (220 nm): 91.1%. 1H NMR (400 MHz, CHCl3-d) δ=8.04 (s, 1H), 7.41 (br s, 2H), 7.39-7.29 (m, 2H), 7.15-7.04 (m, 1H), 6.94-6.85 (d, J=8.9 Hz, 1H), 5.51 (s, 2H), 4.33 (br t, J=6.0 Hz, 2H), 3.87 (br t, J=6.0 Hz, 2H), 3.25 (s, 3H), 1.64 (s, 6H). LCMS (M+H+) m/z: calcd 499.1; found 500.1.
A solution of tert-butyl N-[[2-[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]anilino]oxazol-5-yl]methyl]-N-methylsulfonyl-carbamate (5) (25 mg, 0.04 mmol) in DCM (2 mL) and TFA (0.2 mL) was stirred at 25° C. for 3 hours. LCMS showed the reaction was completed. The mixture was concentrated and purified by prep-HPLC (TFA) to give N-[[2-[4-[1-[3,5-dichloro-4-(2-chloroethoxy)phenyl]-1-methyl-ethyl]anilino]oxazol-5-yl]methyl]methanesulfonamide (4.6 mg, yield: 21.9%) as yellow oil. LCMS purity (220 nm): 86%. 1H NMR (400 MHz, CHCl3-d) δ 7.36-7.33 (m, 2H), 7.25-7.22 (m, 2H), 7.11 (s, 2H), 7.02 (s, 1H), 5.18 (s, 1H), 4.36 (s, 2H), 4.27 (t, J=6.4 Hz, 2H), 3.87 (t, J=6.4 Hz, 2H), 3.00 (s, 3H), 1.64 (s, 6H). LCMS (M+H+) m/z: calcd: 531.0; found 531.6.
2-chloro-4-(chloromethyl)pyrimidine (2): To a mixture of 2-chloro-4-methyl-pyrimidine (50.0 g, 398 mmol) and NCS (77.9 g, 583 mmol) in MeCN (250 mL) was added benzoyl benzenecarboperoxoate (28.3 g, 117 mmol) in portions at 20° C. and the mixture was stirred at 100° C. for 16 hrs under N2 atmosphere. TLC showed most of the starting material consumed and two new spots appeared. The mixture was cooled down to room temperature, poured into water (500 mL) and extracted with EtOAc (200 mL×3). The organic layers were combined and washed with brine (200 mL×2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 2-chloro-4-(chloromethyl) pyrimidine (22 g, yield: 31.2%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ=8.69 (d, J=5.2 Hz, 1H), 7.54 (d, J=5.0 Hz, 1H), 4.61 (s, 2H).
3-chloro-2-(2-chloroethoxy)-5-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propan-2-yl)benzonitrile (4): To a mixture of 3-chloro-2-(2-chloroethoxy)-5-(2-(4-hydroxyphenyl)propan-2-yl)benzonitrile (18.0 g, 51.4 mmol) and 2-chloro-4-(chloromethyl) pyrimidine (10.1 g, 61.7 mmol) in DMF (150 mL) was added Cs2CO3 (33.5 g, 103.4 mmol) at 20° C. and the mixture was stirred at the same temperature for 16 hrs. LCMS showed the reaction was completed. The reaction mixture was poured into H2O (300 mL) and extracted with EtOAc (150 mL×3). The combined organic layers were washed with brine (150 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 3-chloro-2-(2-chloroethoxy)-5-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propan-2-yl)benzonitrile (15.5 g, yield: 63.3%) as white solid. 1H NMR (400 MHz, CDCl3) δ=8.67 (d, J=5.2 Hz, 1H), 7.56 (d, J=5.2 Hz, 1H), 7.45 (d, J=2.4 Hz, 1H), 7.35-7.29 (m, 1H), 7.13 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz, 2H), 5.16 (s, 2H), 4.43 (t, J=6.0 Hz, 2H), 3.88 (t, J=6.0 Hz, 2H), 1.65 (s, 6H).
N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl) pyrimidin-2-yl)methanesulfonamide (A109): To a mixture of 3-chloro-2-(2-chloroethoxy)-5-(2-(4-((2-chloropyrimidin-4-yl)methoxy)phenyl)propan-2-yl)benzonitrile (15.5 g, 32.5 mmol), methane sulfonamide (9.3 g, 97.5 mmol), Cs2CO3 (21.2 g, 65.0 mmol) and Xantphos (1.88 g, 3.25 mmol) in 1,4-dioxane (450 mL) was added Pd2(dba)3 (3.0 g, 3.3 mmol) at 20° C. and the mixture was stirred at 90° C. for 6 hrs under N2 atmosphere. LCMS showed the reaction was completed. The mixture was cooled down to room temperature, poured into water (300 mL) and extracted with EtOAc (300 mL×3). The combined organic layers were washed with brine (300 mL×2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the crude product and then further purified by p-HPLC (TFA) to give N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy) methyl)pyrimidin-2-yl)methanesulfonamide (5.30 g, yield: 30.1%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ=10.02 (br s, 1H), 8.69 (d, J=5.2 Hz, 1H), 7.45 (d, J=2.4 Hz, 1H), 7.34-7.31 (m, 1H), 7.30 (d, J=5.2 Hz, 1H), 7.13 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.8 Hz, 2H), 5.13 (s, 2H), 4.43 (t, J=6.0 Hz, 2H), 3.88 (t, J=6.0 Hz, 2H), 3.47 (s, 3H), 1.65 (s, 6H). LCMS (220 nm): 99.0%. Exact Mass: 534.09; found 535.1, 537.0. See PCT/US2019/057034.
To a mixture of 1,5,5-trimethylimidazolidine-2,4-dione (5) (20 mg, 0.2 mmol) and K2CO3 (70 mg, 0.5 mmol) in DMF (3 mL) was added 1,3-dichloro-2-(2-chloroethoxy)-5-(2-(4-(chloromethyl)phenyl)propan-2-yl)benzene (4) (50 mg, 0.1 mmol) at 25° C. and the mixture was stirred at the same temperature for 2 hours. LCMS showed the reaction was completed. The mixture was poured into H2O (10 mL), extracted with EtOAc (5 mL×2). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give 3-(4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)benzyl)-1,5,5-trimethylimidazolidine-2,4-dione (B2) (20 mg, yield: 31.8%) as colorless oil. LCMS purity (220 nm): 96.1%. 1H NMR (400 MHz, CHCl3-d) δ=7.30-7.25 (m, 1H), 7.28-7.25 (m, 1H), 7.30-7.25 (m, 1H), 7.15-7.10 (m, 2H), 7.10-7.08 (m, 2H), 4.66-4.57 (m, 2H), 4.24 (t, J=6.4 Hz, 2H), 3.89-3.77 (m, 2H), 2.87 (s, 3H), 1.65-1.54 (m, 6H), 1.41-1.34 (m, 6H). LCMS (M+H+) m/z: calcd: 496.1; found 497.1.
To a solution of 3-(4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)benzyl)-5,5-dimethylimidazolidine-2,4-dione (6) ((40 mg, 0.1 mmol) in THF (2 mL) was added Mesyl chloride (0.1 mL, 0.2 mmol) and NaH (60.0%, 6 mg, 0.2 mmol) at 0° C. and the mixture was stirred at 80° C. for 16 hours. TLC showed the reaction was completed. The reaction was quenched with saturated aqueous NH4Cl (10 mL) and extracted with EtOAc (3 mL×2). The combined organic layers were washed with brine (3 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give 3-(4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)benzyl)-5,5-dimethyl-1-(methylsulfonyl)imidazolidine-2,4-dione (5 mg, yield: 10.8%) as yellow oil. LCMS purity (220 nm): 81.8%. 1H NMR (400 MHz, CHCl3-d) δ=7.31-7.28 (m, 2H), 7.20-7.14 (m, 2H), 7.14-7.11 (m, 2H), 4.71-4.65 (m, 2H), 4.27 (t, J=6.4 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 3.38 (s, 3H), 1.76-1.71 (m, 6H), 1.64 (s, 6H). LCMS (M+H+) m/z: calcd: 526, found: 527.
For synthesis of Compounds in Tables C, see WO 2019/226991 for procedures. The disclosures of WO 2019/226991 are hereby incorporated by reference in their entireties.
To a solution of (R)—N-(3-(4-(2-(3,5-dichloro-4-(oxiran-2-ylmethoxy)phenyl)propan-2-yl)phenoxy)-2-oxopropyl)methanesulfonamide (1g) (30 mg, 0.06 mmol, 1.0 eq.) in MeCN (6 mL) was added CeCl3.7H2O (34 mg, 0.09 mmol, 1.5 eq.) and the solution was heated to reflux for 16 hours. The resulting white paste was collected by filtration and washed with ethyl acetate and the clear suspension was concentrated under reduced pressure. The resulting residue was purified by flash silica gel column chromatography (elution: ethyl acetate in hexane) to provide (S)—N-(3-(4-(2-(3,5-dichloro-4-(3-chloro-2-hydroxypropoxy)phenyl) propan-2-yl)phenoxy)-2-oxopropyl)methanesulfonamide (AA51(S)): (13.7 mg, 42.4%) as a colorless oil. LRMS (M+Na+) m/z: calcd 560.05; found 560.0. 1HNMR (400 MHz, DMSO-d6): δ 7.44 (t, J=5.6 Hz, 1H), 7.23 (s, 2H), 7.15 (d, J=8.8 Hz, 2H), 6.84 (d, J=8.8 Hz, 2H), 5.55 (d, J=5.2 Hz, 1H), 4.91 (s, 2H), 4.01-4.10 (m, 3H), 3.96 (d, J=5.6 Hz, 2H), 3.82 (dd, J=4.0, 11.2 Hz, 2H), 3.70 (dd, J=4.0, 11.2 Hz, 2H), 2.93 (s, 3H), 1.60 (s, 6H).
To a solution of (R)—N-(3-(4-(2-(3,5-dichloro-4-(3-CHloropropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide (2a) (25.0 mg, 0.048 mmol, 1.0 eq.) in anhydrous dichloromethane (3 mL) was treated Dess-Martin periodinane (41 mg, 0.096 mmol, 2.0 eq.) at 0° C. for 10 minutes. Then it was warmed to the room temperature for 16 hours. The reaction was quenched by the addition of a saturated solution of ammonium chloride (2 ml) and the mixture was extracted with ethyl acetate (2×30 ml). The combined organic layers were washed with deionized water (2×30 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash silica gel column chromatography (elution: acetate in hexane) to provide N-(3-(4-(2-(3,5-dichloro-4-(3-chloropropoxy)phenyl)propan-2-yl)phenoxy)-2-oxopropyl)methanesulfonamide (AA31) (30 mg, 88% yield) as a colorless oil. LRMS (M+Na+) m/z: calcd 544.06; found 544.2. 1HNMR (400 MHz, DMSO-d6): δ 7.44 (t, J=5.6 Hz, 1H), 7.24 (s, 2H), 7.15 (d, J=8.8 Hz, 2H), 6.85 (d, J=8.8 Hz, 2H), 4.91 (s, 2H), 4.01 (m, 4H), 3.86 (t, J=6.4 Hz, 2H), 2.93 (s, 3H), 2.19 (m, 2H), 1.60 (s, 6H).
Compound (AA55) was synthesized according to Compound (AA31) by using (S)-2,6-dichloro-4-(2-(4-(2-hydroxy-3-(methylsulfonyl)propoxy)phenyl)propan-2-yl)phenol (3d) Yield (94.1%). LRMS (M+Na+) m/z: calcd 529.06; found 529.3. 1HNMR (400 MHz, DMSO-d6): δ 7.24 (s, 2H), 7.15 (d, J=9.2 Hz, 2H), 6.84 (d, J=8.8 Hz, 2H), 4.96 (s, 2H), 4.59 (s, 2H), 4.08 (t, J=6.0 Hz, 2H), 3.86 (t, J=6.0 Hz, 2H), 3.11 (s, 3H), 2.19 (m, 2H), 1.61 (s, 6H).
To a solution of tert-butyl N-(3-(4-(3-(3,5-dichloro-4-(3-chloropropoxy)phenyl)oxetan-3-yl)phenoxy)-2-oxo-propyl)-N-methylsulfonyl-carbamate (60 mg, 0.1 mmol) in DCM (2 mL) was added formic acid (1 mL) and the solution was stirred at 25° C. for 15 min. TLC showed the reaction was completed. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC (HCO2H) to give N-(3-(4-(3-(3,5-dichloro-4-(3-chloropropoxy)phenyl)oxetan-3-yl)phenoxy)-2-oxopropyl)methanesulfonamide (6.7 mg, yield: 13.2%) as colorless oil. LCMS purity (220 nm): 94.5%. 1H NMR (400 MHz, CHCl3-d) δ 7.18-7.10 (m, 4H), 6.93 (br d, J=7.7 Hz, 2H), 5.20 (br d, J=5.1 Hz, 2H), 5.12 (br d, J=5.3 Hz, 2H), 5.05 (br s, 1H), 4.69 (s, 2H), 4.41 (br d, J=4.2 Hz, 2H), 4.21-4.14 (m, 2H), 3.87 (br t, J=5.8 Hz, 2H), 3.01 (s, 3H), 2.30 (br t, J=5.8 Hz, 2H). %). LRMS (M+H+) m/z: calcd 535.0; found 535.
To a solution of 2-bromo-N-[[4-[1-[3,5-dichloro-4-(3-chloropropoxy)phenyl]-1-methyl-ethyl]phenyl]methyl]acetamide (5) (100 mg, 0.20 mol) and Cs2CO3 (321 mg, 0.98 mmol) in DMF (5 mL) was added methanesulfonamide (37.5 mg, 0.39 mmol). Then the resulting solution was stirred at 25° C. for 2 hours. LCMS showed the reaction was completed. The solution was poured into water (5 mL) and the organic layer was separated. The aqueous phase was extracted with EtOAc (3 mL×4). The combined organic layers were washed with brine (4 mL×3), dried over Na2SO4, filtered and concentrated. The crude product was purified by prep-HPLC (TFA) to give the N-[[4-[1-[3,5-dichloro-4-(3-chloropropoxy)phenyl]-1-methyl-ethyl]phenyl]methyl]-2-(methanesulfonamido)acetamide (24.1 mg, yield: 23.4%) as a yellow gum. HPLC purity (220 nm): 98.3%. 1H NMR (400 MHz, CHCl3-d) δ 7.26-7.18 (m, 4H), 7.14 (s, 2H), 6.34 (br s, 1H), 5.02 (br s, 1H), 4.49 (d, J=5.7 Hz, 2H), 4.18 (t, J=5.8 Hz, 2H), 3.92-3.85 (m, 4H), 3.03 (s, 3H), 2.31 (quin, J=6.1 Hz, 2H), 1.66 (s, 6H). LCMS (M+H+) m/z: clcd 522.1; found 523.0.
A solution of tert-butyl (3-(4-(N-(3,5-dichloro-4-(3-chloropropoxy)phenyl)acetamido)phenoxy)-2-oxopropyl)(methylsulfonyl)carbamate (200 mg, 0.2 mmol) in HCl/EtOAc (4 M, 4 mL) was stirred at 25° C. for 15 min. TLC showed the reaction was completed. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give N-(3,5-dichloro-4-(3-chloropropoxy)phenyl)-N-(4-(3-(methylsulfonamido)-2-oxopropoxy)phenyl)acetamide (69 mg, yield: 59.0%) as yellow oil. HPLC purity (220 nm): 93.5%. 1H NMR (400 MHz, CHCl3-d) δ=7.26-7.21 (m, 4H), 7.01-6.92 (m, 2H), 5.05 (br s, 1H), 4.70 (s, 2H), 4.40 (d, J=5.1 Hz, 2H), 4.15 (br s, 2H), 3.85 (t, J=6.4 Hz, 2H), 3.02 (s, 3H), 2.28 (quin, J=6.0 Hz, 2H), 2.10-2.01 (m, 3H). LCMS (M+H+) m/z: clcd: 538.0; found: 539.0.
A solution of tert-butyl (3-((3′,5′-dichloro-4′-(3-chloropropoxy)-[1,1′-biphenyl]-4-yl)oxy)-2-oxopropyl)(methylsulfonyl)carbamate (7) (70.0%, 0.13 g, 0.15 mol) in HCl/EtOAc (2 mL) was stirred at 20° C. for 0.5 hour. LCMS showed the reaction was completed. The solution was concentrated under reduced pressure. The crude product was purified by prep-HPLC (HCl) to give N-(3-((3′,5′-dichloro-4′-(3-chloropropoxy)-[1,1′-biphenyl]-4-yl)oxy)-2-oxopropyl)methanesulfonamide (29 mg, yield: 27.0%) as brown oil. HPLC purity (220 nm): 90.5%. 1H NMR (400 MHz, CHCl3-d) δ=7.51-7.48 (d, J=8.8 Hz, 2H), 7.47 (s, 2H), 7.00-6.96 (d, J=8.6 Hz, 2H), 5.12-4.99 (m, 1H), 4.72 (s, 2H), 4.46-4.37 (d, J=5.2 Hz, 2H), 4.25-4.17 (t, J=5.7 Hz, 2H), 3.96-3.83 (t, J=6.4 Hz, 2H), 3.02 (s, 3H), 2.38-2.25 (m, 2H). LCMS (M+H+) m/z: clcd: 480.0; found 480.0.
A solution of tert-butyl N-(3-(4-(2-(3,5-dichloro-4-(3-chloro-2-(methoxymethoxy)propoxy)phenyl)ethyl)phenoxy)-2-oxo-propyl)-N-methylsulfonyl-carbamate (9) (180 mg, 0.27 mmol) in TFA (2 mL) and DCM (10 mL) was stirred at 20° C. for 3 hours. LCMS showed the reaction was completed. The resulting solution was concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give N-(3-(4-(2-(3, 5-dichloro-4-(3-chloro-2-hydroxy-propoxy)phenyl)ethyl)phenoxy)-2-oxo-propyl)methanesulfonamide (13.9 mg, yield: 9.84%) as white solid. HPLC purity (220 nm): 92%. 1H NMR (400 MHz, CHCl3-d) δ ppm 7.06-7.11 (m, 4H), 6.80-6.86 (m, 2H), 5.02 (br s, 1H), 4.63-4.69 (m, 2H), 4.40 (d, J=5.14 Hz, 2H), 4.23 (br s, 1H), 4.12-4.20 (m, 2H), 3.74-3.90 (m, 2H), 3.00 (s, 3H), 2.83-2.86 (m, 2H), 2.79-2.83 (m, 2H).
A solution of tert-butyl (3-((4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)phenyl)(methyl)amino)-2-oxopropyl) (methylsulfonyl)carbamate (100 mg, 0.2 mmol) in HCl/EtOAc (2 mL) was stirred at 25° C. for 15 min. TLC showed the reaction was completed. The reaction was concentrated under reduced pressure. The residue was purified by prep-HPLC (HCl) to give N-(3-((4-(2-(3,5-dichloro-4-(2-chloroethoxy)phenyl)propan-2-yl)phenyl)(methyl)amino)-2-oxopropyl)methanesulfonamide hydrochloride (7.6 mg, yield: 9.1%) as yellow oil. 1H NMR (400 MHz, CHCl3-d) δ 7.16 (br s, 2H), 7.12 (s, 2H), 6.95 (br s, 2H), 5.70 (br s, 1H), 4.49-4.22 (m, 4H), 4.15-3.81 (m, 4H), 3.18 (br s, 3H), 2.94 (br s, 3H), 1.62 (s, 6H). LCMS (M+H+) m/z: clcd: 520.1; found 521.0.
For synthesis of Compounds in Tables D, see WO 2017/177307 for procedures. The disclosures of WO 2017/177307 are hereby incorporated by reference in their entireties.
To a solution of (S)-4-((4-(2-(3,5-dichloro-4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)methyl)-2,2-dimethyl-1,3-dioxolane (560 mg, 1.2 mmol, 1.0 equiv) in MeCN (12 mL) was added CeCl3.7H2O (1118 mg, 3.0 mmol, 2.5 equiv) and the mixture was heated to reflux for 16 h. The resulting white paste was collected by filtration and washed with ethyl acetate and the clear suspension was concentrated under reduced pressure. The resulting residue was purified by column chromatography to provide the titled compound (512 mg, 92%) as a sticky oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.15-7.12 (m, 4H), 6.86 (d, J=9.0 Hz, 2H), 4.26-4.23 (m, 1H), 4.21-4.15 (m, 2H), 4.15-4.11 (m, 1H), 4.08-4.03 (m, 2H), 3.86 (dd, J=4.8 Hz, 10.8 Hz, 2H), 3.78 (dd, J=6.6 Hz, 12.6 Hz, 2H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=156.76, 149.30, 148.26, 141.84, 128.52, 127.87, 127.67, 114.35, 73.69, 70.48, 69.26, 63.78, 45.55, 42.34, 30.79; ESI-LRMS calcd for [M+Na]+485.1, found 485.4.
Compound 3a was synthesized by a similar procedure used to prepare Compound 1a in Example 27. 1H NMR (400 MHz, DMSO-D6) δ (ppm)=7.39 (s, 1H), 7.30 (dd, J=2.0 Hz, 34.4 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 6.86 (d, J=8.8 Hz, 2H), 5.57-5.54 (m, 1H), 4.91 (d, J=4.8 Hz, 1H), 4.64 (t, J=5.6 Hz, 1H), 4.10-4.08 (m, 1H), 3.98-3.92 (m, 3H), 3.86-3.81 (m, 2H), 3.79-3.76 (m, 1H), 3.71 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.45-3.42 (m, 2H), 1.60 (s, 6H).
To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (15 mg, 0.034 mmol, 1.0 equiv) in anhydrous methanol (2 mL) was added Erbium (III) trifluoromethanesulfonate (2.1 mg, 0.0034 mmol, 0.1 equiv) and the mixture was stirred at room temperature for 40 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (0.5 ml) and the mixture was extracted with ethyl acetate (2×10 ml). The organic layer was washed with deionized water (2×10 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on silica gel (elution: 30% ethyl acetate in hexane to 50% ethyl acetate in hexane) to provide Compound 5a (12.5 mg, 77.1%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.14-7.10 (m, 4H), 6.87 (d, J=6.0 Hz, 2H), 4.26-4.22 (m, 1H), 4.21-4.15 (m, 3H), 4.06-4.01 (m, 2H), 3.87 (dd, J=6.0 Hz, 11.4 Hz, 1H), 3.79 (dd, J=5.4 Hz, 11.4 Hz, 1H), 3.61 (dd, J=4.2 Hz, 9.6 Hz, 1H), 3.57 (dd, J=6.0 Hz, 9.6 Hz, 1H), 3.44 (s, 3H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=156.37, 148.81, 147.69, 141.04, 127.95, 127.25, 127.05, 113.81, 73.13, 73.00, 69.93, 68.58, 68.44, 58.88, 45.00, 41.78, 30.25.
Compound 7a was synthesized by a similar procedure used to prepare Compound 3a in Example 28. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.10 (m, 4H), 6.86 (d, J=8.8 Hz, 2H), 4.25-4.12 (m, 4H), 4.03-3.98 (m, 2H), 3.85 (dd, J=5.2 Hz, 10.8 Hz, 1H), 3.77 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.67-3.53 (m, 3H), 2.83 (s, 1H), 2.57 (s, 1H), 1.62 (s, 6H), 1.18 (d, J=6.0 Hz, 6H).
To a solution of Compound 1a (1 equiv; synthesized according to Example 27) in dichloromethane were successively added triethylamine trihydrofluoride (2 equiv) and XtalFluor-M (2 equiv). After 3 h, the reaction mixture was quenched at room temperature with a 5% aqueous sodium bicarbonate solution and stirred for 15 min, and the resulting mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous magnesium sulfate, and filtered. Solvents were evaporated, and the resulting crude material was purified by silica gel chromatography to provide Compound 8a. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.16-7.14 (m, 4H), 6.87 (d, J=8.4 Hz, 2H), 4.69-4.56 (m, 2H), 4.30-4.22 (m, 2H), 4.22-4.16 (m, 2H), 4.10-4.09 (m, 2H), 3.87 (dd, J=6.0 Hz, 11.4 Hz, 1H), 3.79 (dd, J=5.4 Hz, 10.8 Hz, 1H), 1.64 (s, 6H).
To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-(((R)-oxiran-2-yl)methoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (12.6 mg, 0.028 mmol, 1.0 equiv) in anhydrous MeCN (2 mL) was added Bismuth (III) trifluoromethanesulfonate (1.8 mg, 0.0028 mmol, 0.1 equiv) and the mixture was stirred at room temperature for 40 h. The reaction was quenched by the addition of a saturated solution of ammonium chloride (0.5 ml) and the mixture was extracted with ethyl acetate (2×10 ml). The organic layer was washed with deionized water (2×10 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash column chromatography to provide Compound 9a (8.7 mg, 60.4%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.56 (s, 1H), 7.16-7.14 (m, 4H), 7.04 (s, 1H), 7.01 (s, 1H), 6.86 (d, J=8.4 Hz, 2H), 4.29-4.23 (m, 3H), 4.22-4.13 (m, 3H), 3.98-3.92 (m, 2H), 3.87 (dd, J=6.0 Hz, 11.4 Hz, 1H), 3.79 (dd, J=4.8 Hz, 10.8 Hz, 1H), 1.65 (s, 6H).
Compound 11a was synthesized by a similar procedure used to prepare Compound 9a in Example 32. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.16-7.11 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 4.27-4.13 (m, 4H), 4.07-3.98 (m, 2H), 3.90-3.77 (m, 6H), 2.84-2.80 (m, 2H), 2.73-2.72 (m, 2H), 2.71-2.67 (m, 2H), 1.65 (s, 6H); ESI-LRMS calcd for [M+H]+ 532.1, found 534.6.
Synthesis of (R)-1-amino-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (Compound 12a). To a solution of (R)-1-azido-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (57 mg, 0.117 mmol, 1.0 equiv) in MeCN (6 mL) was added triphenylphosphine (36.7 mg, 0.14 mmol, 1.2 equiv) and the mixture was heated to reflux for 16 h. The reaction was quenched by deionized water (2 ml) and the mixture was extracted with ethyl acetate (2×30 ml). The organic layer was washed with deionized water (2×30 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on Si gel (elution: 2% methanol in dichloromethane to 30% methanol in dichloromethane) to provide Compound 12a (24.3 mg, 44.9%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.12-7.09 (m, 4H), 6.84 (d, J=8.4 Hz, 2H), 4.24-4.21 (m, 1H), 4.17-4.13 (m, 2H), 3.97 (m, 3H), 3.84 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.76 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.00-2.85 (m, 2H), 1.61 (s, 6H); 13C NMR (100 MHz, CDCl3) δ (ppm)=157.00, 149.35, 148.31, 141.60, 128.52, 127.81, 127.61, 114.37, 73.78, 70.47, 70.42, 70.14, 45.65, 44.11, 42.34, 30.25; ESI-LRMS calcd for [M+H]+ 462.1, found 463.9.
Synthesis of N—((R)-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)-2-hydroxypropyl)methanesulfonamide (Compound 13a). To a solution of (R)-1-azido-3-(4-(2-(3,5-dichloro-4-((S)-3-chloro-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (14.3 mg, 0.031 mmol, 1.0 equiv) in anhydrous dichloromethane (3 mL) was treated triethylamine (12.5 mg, 0.124 mmol, 4.0 equiv) and methane sulfonyl chloride (3.6 mg, 0.031 mmol, 1.0 equiv) sequentially at 0° C. for 10 minutes. Then it was warmed to room temperature for 16 hours. The reaction was quenched by the addition of a saturated solution of ammonium chloride (2 ml) and the mixture was extracted with ethyl acetate (2×20 ml). The organic layer was washed with deionized water (2×20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on silica gel (elution: 50% ethyl acetate in hexane to 75% ethyl acetate in hexane) to provide Compound 13a (9.7 mg, 57.9%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ (ppm)=7.15-7.13 (m, 4H), 6.87 (d, J=5.4 Hz, 2H), 4.93-4.90 (m, 1H), 4.26-4.23 (m, 1H), 4.21-4.13 (m, 3H), 4.06-4.01 (m, 2H), 3.87 (dd, J=5.4 Hz, 11.4 Hz, 1H), 3.79 (dd, J=5.4 Hz, 10.8 Hz, 1H), 3.50-3.45 (m, 1H), 3.26-3.31 (m, 1H), 3.03 (s, 3H), 1.64 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=155.94, 148.69, 147.73, 141.57, 127.99, 127.39, 127.05, 113.81, 73.14, 69.92, 68.85, 68.54, 45.19, 44.99, 41.81, 39.98, 30.22.
To a solution of (S)-1-chloro-3-(2,6-dichloro-4-(2-(4-((S)-3-(ethylthio)-2-hydroxypropoxy)phenyl)propan-2-yl)phenoxy)propan-2-ol (14.6 mg, 0.029 mmol, 1.0 equiv) in anhydrous dichloromethane (3 mL) was treated 3-chloroperbenzoic acid (14.0 mg, 0.081 mmol, 2.8 equiv) at 0° C. for 10 minutes. Then it was warmed to room temperature for 3 hours. The reaction was quenched by the addition of a saturated solution of ammonium chloride (2 ml) and the mixture was extracted with ethyl acetate (2×20 ml). The organic layer was washed with saturated NaHCO3 (20 ml), deionized water (2×20 ml), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by gradient flash column chromatography on Si gel (elution: 30% ethyl acetate in hexane to 75% ethyl acetate in hexane) to provide Compound 14a (4.7 mg, 31.0%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ (ppm)=7.18-7.15 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 4.69-4.67 (m, 1H), 4.27-4.15 (m, 3H), 4.10-4.07 (m, 2H), 3.88 (dd, J=5.2 Hz, J=11.2 Hz, 1H), 3.80 (dd, J=5.2 Hz, J=10.8 Hz, 1H), 3.39-3.20 (m, 4H), 1.66 (s, 6H), 1.48 (t, J=7.2 Hz, 3H); ESI-LRMS calcd for [M+Na]+561.1, found 561.5.
Compound 22a was synthesized by a similar procedure used to prepare Compound 1a in Example 27. 1H NMR (400 MHz, DMSO-D6) δ (ppm)=6.97-6.94 (m, 4H), 6.81-6.76 (m, 2H), 5.50 (d, J=4.8 Hz, 1H), 4.86 (s, 1H), 4.61 (s, 1H), 4.06-4.00 (m, 1H), 3.97-3.89 (m, 3H), 3.86-3.76 (m, 3H), 3.69 (dd, J=5.6 Hz, 11.2 Hz, 1H), 3.50-3.44 (m, 2H), 2.10 (s, 6H), 1.55 (s, 6H); 13C NMR (100 MHz, DMSO-D6) δ (ppm)=155.14, 154.74, 143.23, 142.75, 129.32, 129.23, 125.66, 125.62, 125.22, 125.16, 111.28, 111.16, 70.67, 70.02, 69.48, 69.32, 63.43, 55.50, 47.53, 31.42, 16.86, 16.79.
Ac2O (128 mg, 1.26 mmol, 6.0 equiv.), Et3N (127 mg, 1.26 mmol, 6.0 equiv.) and DMAP (26 mg, 0.21 mmol, 1.0 equiv.) were added to a solution of Compound 5a (100 mg, 0.21 mmol, 1.0 equiv., see Example 29) in anhydrous DCM (5 mL) at room temperature and the resultant mixture was stirred at the same temperature overnight. The mixture was diluted with EtOAc (30 mL) and the organic layer was washed with water (15 mL) and brine (15 mL). The organic layer was further dried over anhydrous MgSO4 and evaporated under reduced pressure. The crude was loaded onto a silica gel column and eluted with Hexane/EtOAc (13/1 to 6/1) to give 111 mg of the titled compound as colorless oil (yield: 95.0%). 1H NMR (600 MHz, CHLOROFORM-d) δ 7.11-7.12 (m, 2H), 7.09-7.11 (m, 2H), 6.82-6.87 (m, 2H), 5.32-5.35 (m, 1H), 5.28-5.32 (m, 1H), 4.18-4.26 (m, 2H), 4.09-4.16 (m, 2H), 3.97 (dd, J=5.14, 11.74 Hz, 1H), 3.88 (dd, J=5.14, 11.74 Hz, 1H), 3.66 (dd, J=2.20, 4.40 Hz, 2H), 3.40 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H), 1.61 (s, 6H). 13C NMR (151 MHz, CHLOROFORM-d) δ 170.8, 170.4, 156.9, 149.4, 148.4, 141.8, 128.7, 127.9, 127.7, 114.5, 71.9, 71.1, 70.9, 66.4, 59.6, 42.7, 42.4, 30.9, 21.4, 21.2.
Acetic Anhydride (4.1 mg, 0.04 mmol, 4.0 equiv) was added to a solution of Compound 5a (5.0 mg, 0.01 mmol, 1.0 equiv, see Example 29), DMAP (0.1 mg, 0.001 mmol, 0.1 equiv) and Et3N (4.1 mg, 0.04 mmol, 4.0 equiv) in anhydrous dichloromethane (1 mL). The resulting solution was stirred overnight at room temperature. Dichloromethane was removed under reduced pressure and the residue was purified by column chromatography to afford the title compound as a colorless oil (5.8 mg, 98.6%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.11-7.08 (m, 4H), 6.83 (d, J=8.8, 2H), 5.35-5.26 (m, 2H), 4.26-4.17 (m, 2H), 4.16-4.07 (m, 2H), 3.96 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.86 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.66-3.61 (m, 2H), 3.38 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 1.60 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.80, 170.45, 156.96, 149.41, 148.39, 141.80, 128.69, 127.90, 127.70, 114.54, 71.91, 71.12, 70.54, 66.44, 59.62, 42.73, 42.43, 30.90, 21.38, 21.18; ESI-LRMS calcd for [M+H]+ 561.1, found 561.1.
Compound 7aA was synthesized by a similar procedure used to prepare Compound 5aA in Examples 38 by using Compound 7a prepared according to Example 30. Compound 7aA was obtained as a colorless oil (6.4 mg, 96.2%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.12-7.08 (m, 4H), 6.85 (d, J=8.8, 2H), 5.36-5.30 (m, 1H), 5.28-5.22 (m, 1H), 4.27-4.09 (m, 4H), 3.97 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.71-3.57 (m, 3H), 2.14 (s, 3H), 2.09 (s, 3H), 1.61 (s, 6H), 1.15 (dd, J=2.0 Hz, 6.0 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.16, 169.78, 156.42, 148.77, 147.72, 141.03, 128.02, 127.20, 127.03, 113.91, 71.97, 71.25, 70.98, 70.30, 66.01, 65.72, 42.06, 41.76, 30.24, 21.60, 21.54, 20.74, 20.52; ESI-LRMS calcd for [M+Na]+611.1, found 611.1.
Compound 14aA was synthesized by a similar procedure used to prepare Compound 5aA in Examples 38 by using Compound 14a prepared according to Example 35. Compound 14aA was obtained as a colorless oil (3.4 mg, 97.3%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.08 (m, 4H), 6.84 (d, J=8.8, 2H), 5.63-5.57 (m, 1H), 5.36-5.30 (m, 1H), 4.29-4.18 (m, 4H), 3.97 (dd, J=5.2 Hz, 12.0 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.54-3.40 (m, 2H), 3.10 (q, J=7.2 Hz, 2H), 2.14 (s, 3H), 2.12 (s, 3H), 1.61 (s, 6H), 1.44 (t, J=7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.41, 170.16, 158.50, 154.94, 142.86, 142.39, 128.70, 128.03, 127.66, 114.48, 71.87, 71.46, 67.79, 67.05, 52.48, 48.82, 42.69, 42.44, 30.86, 21.15, 20.90, 6.80; ESI-LRMS calcd for [M+Na]+645.1, found 645.1.
Compound 11aA was synthesized by a similar procedure used to prepare Compound 5aA in Examples 38 by using Compound 11a prepared according to Example 33. Compound 11aA was obtained as a colorless oil (6.8 mg, 97.6%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.14-7.07 (m, 4H), 6.83 (d, J=8.8, 2H), 5.72-5.70 (m, 1H), 5.36-5.30 (m, 1H), 4.47-4.40 (m, 1H), 4.39-4.32 (m, 1H), 4.29-4.14 (m, 4H), 3.99-3.94 (m, 3H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.58-3.37 (m, 4H), 2.97 (m, 2H), 2.23 (s, 3H), 2.14 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.54, 170.37, 156.02, 149.12, 148.39, 142.61, 128.67, 128.06, 127.60, 114.34, 71.81, 70.90, 67.26, 65.89, 63.60, 58.52, 53.17, 52.58, 42.64, 42.40, 30.78, 29.87, 21.56, 21.11; ESI-LRMS calcd for [M+H]+ 616.1, found 616.1.
Compound 9aA was synthesized by a similar procedure used to prepare Compound 5aA in Examples 38 by using Compound 9a prepared according to Example 32. Compound 9aA was obtained as a colorless oil (5.6 mg, 93.6%). 1H NMR (400 MHz, CDCl3) δ (ppm)=9.40 (s, 1H), 7.39 (s, 1H), 7.20 (s, 1H), 7.14-7.10 (m, 4H), 6.82 (d, J=8.4, 2H), 5.50 (m, 1H), 5.35-5.31 (m, 1H), 4.78-4.70 (m, 2H), 4.27-4.18 (m, 4H), 3.96 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.21, 169.67, 155.72, 148.93, 142.61, 136.02, 128.53, 127.97, 127.46, 121.62, 120.13, 114.19, 71.66, 70.76, 69.72, 65.27, 49.70, 42.49, 42.26, 30.65, 20.96, 20.91; ESI-LRMS calcd for [M+H]+ 597.1, found 597.1.
Compound 13aA was synthesized according to Examples 38 by using Compound 13a. Compound 13aA was obtained as a colorless oil (6.0 mg, 100%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.08 (m, 4H), 6.82 (d, J=8.4, 2H), 5.47-5.42 (m, 1H), 5.36-5.30 (m, 1H), 4.29-4.07 (m, 6H), 3.97 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 3.33 (s, 3H), 2.44 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=171.33, 170.47, 170.29, 156.42, 149.13, 148.29, 142.17, 128.58, 127.88, 127.54, 114.33, 71.74, 70.82, 70.36, 67.19, 46.69, 42.66, 42.57, 42.31, 30.73, 24.49, 21.07, 20.03; ESI-LRMS calcd for [M+H]+ 666.1, found 666.1.
Compound 8aA was synthesized according to Examples 38 by using Compound 8a prepared according to Example 31. Compound 8aA was obtained as a colorless oil (5.8 mg, 95.9%). 1H NMR (400 MHz, CDCl3) δ (ppm)=7.13-7.10 (m, 4H), 6.84 (d, J=8.8 Hz, 2H), 5.39-5.29 (m, 2H), 4.79-4.71 (m, 1H), 4.67-4.59 (m, 1H), 4.27-4.18 (m, 2H), 4.16-4.14 (m, 2H), 3.97 (dd, J=5.2 Hz, 11.6 Hz, 1H), 3.87 (dd, J=5.6 Hz, 11.6 Hz, 1H), 2.14 (s, 3H), 2.13 (s, 3H), 1.61 (s, 6H); 13C NMR (150 MHz, CDCl3) δ (ppm)=170.58, 170.46, 156.65, 149.33, 148.43, 142.14, 128.73, 127.99, 127.70, 114.48, 82.13, 80.99 (d, J=513.0 Hz), 71.92, 70.98, 70.77, 70.64 (d, J=19.5 Hz), 65.19, 65.15 (d, J=6.0 Hz), 42.73, 42.46, 30.91, 21.22, 21.19; ESI-LRMS calcd for [M+H]+ 549.1, found 549.1.
Compound 1aA was synthesized according to Examples 38 by using Compound 1a prepared according to Example 27. Compound 1aA was obtained as a colorless oil (63.0 mg, 97.1%). 1H NMR (600 MHz, CDCl3) δ (ppm)=7.14-7.11 (m, 4H), 6.85 (d, J=12.0 Hz, 2H), 5.39-5.33 (m, 2H), 4.45 (dd, J=4.2 Hz, 12.0 Hz, 1H), 4.32 (dd, J=6.0 Hz, 12.0 Hz, 1H), 4.26 (dd, J=4.8 Hz, 10.2 Hz, 1H), 4.22 (dd, J=4.8 Hz, 10.2 Hz, 1H), 4.13-4.12 (m, 2H), 3.98 (dd, J=5.4 Hz, 12.0 Hz, 1H), 3.89 (dd, J=5.4 Hz, 12.0 Hz, 1H), 2.16 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 1.63 (s, 6H); 13C NMR (150 MHz, CDCl3) δ(ppm)=170.21, 169.90, 169.77, 156.07, 148.66, 147.76, 141.40, 128.04, 127.28, 127.02, 113.88, 71.24, 70.31, 69.30, 65.55, 62.10, 42.05, 41.77, 30.23, 20.56, 20.50, 20.35; ESI-LRMS calcd for [M+Na]+611.1, found 611.0.
General Synthesis of Protac
A Protac of formula PLM-LI-PTC, or their pharmaceutically acceptable salts can be prepared by the general approaches described herein, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to one skilled in the art. Covalent bond between PLM and LI and between PTC and LI can be formed via chemistries commonly known to one skilled in the art, including but not limited to, amide formation, ester formation, carbamate formation, urea formation, ether formation, amine formation and various C—C and C═C bond formations.
In one embodiment, the PTC can have a chemical group suitable as a leaving group and the linker LI has a chemical group suitable as a nucleophile (Scheme 1).
In Scheme 1, LG can be any leaving group commonly known to person skilled in the art, including but not limited to halogen and sulfonates (e.g., tosylate, mesylate). In Scheme 1, Nu-H can be any nucleophile commonly known to person skilled in the art including but not limited to —OH and —NH2. In Scheme 1, R3 can be a chemical group that would be useful in forming a covalent bond with the PLM. In one embodiment, R3 is protected by a commonly known protecting group such that it does not interfere with the reaction of forming a covalent bond between PTC and LI.
In Scheme 2, LG can be any leaving group commonly known to person skilled in the art, including but not limited to halogen and sulfonates (e.g., tosylate, mesylate). In Scheme 2, electrophile can be any group commonly known to person skilled in the art, including but not limited to carboxylic acid. In Scheme 2, Nu-H can be any nucleophile commonly known to person skilled in the art including but not limited to —OH and —NH2. In one embodiment, when W is an electrophile, an amide or an ester bond formation, or the like, can be performed. In Scheme 2, R3 can be a chemical group that would be useful in forming a covalent bond with the PLM. In one embodiment, R3 is protected by a commonly known protecting group such that it does not interfere with the reaction of forming a covalent bond between PTC and LI.
Schemes 1 and 2 represents examples of means and positions of the covalent bond formation between PTC and LI but is not meant to be limiting examples. Further, in preparation of the protac molecules of the present disclosure, the covalent bond between PLM and LI can be formed first followed by bond formation between LI and PTC.
Scheme 3 demonstrates one way of forming a bond between the linker LI and PLM. The PLM shown in Scheme 3 is an example of a VHL. In Scheme 3, leaving group can be any group commonly known to person skilled in the art, including but not limited to halogen and sulfonates (e.g., tosylate, mesylate). In Scheme 3, electrophile can be any group commonly known to person skilled in the art, including but not limited to carboxylic acid. In Scheme 3, primary amine group is acting as a nucleophile to form a bond between the linker and the PLM. In one embodiment, in Scheme 3, PTC-Linker-R3 can be examples from Schemes 1 and 2.
tert-Butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)pentyl) oxy)propoxy)acetate (3): To a solution of tert-butyl 2-(3-((5-hydroxypentyl)oxy)propoxy) acetate (2.0 g, 7.3 mmol) and 3-chloro-2-hydroxy-5-(2-(4-hydroxyphenyl)propan-2-yl) benzonitrile (2.1 g, 7.3 mmol) in THF (30 mL) was added PPh3 (2.9 g, 10.9 mmol) and DIAD (2.1 mL, 10.9 mmol) at 0° C. under N2 atmosphere. The mixture was stirred at 25° C. for 1 h. TLC showed the reaction was completed. The resulting mixture was poured into water (100 mL), extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)pentyl)oxy) propoxy)acetate (2.2 g, yield: 55.7%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ=7.41 (d, J=2.4 Hz, 1H), 7.32 (d, J=2.4 Hz, 1H), 7.08-7.00 (m, 2H), 6.82-6.74 (m, 2H), 4.18 (t, J=6.4 Hz, 2H), 3.96 (s, 2H), 3.61 (t, J=6.4 Hz, 2H), 3.53 (t, J=6.4 Hz, 2H), 3.45 (t, J=6.4 Hz, 2H), 1.88 (sxt, J=6.4 Hz, 4H), 1.68-1.56 (m, 10H), 1.48 (s, 9H).
tert-Butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylthio)pyrimidin-5-yl)methoxy) phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetate (5): To a solution of tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-hydroxyphenyl) propan-2-yl)phenoxy) pentyl)oxy)propoxy) acetate (3.0 g, 5.5 mmol) and Cs2CO3 (3.2 g, 9.8 mmol) in DMF (30 mL) was added (2-(methylthio)pyrimidin-5-yl)methyl methanesulfonate (1.5 g, 6.6 mmol) at 25° C. The mixture was stirred at the same temperature for 16 hrs. TLC showed the reaction was completed. The mixture was poured into water (50 mL), extracted with EtOAc (40 mL×2). The combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by MPLC to give tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylthio)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl) oxy)propoxy)acetate (1.5 g, yield: 39.9%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ=8.61 (s, 2H), 7.42 (d, J=2.2 Hz, 1H), 7.30 (d, J=2.2 Hz, 1H), 7.13 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz, 2H), 4.99 (s, 2H), 4.18 (t, J=6.4 Hz, 2H), 3.96 (s, 2H), 3.61 (t, J=6.4 Hz, 2H), 3.53 (t, J=6.4 Hz, 2H), 3.46 (t, J=6.4 Hz, 2H), 2.59 (s, 3H), 1.94-1.84 (m, 4H), 1.73-1.54 (m, 10H), 1.48 (s, 9H).
tert-Butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonyl)pyrimidin-5-yl)methoxy) phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetate (6): To a solution of tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylthio)pyrimidin-5-yl) methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetate (1.5 g, 2.2 mmol) in THF (10 mL) and water (10 mL) was added oxone (4.0 g, 6.6 mmol). The mixture was stirred at 25° C. for 16 hrs. TLC showed the reaction was completed. The reaction mixture was poured into saturated aqueous Na2SO3 (40 mL), extracted with EtOAc (30 mL×2), the combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC to give tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonyl)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl) phenoxy)pentyl)oxy)propoxy) acetate (1.5 g, yield: 95.5%) as white solid. 1H NMR (400 MHz, CDCl3) δ=9.02 (s, 2H), 7.42 (d, J=2.2 Hz, 1H), 7.29 (d, J=2.2 Hz, 1H), 7.16 (d, J=8.6 Hz, 2H), 6.92 (d, J=8.6 Hz, 2H), 5.21 (s, 2H), 4.22-4.15 (m, 2H), 3.96 (s, 2H), 3.61 (t, J=6.4 Hz, 2H), 3.53 (t, J=6.4 Hz, 2H), 3.45 (t, J=6.4 Hz, 2H), 3.39 (s, 3H), 1.94-1.84 (m, 4H), 1.71-1.57 (m, 10H), 1.48 (s, 9H).
tert-Butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl) methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetate (7): To a solution of tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonyl)pyrimidin-5-yl)methoxy) phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetate (1.5 g, 2.1 mmol) in MeCN (20 mL) was added MsNH2 (597 mg, 6.3 mmol) and Cs2CO3 (2.1 g, 6.3 mmol). The mixture was stirred at 25° C. for 16 hrs. LCMS showed the reaction was completed. The residue was poured into H2O (40 mL), extracted with EtOAc (20 mL×2), the combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido) pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy) acetate (1.10 g, yield: 71.8%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ=8.70 (br s, 2H), 7.42 (d, J=2.4 Hz, 1H), 7.30 (d, J=2.4 Hz, 1H), 7.13 (br d, J=8.6 Hz, 2H), 6.89 (br d, J=8.6 Hz, 2H), 4.98 (br s, 2H), 4.18 (t, J=6.6 Hz, 2H), 3.96 (s, 2H), 3.61 (t, J=6.4 Hz, 2H), 3.53 (t, J=6.4 Hz, 2H), 3.48-3.37 (m, 5H), 3.11 (s, 1H), 1.93-1.86 (m, 4H), 1.71-1.58 (m, 10H), 1.48 (s, 9H).
2-(3-((5-(2-Chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetic acid (8): To a solution of tert-butyl 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl) methoxy)phenyl) propan-2-yl)phenoxy)pentyl)oxy)propoxy) acetate (1.0 g, 1.5 mmol) in DCM (10 mL) was added TFA (2 mL) and the mixture was stirred at 25° C. for 4 hrs. LCMS showed the reaction was completed. The residue was concentrated under reduced pressure to give 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetic acid (800 mg, yield: 87.3%) as yellow oil. 1H NMR (400 MHz, DMSO-d6) δ=8.72 (s, 2H), 7.60 (d, J=2.3 Hz, 1H), 7.54 (d, J=2.3 Hz, 1H), 7.19 (d, J=8.9 Hz, 2H), 6.97 (br d, J=8.9 Hz, 2H), 5.05 (s, 2H), 4.12 (t, J=6.4 Hz, 2H), 3.96 (s, 2H), 3.48 (t, J=6.4 Hz, 2H), 3.41 (t, J=6.4 Hz, 2H), 3.38-3.32 (m, 5H), 2.91 (s, 1H), 1.81-1.68 (m, 4H), 1.63 (s, 6H), 1.57-1.49 (m, 4H).
(2S,4R)-1-((S)-2-(2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide: To a solution of 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl) oxy)propoxy)acetic acid (200 mg, 0.3 mmol), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (144 mg, 0.3 mmol), EDCI (68 mg, 0.4 mmol) and HOBT (54 mg, 0.4 mmol) in DCM (2 mL) was added DIEA (0.1 mL, 0.6 mmol) and the mixture was stirred at 25° C. for 16 hrs. LCMS showed the reaction was completed. The mixture was poured into H2O (8 mL), extracted with DCM (4 mL×2), and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (FA) to give (2S,4R)-1-((S)-2-(2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (19.8 mg, yield: 5.84%) as white solid. 1H NMR (400 MHz, DMSO-d6) δ=9.04 (s, 1H), 8.73 (s, 2H), 8.38 (br d, J=7.4 Hz, 1H), 7.66 (d, J=2.4 Hz, 1H), 7.60 (d, J=2.4 Hz, 1H), 7.50-7.39 (m, 5H), 7.24 (d, J=8.8 Hz, 2H), 7.02 (d, J=8.8 Hz, 2H), 5.16 (br s, 1H), 5.09 (s, 2H), 4.94 (q, J=7.6 Hz, 1H), 4.60 (d, J=9.4 Hz, 1H), 4.53 (t, J=8.0 Hz, 1H), 4.33 (br s, 1H), 4.18 (t, J=6.4 Hz, 2H), 3.97 (s, 2H), 3.68-3.56 (m, 5H), 3.50 (brt, J=6.4 Hz, 3H), 3.47-3.40 (m, 7H), 2.66-2.59 (m, 4H), 2.52 (s, 3H), 2.25 (s, 6H), 2.15-2.05 (m, 1H), 1.90-1.76 (m, 6H), 1.68 (s, 6H), 1.63-1.53 (m, 4H), 0.99 (s, 9H). LCMS (220 nm): 95.0%, Exact Mass: 1143.1; found: 1144.3/1146.4.
tert-Butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)pentyl) oxy)acetate (3): To a solution of tert-butyl 2-((5-hydroxypentyl)oxy)acetate (1) (1.50 g, 6.87 mmol) and 3-chloro-2-hydroxy-5-(2-(4-hydroxyphenyl)propan-2-yl)benzonitrile (2) (1.98 g, 6.87 mmol) in THF (20 mL) was added PPh3 (2.71 g, 10.3 mmol) and DIAD (2.03 mL, 10.3 mmol) at 0° C. under N2 atmosphere. The mixture was stirred at 25° C. for 16 hrs. TLC showed the starting material was consumed. The reaction mixture was poured into water (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (10 mL×3), filtered and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography to give tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)pentyl) oxy)acetate (3) (80.0% purity, 450 mg, yield: 28.6%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 7.45 (d, J=2.4 Hz, 1H) 7.31 (d, J=2.4 Hz, 1H) 7.04 (d, J=8.8 Hz, 2H) 6.78 (d, J=8.4 Hz, 2H) 5.42 (s, 1H) 4.18 (t, J=6.4 Hz, 2H) 3.96 (s, 2H) 3.55 (t, J=6.4 Hz, 2H) 3.46 (m, 1H) 1.86-1.93 (m, 2H) 1.68-1.73 (m, 2H) 1.63 (s, 6H) 1.48 (s, 9H).
(2-(methylthio) pyrimidin-5-yl) methyl methanesulfonate (4A): To a solution of (2-methylsulfanylpyrimidin-5-yl)methanol (500 mg, 3.2 mmol) and TEA (0.669 mL, 0.48 mmol) in DCM (4 mL) was added MsCl (440 mg, 3.84 mmol) dropwise at 0° C. The mixture was stirred at the same temperature for 15 min. TLC showed the reaction was completed and the resulting mixture was quenched with water (10 mL) and extracted with DCM (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give (2-(methylthio) pyrimidin-5-yl) methyl methanesulfonate (4A) (0.6 g, yield: 80.0%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ ppm 9.46 (d, J=2.4 Hz, 1H) 8.70 (d, J=2.4 Hz, 1H) 5.93 (s, 2H) 2.83 (s, 3H) 2.24 (s, 3H).
tert-Butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylthio)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetate (5): To a solution of tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)pentyl)oxy)acetate (3) (1.25 g, 2.56 mmol) and Cs2CO3 (2.50 g, 7.68 mmol) in DMF (15 mL) was added (2-(methylthio) pyrimidin-5-yl) methyl methanesulfonate (4A) (600 mg, 2.56 mmol). The mixture was stirred at 25° C. for 16 hrs. LCMS showed the starting material was consumed. The solution was quenched with water (15 mL) and extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (15 mL×4), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by silica gel column to give tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylthio)pyrimidin-5-yl)methoxy)phenyl) propan-2-yl)phenoxy)pentyl)oxy)acetate (5) (1.08 g, yield: 67.3%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.60 (s, 2H) 7.42 (d, J=2.4 Hz, 1H) 7.30 (d, J=2.4 Hz, 1H) 7.13 (d, J=8.8 Hz, 2H) 6.90 (d, J=8.4 Hz, 2H) 4.99 (s, 2H) 4.19 (t, J=6.4 Hz, 2H) 3.56 (t, J=6.4 H.z, 2H) 2.59 (s, 3H) 1.87-1.94 (m, 2H) 1.65-1.74 (m, 2H) 1.63-1.64 (m, 8H) 1.49 (s, 9H).
tert-Butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonyl) pyrimidin-5-yl)methoxy) phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetate (6): To a solution of tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylthio)pyrimidin-5-yl)methoxy)phenyl) propan-2-yl)phenoxy)pentyl)oxy)acetate (5) (1.08 g, 1.72 mmol) in THF (10 mL) and water (10 mL) was added Oxone (2.65 g, 4.31 mmol). The mixture was stirred at 25° C. for 16 hrs. LCMS showed the reaction was completed. The reaction was quenched with water (10 mL) and extracted with EtOAc (10 mL×3), the combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by silica gel column to give tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonyl)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetate (6) (0.410 g, yield: 36.1%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ ppm 9.02 (s, 2H) 7.42 (d, J=2.4 Hz, 1H) 7.29 (d, J=2.4 Hz, 1H) 7.16 (d, J=8.8 Hz, 2H) 6.92 (d, J=9.2 Hz, 2H) 5.21 (s, 2H) 4.19 (t, J=6.4 Hz, 2H) 3.96 (s, 2H) 3.56 (t, J=6.0 Hz, 2H) 3.39 (s, 3H) 1.88-1.91 (m, 2H) 1.70-1.74 (m, 2H) 1.60-1.65 (m, 8H) 1.49 (s, 9H).
tert-Butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido) pyrimidin-5-yl)methoxy) phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetate (7): To a solution of tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonyl)pyrimidin-5-yl)methoxy) phenyl)propan-2-yl) phenoxy)pentyl)oxy)acetate (6) (190 mg, 2.83 mmol) in CH3CN (3 mL) was added MsNH2 (80.6 mg, 0.85 mmol) and Cs2CO3 (276 mg, 0.85 mmol) at 20° C. The mixture was stirred for 16 hrs at 20° C. LCMS showed the reaction was completed and the resulting mixture was quenched with H2O (10 mL) and EtOAc (10 mL×2). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetate (7) (160 mg, yield: 82.4%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.68 (s, 2H) 7.42 (d, J=2.4 Hz, 1H) 7.29 (d, J=2.4 Hz, 1H) 7.14 (d, J=8.8 Hz, 2H) 6.90 (d, J=8.8 Hz, 2H) 5.02 (s, 2H) 4.19 (t, J=6.4 Hz, 2H) 3.96 (s, 2H) 3.56 (t, J=6.4 Hz, 2H) 3.49 (s, 3H) 1.88-1.92 (m, 2H) 1.70-1.72 (m, 2H) 1.69 (s, 6H) 1.60-1.65 (m, 2H) 1.49 (s, 9H).
2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetic acid (8): A mixture of tert-butyl 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy) phenyl)propan-2-yl)phenoxy) pentyl)oxy)acetate (7) (150 mg, 0.23 mmol) in DCM (3 mL) was added TFA (0.50 mL) and stirred at 20° C. for 2 hrs. TLC showed most of the starting materiel consumed and ˜50% of desired product. The mixture was concentrated under reduced pressure to give 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl) propan-2-yl)phenoxy) pentyl) oxy)acetic acid (8) (140 mg, yield: 99%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.71 (s, 2H) 7.42 (d, J=2.4 Hz, 1H) 7.31 (d, J=2.4 Hz, 1H) 7.13 (d, J=8.8 Hz, 2H) 6.90 (d, J=8.8 Hz, 2H) 5.03 (s, 2H) 4.20 (t, J=6.4 Hz, 2H) 4.11 (s, 2H) 3.63 (t, J=6.0 Hz, 2H) 3.48 (s, 3H) 1.88-1.93 (m, 2H) 1.67-1.75 (m, 4H) 1.65 (s, 6H).
(2S, 4R)-1-((S)-2-(2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide: To a solution of 2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido) pyrimidin-5-yl)methoxy)phenyl) propan-2-yl)phenoxy)pentyl) oxy)acetic acid (8) (100 mg, 0.16 mmol), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (9) (114 mg, 0.19 mmol), EDC HCl (31.1 mg, 0.16 mmol) and HOBT (24.8 mg, 0.16 mmol) in DCM (2 mL) was added DIEA (0.139 mL, 0.81 mmol) and the mixture was stirred at 25° C. for 16 hrs. LCMS showed the reaction was completed. The mixture was poured into H2O (5 mL) and extracted with DCM (5 mL×3), and the combined organic layers were washed with brine (5 mL×2), dried over Na2SO4, filtered and concentrated in vacuum to give the crude. The crude was purified by p-HPLC (FA) to give (2S, 4R)-1-((S)-2-(2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl) methoxy)phenyl)propan-2-yl) phenoxy)pentyl)oxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (57.6 mg, yield: 29.9%) as white solid. 1H NMR (400 MHz, CDCl3) δ ppm 9.53 (d, J=9.6 Hz, 1H) 8.87 (s, 1H) 8.72 (s, 2H) 7.43-7.51 (m, 5H) 7.29 (d, J=2.0 Hz, 1H) 7.13 (d, J=8.8 Hz, 2H) 6.89 (d, J=8.8 Hz, 2H) 5.56-5.61 (m, 1H) 5.02 (s, 2H) 4.51-4.68 (m, 4H) 4.17 (t, J=6.4 Hz, 2H) 3.92-4.03 (m, 4H) 3.55 (d, J=6.4 Hz, 1H) 3.46-3.53 (m, 2H) 3.13 (s, 3H) 2.99-3.02 (m, 1H) 2.98 (s, 6H) 2.53 (s, 3H) 2.27-2.29 (m, 1H) 1.86-1.97 (m, 3H) 1.69-1.74 (m, 2H) 1.65 (s, 6H) 1.04 (s, 9H) LCMS (220 nm): 95.36%, Exact Mass: 1085.4, Founded: 1086.4.
To a solution of 2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy) acetic acid (200 mg, 0.3 mmol), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (144 mg, 0.3 mmol), EDCI (68 mg, 0.4 mmol) and HOBT (55 mg, 0.4 mmol) in DCM (2 mL) was added DIEA (0.1 mL, 0.6 mmol) and the mixture was stirred at 25° C. for 16 hrs. LCMS showed the reaction was completed. The mixture was poured into H2O (8 mL), extracted with DCM (4 mL×2), and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by prep-HPLC (FA) to give (2S,4R)-1-((S)-2-(2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-5-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetamido)-3,3-dimethyl butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carbox-amide (13.0 mg, yield: 4.03%) as white solid. 1H NMR (400 MHz, DMSO-d6) δ=8.99-8.94 (m, 1H), 8.67 (s, 2H), 8.60 (br t, J=5.8 Hz, 1H), 7.60 (d, J=2.2 Hz, 1H), 7.54 (d, J=2.2 Hz, 1H), 7.45-7.31 (m, 5H), 7.18 (d, J=8.8 Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 5.15 (br s, 1H), 5.03 (s, 2H), 4.56 (d, J=9.6 Hz, 1H), 4.48-4.32 (m, 3H), 4.30-4.22 (m, 1H), 4.10 (t, J=6.4 Hz, 2H), 3.92 (s, 2H), 3.69-3.58 (m, 2H), 3.54 (br t, J=6.4 Hz, 2H), 3.45 (br t, J=6.4 Hz, 2H), 3.37 (br t, J=6.2 Hz, 2H), 3.31 (br s, 6H), 2.46-2.43 (m, 3H), 2.14-2.02 (m, 1H), 1.97-1.85 (m, 1H), 1.82-1.68 (m, 4H), 1.63 (s, 6H), 1.57-1.44 (m, 4H), 1.02-0.85 (m, 9H). LCMS (220 nm): 96.2%, Exact Mass: 1086.4; found: 1087.1/1089.2.
tert-Butyl 2-(3-(5-hydroxypentoxy)propoxy)acetate (21B): To a solution of tert-butyl 2-(3-(5-benzyloxypentoxy)propoxy)acetate (2A) (3.60 g, 11.7 mmol) in MeOH (108 mL) was added Pd/C (1000 purity, 1.50 g, 12.1 mmol) at 20° C. The mixture was stirred at 40° C. for 16 hrs under H2 balloon (˜15 psi). LCMS showed the reaction was completed. The mixture was filtered by Celite, the filtrate was concentrated under reduced pressure to give tert-butyl 2-(3-(5-hydroxypentoxy)propoxy)acetate (21B) (3.20 g, yield: 86.7% o) as white oil. 1H NMR (400 MHz, CDCl3) δ ppm 3.96 (s, 2H) 3.63-3.68 (m, 2H) 3.61 (t, J=6.4 Hz, 2H) 3.53 (t, J=6.4 Hz, 2H) 3.44 (t, J=6.4 Hz, 2H) 1.89 (quin, J=6.4 Hz, 2H) 1.55-1.65 (m, 5H) 1.49 (s, 9H) 1.43-1.46 (m, 1H).
tert-Butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-hydroxyphenyl)-1-methyl-ethyl)phenoxy) pentoxy)propoxy)acetatete (3): To a solution of tert-butyl 2-(3-(5-hydroxypentoxy) propoxy)acetate (2B) (2.0 g, 9.16 mmol) and 3-chloro-2-hydroxy-5-(1-(4-hydroxyphenyl)-1-methyl-ethyl)benzonitrile (1) (2.64 g, 9.16 mmol) in THF (20 mL) was added PPh3 (3.62 g, 13.7 mmol) and DIAD (2.71 mL, 13.7 mmol) at 0° C. under N2 atmosphere. The mixture was stirred at 25° C. for 16 hrs under N2. TLC showed the reaction was completed. The solution was poured into water (40 mL), extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography (petroleum ether: ethyl acetate=6:1-2:1) to give tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-hydroxyphenyl)-1-methyl-ethyl)phenoxy)pentoxy) propoxy)acetate (3) (5.5 g, yield: 95%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 7.41 (d, J=2.0 Hz, 1H), 7.31 (d, J=2.0 Hz, 1H), 7.04 (d, J=8.8 Hz, 2H), 6.78 (d, J=8.4 Hz, 2H), 5.70 (s, 1H), 4.17 (t, J=6.4 Hz, 2H), 3.96 (s, 2H), 3.60 (t, J=6.4 Hz, 2H), 3.53 (t, J=6.4 Hz, 2H), 3.45 (t, J=6.4 Hz, 2H), 1.88 (sxt, J=6.4 Hz, 4H) 1.56-1.67 (m, 10H), 1.48 (s, 9H).
tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-5-yl) methoxy)phenyl)ethyl) phenoxy)pentoxy)propoxy)acetate (5): To a solution of tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-hydroxyphenyl)-1-methyl-ethyl)phenoxy)pentoxy)propoxy) acetate (3) (2.0 g, 3.66 mmol) in DMF (20 mL) was added 5-(chloromethyl)-2-methylsulfanyl-pyrimidine hydrochloride (774 mg, 3.76 mmol) and Cs2CO3 (4.77 g, 14.6 mmol) at 20° C. under N2. The mixture was stirred at 20° C. for 16 hrs under N2. LCMS showed the starting material consumed. The reaction mixture was poured into water (20 mL), extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (10 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether:ethyl acetate=6:1-2:1) to give tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-5-yl)methoxy)phenyl)ethyl)phenoxy)pentoxy) propoxy)acetate (5) (1.28 g, yield: 46.0%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.54 (d, J=4.2 Hz, 1H), 7.42 (d, J=2.4 Hz, 1H), 7.30 (d, J=2.0 Hz, 1H), 7.22 (d, J=4.2 Hz, 1H), 7.12 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz, 2H), 5.09 (s, 2H), 4.17 (t, J=6.8 Hz, 2H), 3.96 (s, 2H), 3.61 (t, J=6.4 Hz, 2H), 3.53 (t, J=6.4 Hz, 2H), 3.45 (t, J=6.4 Hz, 2H), 2.59 (s, 3H), 1.83-1.93 (m, 4H), 1.57-1.72 (m, 10H), 1.48 (s, 9H).
tert-Butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-4-yl)methoxy)phenyl)ethyl)phenoxy)pentoxy)propoxy) acetate (6): To a solution of tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-4-yl)methoxy)phenyl) ethyl)phenoxy)pentoxy)propoxy)acetate (5) (1.28 g, 1.87 mmol) in THF (13 mL) and H2O (13 mL) was added Oxone (3.45 g, 5.61 mmol) at 20° C. The mixture was stirred for 16 hrs at 20° C. under N2. LCMS showed the starting material consumed. The reaction mixture was poured into water (20 mL), extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-4-yl)methoxy)phenyl)ethyl) phenoxy)pentoxy)propoxy)acetate (6) (1.22 g, yield: 73.3%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.94 (d, J=4.2 Hz, 1H), 7.86 (d, J=4.2 Hz, 1H), 7.43 (d, J=2.4 Hz, 1H), 7.29 (d, J=2.0 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 6.91 (d, J=9.2 Hz, 2H), 5.30 (s, 2H), 4.18 (t, J=6.4 Hz, 2H), 3.96 (s, 2H), 3.61 (t, J=6.4 Hz, 1H), 3.53 (t, J=6.4 Hz, 2H), 3.45 (t, J=6.4 Hz, 2H), 3.40 (s, 3H), 1.83-1.93 (m, 4H), 1.57-1.69 (m, 10H), 1.48 (s, 9H).
tert-Butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl) methoxy)phenyl)-1-methyl-ethyl)phenoxy)pentoxy)propoxy)acetate (7): To a solution of tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfonylpyrimidin-4-yl)methoxy)phenyl)ethyl)phenoxy)pentoxy)propoxy)acetate (6) (1.22 g, 1.70 mmol) in DMF (13 mL) was added Methanesulfonamide (567 mg, 5.96 mmol) and Cs2CO3 (1.94 g, 5.96 mmol) at 20° C. The mixture was stirred at 20° C. for 16 hrs. LCMS showed the reaction was completed. The solution was poured into water (20 mL), extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl)phenoxy)pentoxy) propoxy)acetate (7) (820 mg, yield: 65.8%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.64 (d, J=4.2 Hz, 1H) 7.42 (d, J=2.4 Hz, 1H) 7.28-7.30 (m, 2H) 7.12 (d, J=8.8 Hz, 2H) 6.90 (d, J=8.8 Hz, 2H) 5.11 (s, 2H) 4.18 (t, J=6.4 Hz, 2H) 3.96 (s, 2H) 3.61 (t, J=6.4 Hz, 2H) 3.53 (t, J=6.4 Hz, 2H) 3.40-3.48 (m, 4H) 2.05 (s, 3H) 1.82-1.95 (m, 4H) 1.56-1.68 (m, 10H) 1.48 (s, 9H).
2-(3-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy) phenyl)-1-methyl-ethyl)phenoxy)pentoxy) acetic acid (8): To a solution of tert-butyl 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl)phenoxy)pentoxy)propoxy)acetate (7) (500 mg, 0.684 mmol) in DCM (5 mL) was added TFA (2.5 mL) at 20° C., and the mixture were stirred at 25° C. for 2 hrs. TLC showed the reaction was completed. The solution was concentrated under reduced pressure. The residue was dissolved with DCM (5 mL), and added water (2 mL). The aqueous layers were extracted with DCM (2 mL×3). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl)phenoxy) pentoxy) acetic acid (8) (350 mg, yield: 75.8%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.62 (d, J=4.8 Hz, 1H), 7.42 (d, J=2.4 Hz, 1H), 7.28-7.30 (m, 2H), 7.12 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz, 2H), 5.11 (s, 2H), 4.19 (t, J=6.4 Hz, 2H), 4.09 (s, 2H), 3.70 (t, J=5.6 Hz, 2H), 3.62 (t, J=5.6 Hz, 2H), 3.51 (br t, J=6.8 Hz, 2H), 3.47 (s, 3H), 1.83-1.95 (m, 6H), 1.66 (m, 9H).
(2S,4R)-1-((S)-2-(2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide: To a solution of 2-(3-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl) henoxy)pentoxy) propoxy)acetic acid (8) (100 mg, 0.148 mmol), (2S,4R)-1-((2S)-2-amino-3,3-dimethyl-butanoyl)-N-((1R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxy-pyrrolidine-2-carboxamide (72.2 mg, 0.148 mmol), EDC HCl (34.1 mg, 0.178 mmol) and HOBT (27.2 mg, 0.178 mmol) in DCM (1.5 mL) was added DIEA (0.0507 mL, 0.296 mmol) and the mixture was stirred at 25° C. for 16 hrs. LCMS showed the starting material consumed and the desired was observed. The mixture was poured into H2O (3 mL), extracted with DCM (2 mL×2), and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by prep-HPLC (NH4HCO3) to give (2S,4R)-1-((S)-2-(2-(3-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)propoxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (18.1 mg, yield: 10.1%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.68 (s, 1H), 8.60 (d, J=5.2 Hz, 1H), 7.70 (br d, J=5.2 Hz, 1H), 7.42 (d, J=2.0 Hz, 1H), 7.39 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 7.30 (d, J=2.0 Hz, 1H), 7.25 (d, J=5.2 Hz, 1H), 7.22 (br d, J=8.4 Hz, 1H), 7.12 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz, 2H), 5.09 (s, 2H), 4.90 (dt, J=10.4, 4.8 Hz, 1H), 4.78 (t, J=8.0 Hz, 1H), 4.54 (d, J=8.4 Hz, 1H), 4.50 (br s, 1H), 4.11-4.22 (m, 3H), 3.96 (s, 2H), 3.62 (t, J=6.4 Hz, 3H), 3.52 (t, J=6.4 Hz, 2H), 3.39-3.49 (m, 5H), 2.59-2.70 (m, 1H), 2.53 (s, 3H), 2.36-2.49 (m, 2H), 2.25 (s, 6H), 2.06-2.19 (m, 1H), 1.80-1.95 (m, 4H), 1.50-1.73 (m, 11H), 1.09 (s, 9H) LCMS (220 nm): 95.4%, Exact Mass: 1143.5; found: 1144.4/1145.4.
tert-Butyl 2-(5-(2-chloro-6-cyano-4-(1-(4-hydroxyphenyl)-1-methyl-ethyl)phenoxy) pentoxy)acetate (3): To a solution of tert-butyl 2-(5-hydroxypentoxy)acetate (1) (2.0 g, 9.16 mmol) and 3-chloro-2-hydroxy-5-(1-(4-hydroxyphenyl)-1-methyl-ethyl)benzonitrile (2) (2.64 g, 9.16 mmol) in THF (20 mL) was added PPh3 (3.62 g, 13.7 mmol) and DIAD (2.71 mL, 13.7 mmol) at 0° C. under N2 atmosphere. The mixture was stirred at 25° C. for 16 hrs. TLC showed the reaction was completed. The solution was poured into water (40 mL), extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (20 mL×2), filtered and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography (20:1-3:1) to give tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-(4-hydroxyphenyl)-1-methyl-ethyl)phenoxy)pentoxy)acetate (3) (4.5 g, yield: 80.5%) as yellow oil.
2-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-4-yl)methoxy)phenyl) ethyl)phenoxy)pentoxy)acetate (5): To a solution of tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-(4-hydroxyphenyl)-1-methyl-ethyl)phenoxy)pentoxy)acetate (3) (4.0 g, 8.20 mmol) and 4-(chloromethyl)-2-methylsulfanyl-pyrimidine; hydrochloride (4) (1.90 g, 9.02 mmol) in DMF (40 mL) was added Cs2CO3 (6.68 g, 20.5 mmol) at 20° C. The mixture was stirred at 20° C. for 16 hrs. LCMS showed the reaction was completed. The solution was poured into water (40 mL), extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (60 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was combined with another batch of EXP-19-HR0311 and purified by silica gel column to give tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-4-yl)methoxy) phenyl) ethyl)phenoxy)pentoxy)acetate (5) (2.74 g, yield: 53.4%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.53 (d, J=5.2 Hz, 1H) 7.41 (d, J=2.4 Hz, 1H) 7.29 (d, J=2.0 Hz, 1H) 7.21 (d, J=5.2 Hz, 1H) 7.10 (dd, J=6.8, 2.0 Hz, 2H) 6.89 (dd, J=6.8, 2.0 Hz, 2H) 5.09 (s, 2H) 4.18 (t, J=6.8 Hz, 2H) 3.96 (s, 2H) 3.56 (t, J=6.8 Hz, 2H) 2.59 (s, 3H) 1.90 (quin, J=7.00 Hz, 2H) 1.67-1.77 (m, 2H) 1.57-1.66 (m, 8H) 1.49 (s, 9H).
2-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfonylpyrimidin-4-yl)methoxy)phenyl) ethyl)phenoxy)pentoxy)acetate (6): To a mixture of tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfanylpyrimidin-4-yl)methoxy)phenyl)ethyl)phenoxy)pentoxy)acetate (5) (2.70 g, 4.31 mmol) in THF (30 mL) and H2O (30 mL) was added Oxone (7.95 g, 12.9 mmoL) at 20° C. and the mixture was stirred at 30° C. for 16 hrs. LCMS showed the reaction was completed. The solution was poured into water (40 mL), extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (90 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfonylpyrimidin-4-yl)methoxy)phenyl)ethyl)phenoxy)pentoxy)acetate (6) (2.55 g, yield: 89.9%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.94 (d, J=5.2 Hz, 1H) 7.85 (d, J=5.2 Hz, 1H) 7.42 (d, J=2.4 Hz, 1H) 7.29 (d, J=2.4 Hz, 1H) 7.15 (d, J=8.8 Hz, 2H) 6.91 (d, J=8.8 Hz, 2H) 5.30 (s, 2H) 4.19 (t, J=6.4 Hz, 2H) 3.96 (s, 2H) 3.56 (t, J=6.8 Hz, 2H) 3.39 (s, 3H) 1.90 (quin, J=7.0 Hz, 2H) 1.68-1.77 (m, 2H) 1.59-1.67 (m, 8H) 1.49 (s, 9H).
tert-Butyl 2-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl) methoxy)phenyl)-1-methyl-ethyl)phenoxy)pentoxy)acetate (7): To a solution of tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-methyl-1-(4-((2-methylsulfonylpyrimidin-4-yl)methoxy)phenyl)ethyl) phenoxy)pentoxy)acetate (6) (2.55 g, 3.87 mmol) and Methanesulfonamide (1.11 g, 11.6 mmol) in CH3CN (30 mL) was added Cs2CO3 (3.79 g, 11.6 mmol) at 20° C. The mixture was stirred at 20° C. for 16 hrs. LCMS showed the reaction was completed. The solution was poured into water (30 mL), extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column to give tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl)phenoxy) pentoxy) acetate (7) (1.39 g, yield: 53.3%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ ppm 9.0 (br s, 1H) 8.65 (d, J=5.2 Hz, 1H) 7.42 (d, J=2.0 Hz, 1H) 7.28-7.32 (m, 2H) 7.13 (d, J=8.8 Hz, 2H) 6.90 (d, J=8.8 Hz, 2H) 5.11 (s, 2H) 4.18 (t, J=6.8 Hz, 2H) 3.96 (s, 2H) 3.56 (t, J=6.4 Hz, 2H) 3.48 (s, 3H) 1.84-1.95 (m, 2H) 1.67-1.77 (m, 2H) 1.59-1.67 (m, 8H) 1.49 (s, 9H).
2-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl)phenoxy)pentoxy)acetic acid (8): To a solution of tert-butyl 2-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl) phenoxy)pentoxy)acetate (7) (1.0 g, 1.49 mmol) in DCM (10 mL) was added TFA (2 mL) and the mixture was stirred at 25° C. for 6 hrs. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure. Then the crude was purified by p-HPLC (NH4HCO3) to give 2-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl) methoxy) phenyl)-1-methyl-ethyl)phenoxy)pentoxy)acetic acid (8) (0.26 g, yield: 24.1%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ ppm 8.62 (d, J=5.2 Hz, 1H) 7.42 (d, J=2.0 Hz, 1H) 7.27-7.30 (m, 3H) 7.12 (d, J=8.8 Hz, 2H) 6.89 (d, J=8.8 Hz, 2H) 5.11 (s, 2H) 4.19 (t, J=6.0 Hz, 2H) 4.11 (s, 2H) 3.63 (t, J=6.4 Hz, 2H) 3.47 (s, 3H) 1.89 (quin, J=6.8 Hz, 2H) 1.67-1.79 (m, 4H) 1.62-1.66 (m, 7H)
(2S,4R)-1-((S)-2-(2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy)acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide: To a solution of 2-(5-(2-chloro-6-cyano-4-(1-(4-((2-(methanesulfonamido)pyrimidin-4-yl)methoxy)phenyl)-1-methyl-ethyl)phenoxy)pentoxy)acetic acid (8) (100 mg, 0.162 mmol), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (79.0 mg, 0.162 mmol), HOBT (24.8 mg, 0.162 mmol) in DCM (2 mL) was added DIEA (0.139 mL, 0.810 mmol) and EDC HCl (0.0311 g, 0.162 mmol) at 20° C., then the mixture was stirred at 25° C. for 16 hrs. LCMS showed the reaction was completed. The mixture was poured into H2O (5 mL), extracted with DCM (2 mL×3), and the combined organic layers were was washed with brine (2 mL×2), dried over Na2SO4, filtered and concentrated in vacuo to give the crude. The crude was purified by p-HPLC (HCl) to give (2S,4R)-1-((S)-2-(2-((5-(2-chloro-6-cyano-4-(2-(4-((2-(methylsulfonamido)pyrimidin-4-yl)methoxy)phenyl)propan-2-yl)phenoxy)pentyl)oxy) acetamido)-3,3-dimethylbutanoyl)-N—((R)-2-(dimethylamino)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)-4-hydroxypyrrolidine-2-carboxamide (97.0% purity, 21.3 mg, yield: 11.7%) as yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.10 (br s, 1H) 9.29 (br d, J=8.4 Hz, 1H) 9.06 (s, 1H) 8.63 (d, J=5.0 Hz, 1H) 7.46-7.66 (m, 6H) 7.34 (d, J=5.6 Hz, 1H) 7.10-7.24 (m, 3H) 6.97 (br d, J=8.4 Hz, 2H) 6.58 (s, 1H) 5.35-5.51 (m, 1H) 5.13 (s, 2H) 4.48-4.61 (m, 5H) 4.33 (br s, 2H) 4.13 (br t, J=6.4 Hz, 2H) 3.94 (s, 2H) 3.58-3.74 (m, 2H) 3.41-3.56 (m, 4H) 3.35 (s, 3H) 2.83-3.04 (m, 6H) 2.47 (s, 3H) 2.01-2.17 (m, 1H) 1.74-1.90 (m, 3H) 1.46-1.69 (m, 9H) 0.94 (s, 9H) LCMS (220 nm): 97.0%. Exact Mass: 1085.4; found: 1086.4/1087.4.
3-Chloro-2-(3-chloropropoxy)-5-(2-(4-hydroxyphenyl)propan-2-yl)benzonitrile (2): To a solution of 3-chloro-2-hydroxy-5-[1-(4-hydroxyphenyl)-1-methyl-ethyl]benzonitrile (2.00 g, 6.26 mmol) in THF (20 mL) was added 3-chloropropan-1-ol (0.591 g, 6.26 mmol), (E)-1-tert-butyl 2-isopropyl diazene-1,2-dicarboxylate (1.85 mL, 9.38 mmol) at 0° C. The reaction was stirred at 20° C. for 4 hrs under N2. LCMS showed the reaction was completed. The mixture was quenched with water (20 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by MPLC to give 3-chloro-2-(3-chloropropoxy)-5-(2-(4-hydroxyphenyl)propan-2-yl)benzonitrile (2.20 g, yield: 86.9%) as brown oil. 1H NMR (400 MHz, CDCl3) δ=7.43 (d, J=2.4 Hz, 1H), 7.33 (d, J=2.4 Hz, 1H), 7.06 (d, J=2.4 Hz, 2H), 6.79 (d, J=2.0 Hz, 2H), 4.33 (t, J=5.2 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 2.32-2.29 (m, 2H), 1.64 (s, 6H).
3-Chloro-2-(3-chloropropoxy)-5-(2-(4-hydroxyphenyl)propan-2-yl)benzonitrile (3): To a solution of 3-chloro-2-(3-chloropropoxy)-5-[1-(4-hydroxyphenyl)-1-methyl-ethyl]benzonitrile (1.10 g, 2.72 mmol) in DMF (10 mL) was added Cs2CO3 (1.77 g, 5.44 mmol), 4-(chloromethyl)-2-methylsulfanyl-pyrimidine (0.828 g, 4.74 mmol) at 20° C. The reaction was stirred at 20° C. for 16 hrs under N2. LCMS showed the reaction was completed. The mixture was quenched with water (20 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by silica gel column (PE:EtOAc=20:1-3:1) to give 3-chloro-2-(3-chloropropoxy)-5-(2-(4-((2-(methylthio)pyrimidin-4-yl) methoxy)phenyl) propan-2-yl)benzonitrile (90.0% purity, 1.10 g, yield: 72.5%) as brown oil. 1H NMR (400 MHz, CDCl3) δ=8.54 (s, 1H), 7.44 (d, J=2.0 Hz, 1H), 7.32 (d, J=2.4 Hz, 1H), 7.21 (d, J=5.2 Hz, 1H), 7.11 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz, 2H), 5.09 (s, 2H), 4.34 (t, J=5.6 Hz, 2H), 3.86 (t, J=6.0 Hz, 2H), 2.59 (s, 3H), 2.32-2.29 (m, 2H), 1.65 (s, 6H).
3-Chloro-2-(3-chloropropoxy)-5-(2-(4-((2-(methylsulfonyl)pyrimidin-4-yl)methoxy) phenyl)propan-2-yl)benzonitrile (4): To a solution of 3-chloro-2-(3-chloropropoxy)-5-[1-methyl-1-[4-[(2-methylsulfanylpyrimidin-4-yl)methoxy]phenyl]ethyl]benzonitrile (90.0%, 1.10 g, 1.97 mmol) in THF (10 mL)/water (10 mL) was added Oxone (3.03 g, 4.93 mmol) at 0° C. The reaction was stirred at 20° C. for 16 hrs under N2. LCMS showed the reaction was completed. The mixture was quenched with aq.Na2SO3 (20 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 3-chloro-2-(3-chloropropoxy)-5-(2-(4-((2-(methylsulfonyl)pyrimidin-4-yl)methoxy)phenyl)propan-2-yl)benzonitrile (90.0% purity, 1.10 g, yield: 94.0%) as brown oil. 1H NMR (400 MHz, CDCl3) δ=8.94 (d, J=5.2 Hz, 1H), 7.85 (d, J=5.2 Hz, 1H), 7.44 (d, J=2.4 Hz, 1H), 7.30 (d, J=2.4 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 6.92 (d, J=8.8 Hz, 2H), 5.29 (s, 2H), 4.34 (t, J=5.6 Hz, 2H), 3.86 (t, J=6.4 Hz, 2H), 3.39 (s, 3H), 2.32-2.29 (m, 2H), 1.65 (s, 6H).
N-(4-((4-(2-(3-Chloro-4-(3-chloropropoxy)-5-cyanophenyl)propan-2-yl)phenoxy) methyl) pyrimidin-2-yl)methanesulfonamide (5): To a solution of 3-chloro-2-(3-chloropropoxy)-5-[1-methyl-1-[4-[(2-methylsulfonylpyrimidin-4-yl)methoxy]phenyl]ethyl]benzonitrile (90.0% purity, 1.10 g, 0.185 mmol) in MeCN (10 mL) was added Cs2CO3 (1.81 g, 0.556 mmol) and methanesulfonamide (0.529 g, 0.556 mmol) into the reaction at 20° C. The reaction was stirred at 20° C. for 16 hrs under N2. LCMS showed the reaction was completed. The mixture was quenched with water (20 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by silica gel column (PE:EtOAc=20:1-1:1) to give N-(4-((4-(2-(3-chloro-4-(3-chloropropoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (90.0% purity, 2.10 g, yield: 74.6%) as brown oil. 1H NMR (400 MHz, CDCl3) δ=8.38 (s, 1H), 7.40 (d, J=1.6 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H), 6.90 (d, J=9.2 Hz, 2H), 6.82 (d, J=7.6 Hz, 3H), 4.91 (s, 2H), 4.32 (t, J=5.6 Hz, 2H), 3.84 (t, J=6.0 Hz, 2H), 3.07 (s, 3H), 2.31-2.25 (m, 2H), 1.59 (s, 6H).
N-(4-((4-(2-(4-(3-Azidopropoxy)-3-chloro-5-cyanophenyl)propan-2-yl)phenoxy)methyl) pyrimidin-2-yl)methanesulfonamide (6): To a solution of N-[4-[[4-[1-[3-chloro-4-(3-chloropropoxy)-5-cyano-phenyl]-1-methyl-ethyl]phenoxy]methyl]pyrimidin-2-yl]methanesulfonamide (99.3% purity, 0.200 g, 0.361 mmol) in DMF (2 mL) was added 18-Crown-6 (0.0287 g, 0.108 mmol), NaN3 (0.0705 g, 1.08 mmol) at 20° C. The reaction was stirred at 80° C. for 4 hrs under N2. LCMS showed the reaction was completed. The mixture was quenched with water (10 mL) and extracted with EtOAC (5 mL×3). The combined organic layers were washed with water (20 mL×4), dried over Na2SO4, filtered and concentrated under reduced pressure to give N-(4-((4-(2-(4-(3-azidopropoxy)-3-chloro-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (90.0% purity, 0.170 g, 0.275 mmol, yield: 76.1%) as brown oil. 1H NMR (400 MHz, CDCl3) δ=9.34 (s, 1H), 8.66 (d, J=5.2 Hz, 1H), 7.44 (d, J=2.4 Hz, 1H), 7.31 (d, J=2.0 Hz, 1H), 7.12 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz, 2H), 5.12 (s, 2H), 4.26 (t, J=5.6 Hz, 2H), 3.66 (t, J=6.8 Hz, 2H), 3.47 (s, 3H), 2.14-2.07 (m, 2H), 1.64 (s, 6H).
N-(4-((4-(2-(3-chloro-5-cyano-4-(3-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)-1H-1,2,3-triazol-1-yl)propoxy)phenyl)propan-2-yl)phenoxy)methyl) pyrimidin-2-yl)methanesulfonamide: To a solution of 2-(2,6-dioxo-3-piperidyl)-4-(prop-2-ynylamino)isoindoline-1,3-dione (0.143 g, 0.459 mmol) in THF (2 mL) was added N-[4-[[4-[1-[4-(3-azidopropoxy)-3-chloro-5-cyano-phenyl]-1-methyl-ethyl]phenoxy]methyl]pyrimidin-2-yl]methanesulfonamide (0.170 g, 0.306 mmol), CuI (0.0291 g, 0.153 mmol), DIEA (0.105 mL, 0.611 mmol) at 20° C. The reaction was stirred at 20° C. for 4 hrs under N2. LCMS showed the reaction was completed. The mixture was quenched with water (10 mL) and extracted with EtOAc (5 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by p-HPLC (NH4HCO3) to give N-(4-((4-(2-(3-chloro-5-cyano-4-(3-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)-1H-1,2,3-triazol-1-yl)propoxy)phenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide (96.0% purity, 0.0172 g, yield: 6.23%) as brown oil. 1H NMR (400 MHz, CDCl3) δ=9.31 (s, 1H), 8.61 (d, J=5.2 Hz, 1H), 7.74 (s, 1H), 7.41 (d, J=2.4 Hz, 1H), 7.30 (s, 1H), 7.28 (d, J=10.0 Hz, 1H), 7.10 (d, J=8.8 Hz, 3H), 7.07-7.04 (m, 1H), 6.88 (d, J=8.8 Hz, 2H), 6.72 (s, 1H), 5.12 (s, 2H), 4.94-4.70 (m, 1H), 4.65 (t, J=6.0 Hz, 2H), 4.14-4.07 (m, 2H), 3.46 (s, 3H), 2.93 (d, J=15.2 Hz, 1H), 2.82-2.76 (m, 2H), 2.48 (d, J=6.0 Hz, 2H), 2.15 (d, J=7.6 Hz, 2H), 1.65 (s, 6H). LCMS: (220 nm): 96.2%. Exact Mass: 866.2; found 867.2/869.2.
The titled compound is synthesized according to the scheme shown above.
Titled compound is synthesized according to Example 52 with the modification of the last step as follows:
Titled compound is synthesized according to Example 52 with the modification of the last step as follows:
Titled compound is synthesized according to Example 52 with the modification of the last step as follows:
The titled compound is synthesized according to the scheme shown above.
The titled compound is synthesized according to the scheme shown above.
The titled compound is synthesized according to the scheme shown above.
The titled compound is synthesized according to the scheme shown above.
5-(2-(4-((2-aminopyrimidin-4-yl)methoxy)phenyl)propan-2-yl)-3-chloro-2-(2-chloroethoxy) benzonitrile (2): To a solution of 3-chloro-2-(2-chloroethoxy)-5-(2-(4-((2-(methylsulfonyl) pyrimidin-4-yl)methoxy)phenyl)propan-2-yl)benzonitrile (1) (10 g, 19.2 mmol) in THF (100 mL) was added NH3.H2O (100 mL) at 20° C. The mixture was stirred at 50° C. under N2 for 16 hrs. LCMS showed the reaction was completed. The mixture was poured into water (400 mL) (lot of solid appeared), then filtered and the filter cake was concentrated under reduced pressure to give 5-(2-(4-((2-aminopyrimidin-4-yl)methoxy)phenyl)propan-2-yl)-3-chloro-2-(2-chloroethoxy) benzonitrile (2) (8.7 g, yield: 97.3%) as yellow solid. 1H NMR (400 MHz, CDCl3) δ=8.32 (d, J=5.2 Hz, 1H), 7.44 (d, J=2.4 Hz, 1H), 7.33 (d, J=2.4 Hz, 1H), 7.11 (d, J=8.8 Hz, 2H), 6.93-6.82 (m, 3H), 5.08 (br s, 2H), 4.96 (s, 2H), 4.42 (t, J=6.4 Hz, 2H), 3.88 (t, J=6.4 Hz, 2H), 1.64 (s, 6H).
N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)ethenesulfonamide (4): To a solution of 5-(2-(4-((2-aminopyrimidin-4-yl)methoxy)phenyl)propan-2-yl)-3-chloro-2-(2-chloroethoxy)benzonitrile (2) (5.0 g, 10.9 mmol) and Pyridine (1.73 g, 21.9 mmol) in DCM (100 mL) was added 2-chloroethanesulfonylchloride (3) (2.67 g, 16.4 mmol) at 0° C. and stirred at the same temperature for 3 hrs. TLC showed the reaction was completed. The mixture was poured into water (200 mL) and extracted with DCM (100 mL×3) and the combined organic layers were washed with brine (100 mL×2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column to give N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl) pyrimidin-2-yl)ethenesulfonamide (4) (1.0 g, yield: 15.7%) as white solid. 1H NMR (400 MHz, CDCl3) δ=10.49 (br s, 1H), 8.69 (d, J=5.2 Hz, 1H), 7.45 (d, J=2.4 Hz, 1H), 7.32 (d, J=2.4 Hz, 1H), 7.29 (d, J=5.2 Hz, 1H), 7.15-7.11 (d, J=8.8 Hz, 2H), 7.11-7.03 (m, 1H), 6.90 (d, J=8.8 Hz, 2H), 6.55 (d, J=16.4 Hz, 1H), 6.10 (d, J=10.0 Hz, 1H), 5.11 (s, 2H), 4.42 (t, J=6.0 Hz, 2H), 3.88 (t, J=6.0 Hz, 2H), 1.65 (s, 6H).
2-azido-N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy) methyl)pyrimidin-2-yl)ethanesulfonamide (5): To a solution of N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)ethenesulfonamide (4) (900 mg, 1.64 mmol) in DMF (2.5 mL) and MeOH (2.5 mL) was added azido(trimethyl)silane (2.5 mL) and stirred at 100° C. for 6 hrs under N2. LCMS showed the reaction was completed. The mixture was poured into water (10 mL) and extracted with EtOAc (5 mL×3), the combined organic layers were washed with brine (10 mL×4), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column to give 2-azido-N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl) ethanesulfonamide (5) (350 mg, yield: 34.3%) as yellow oil. 1H NMR (400 MHz, CDCl3) δ=9.03 (br s, 1H), 8.57 (d, J=5.2 Hz, 1H), 7.37 (d, J=2.0 Hz, 1H), 7.27-7.22 (m, 2H), 7.05 (d, J=8.8 Hz, 2H), 6.82 (d, J=8.4 Hz, 2H), 5.04 (s, 2H), 4.35 (t, J=6.0 Hz, 2H), 3.86-3.73 (m, 6H), 1.57 (s, 6H).
2-azido-N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl) propan-2-yl) phenoxy) methyl) pyrimidin-2-yl) ethanesulfonamide: To a solution of 2-azido-N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl) ethanesulfonamide (5) (150 mg, 0.25 mmol), 2-(2,6-dioxo-3-piperidyl)-4-(prop-2-ynylamino)isoindoline-1,3-dione (6) (79.1 mg, 0.25 mmol) and DIEA (0.0870 mL, 0.51 mmol) in THF (3 mL) was added CuI (24.3 mg, 0.13 mmol) and stirred at 25° C. for 3 hrs under N2. LCMS showed the reaction was completed. The mixture was poured into water (5 mL) and extracted with EtOAc (5 mL×3), the combined organic layers were washed with brine (5 mL×2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by p-HPLC (FA) to give 2-azido-N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl) propan-2-yl) phenoxy) methyl) pyrimidin-2-yl) ethanesulfonamide (purity: 95%, 67.5 mg, yield: 28.0%) as yellow solid. 32.5 mg was delivered. 1H NMR (400 MHz, CDCl3) δ=9.26-8.96 (m, 1H), 8.53 (br d, J=5.2 Hz, 1H), 7.65 (br s, 1H), 7.45 (d, J=2.0 Hz, 1H), 7.44-7.37 (m, 1H), 7.32 (d, J=2.2 Hz, 1H), 7.23 (br d, J=4.8 Hz, 1H), 7.12 (br d, J=8.2 Hz, 2H), 7.06 (br t, J=6.6 Hz, 1H), 6.96-6.86 (m, 3H), 6.62 (br s, 1H), 5.06 (s, 2H), 4.97-4.90 (m, 1H), 4.85 (br s, 2H), 4.50 (br s, 2H), 4.42 (t, J=6.4 Hz, 2H), 4.26 (s, 2H), 3.87 (t, J=6.0 Hz, 2H), 2.89-2.66 (m, 3H), 2.10 (br s, 1H), 1.64 (s, 6H). LCMS (220 nm): 95.35%, Exact Mass: 900.20, Founded: 901.2/903.2.
LNCaP cells were transiently transfected with the PSA (6.1 kb)-luciferase reporter for 24 h, and then treated with indicated concentration of representative compounds with synthetic androgen, R1881 (1 nM) for 24 h. After 24 h of incubation with R1881, the cells were harvested, and relative luciferase activities were determined. To determine the IC50, treatments were normalized to the maximum activity with androgen-induction (in the absence of test compounds, vehicle only) (Table 1).
Luciferase Assay: Lysates were thawed on ice then collected into V-bottom 96-well tissue culture plates. Lysates were centrifuged at 4° C. for 5 minutes at 4000 rpm. To measure luminescence of LNCaP cell lysates the Firefly Luciferase Assay System (Promega) was employed, according to manufacturer's protocol.
Statistical analyses were performed using GraphPad Prism (Version 6.01 for Windows; La Jolla, Calif., USA). Comparisons between treatment and control groups were compared using Two-Way ANOVA with post-hoc Dunnett's and Tukey's tests. Differences were considered statistically significant at P values less than 0.05. Densitometric quantification of relative AR levels was determined by Image.
Table 1 shows the IC50 of representative Compounds from Tables A-D from androgen-induced PSA-luciferase assay. EPI-002 have the following structures:
The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
While the invention has been described in connection with proposed specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.
A compound of formula (Q):
PLM-LI-PTC (Q);
or a pharmaceutically acceptable salt thereof, wherein:
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 1, wherein the linker LI corresponds to formula
-LXA-(CH2)m1—(CH2—CH2-LXB)m2—(CH2)m3-LXC-, wherein:
The compound of embodiment 2, wherein LXA is absent (a bond), —CH2C(O)NR20—, or —NR20C(O)CH2—; wherein R20 is hydrogen or C1-C3 alkyl.
The compound of embodiment 2 or 3, wherein LXB is absent (a bond), —CH2—, —O— or —N(R20)—; wherein R20 is hydrogen or C1-C3 alkyl.
The compound of any one of embodiments 2-4, wherein LXC is absent (a bond), —CH2—, —O—, or —NH—.
The compound of any one of embodiments 2-5, wherein
The compound of embodiment 2, wherein the linker LI corresponds to formula:
—(CH2—CH2—O)m2—CH2CH2-LXC-;
—CH2C(O)NH—(CH2—CH2)m2—CH2CH2-LXC-;
—CH2C(O)NH—(CH2—CH2—O)m2—CH2-LXC-;
—CH2C(O)NH—(CH2—CH2—O)m2—CH2CH2-LXC-; or
—CH2C(O)NH—CH2—(CH2—CH2—O)m2—CH2CH2CH2-LXC-; wherein —(CH2—CH2—O)m2 or —CH2C(O)NH or is covalently bound to the PTC or PLM, and LXC- is covalently bound to the PLM or PTC;
The compound of embodiment 1, wherein the linker LI corresponds to formula
—(CH2)m1-LX1-(CH2—CH2-LX2)m2—(CH2)m3—C(LX3)-, wherein:
The compound of embodiment 8, wherein LX1, LX2, and LX3 are —O—.
The compound of embodiment 1, wherein the Linker corresponds to formula
—(CH2)m1-LXB-(CH2)m2-LXC-(CH2)m3-LXD-(CH2)m4—C(O)—, wherein:
The compound of embodiment 10, wherein the Linker corresponds to formula
—(CH2)m1-LXB-(CH2)m2-LXC-(CH2)m3—O—(CH2)m4—C(O)—, wherein:
The compound of any one of embodiments 2-11, wherein the sum of m1, m2, and m3 is less than or equal to 24.
The compound of any one of embodiments 2-12, wherein the sum of m1, m2, and m3 is less than or equal to 12.
The compound of embodiment 1, wherein the linker LI is a polyethylene glycol chain ranging in size from about 1 to about 12 ethylene glycol units, wherein each —CH2— in the polyethylene glycol is optionally substituted.
The compound of embodiment 14, wherein the linker LI is a polyethylene glycol chain ranging in size from about 2 to about 10 ethylene glycol units, wherein each —CH2— in the polyethylene glycol is optionally substituted.
The compound of embodiment 14, wherein the linker LI is a polyethylene glycol chain ranging in size from about 3 to about 5 ethylene glycol units, wherein each —CH2— in the polyethylene glycol is optionally substituted.
The compound of any one of embodiments 2-16, wherein the total number of atoms in a straight chain of LI connecting PTC and PLM is 20 or less.
The compound of embodiment 1, wherein the linker LI corresponds to the formula:
-LI-LII(q)-,
wherein:
The compound of embodiment 18, wherein q is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24.
The compound of embodiment 18 or 19, wherein LI and LII are independently selected from a bond, —(CH2)i—O—, —(CH2)i—O—, —O—(CH2)i—, —(CH2)i—S—, —(CH2)i—N—(CH2)i—, —S—, —S(O)—, —S(O)2—, —OP(O)O—(CH2)i—, —Si—(CH2)i—, wherein i is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and at least one of LI and LII is not a bond.
The compound of embodiment 1, wherein the linker LI is selected from Table L1, wherein LI is covalently bound to PLM by replacing a hydrogen from LI with a covalent bond to the PLM; and wherein LI is covalently bound to PTC by replacing a hydrogen from LI with a covalent bond the PTC.
The compound of embodiment 1, wherein the linker LI is selected from Table L2.
The compound of embodiment 1, wherein the linker LI is selected from Table L3.
The compound of any one of embodiments 1-23, wherein the PLM is a von Hippel-Lindau (VHL) binding group, an E3 ligase substrate receptor cereblon (CRBN), a mouse double minute 2 homolog (MDM2), or an inhibitor of apoptosis (IAP).
The compound of any one of embodiments 1-24, wherein the PLM is a von Hippel-Lindau (VHL) binding group.
The compound of any one of embodiments 1-25, wherein the PLM has the formula (E3B):
The compound of any one of embodiments 1-26, wherein the PLM has the formula (E3D):
The compound of embodiment 27, wherein the PLM is represented by formula (W-II):
wherein the PLM is covalently bound to the LI via
The compound of embodiment 28, wherein the PLM is:
wherein the PLM is covalently bound to the LI via
The compound of any one of embodiments 1-25, wherein the PLM is represented by formula (W-IIIA):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
The compound of embodiment 30, wherein the PLM is represented by formula (W-IIIB):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
The compound of embodiment 30 or 31, wherein X is —C(C1-3 alkyl)2.
The compound of any one of embodiments 30-32, wherein the PLM is selected from the group consisting of:
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
The compound of any one of embodiments 30-34, wherein the PLM is:
The compound of any one of embodiments 1-25, wherein the PLM is represented by:
and wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
The compound of any one of embodiments 1-25, wherein the PLM is represented by
wherein any one of the hydrogen atoms in the PLM can be replaced to form a covalent bond to the LI.
The compound of any one of embodiments 1-25, wherein the PLM is
The compound of any one of embodiments 1-37, wherein the PTC has the structure of formula (IVA):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 38, wherein C is 5- to 10-membered heteroaryl or aryl.
The compound of embodiment 38 or 39, wherein C is 5- to 7-membered heteroaryl comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member.
The compound of any one of embodiments 38-40, wherein C, which is substituted with (R3)n3, is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, pyrazine, furan or pyrimidyl.
The compound of any one of embodiments 38-40, wherein C, which is substituted with (R3)n3, is selected from the group consisting of:
wherein R3a is C1-C3 alkyl.
The compound of any one of embodiments 38-42, wherein R1 and R2 are each independently Cl, —CN, —CF3, —OH, methyl, methoxy, or —CONH2.
The compound of any one of embodiments 38-43, wherein:
The compound of embodiment 44, wherein:
The compound of embodiment 38, wherein the PTC has the structure of formula (A-I)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of any one of embodiments 38-46, wherein: at least one R3 is selected from the group consisting of —CN, C1-C3 alkoxy, —CONH2, —NHSO2CH3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, or —SO2CH3 and the other R3, if present, is selected from —CN, —CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —(C1-C3 alkyl)NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), and —N(CH3)COO(C1-C3 alkyl).
The compound of embodiment 46, wherein:
The compound of embodiment 1, wherein the PTC has the structure of formula (G-II):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 49, wherein: at least one R3 is selected from the group consisting of —NHSO2CH3, —NHSO2CH2CH3, or —SO2CH3 and the other R3, if present, is selected from —CN, C1-C3 alkyl, C1-C3 alkoxy, —SO2(C1-C3 alkyl), —NH2, —(C1-C3 alkyl)NH2, —NHSO2CH3, —N(CH3)SO2CH3, —NHSO2CH2CH3, —N(CH3)SO2CH2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), —N(CH3)COO(C1-C3 alkyl), —NHCO(C1-C3 alkyl), and —N(CH3)COO(C1-C3 alkyl).
The compound of any one of embodiments 1-50 wherein an atom in L is replaced with a covalent bond to the LI.
The compound of embodiment 51, wherein a halogen is replaced with a covalent bond to the LI
The compound of any one of embodiments 1-50, wherein an atom in ring C, R1, or R3, is replaced with a covalent bond to the LI.
The compound of embodiment 53, wherein a hydrogen atom is replaced with a covalent bond to the LI
The compound of embodiment 1, wherein the PTC is selected from Table A or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI.
The compound of embodiment 55, wherein the PTC is selected from the group consisting of:
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof; and wherein one atom or one chemical group in the PTC is replaced to form a covalent bond to the LI.
The compound of embodiment 55 or 56, wherein a Cl atom is replaced with a covalent bond to the LI.
The compound of embodiment 55 or 56, wherein a hydrogen atom is replaced with a covalent bond to the LI.
The compound of any one of the preceding embodiments, wherein the PTC is selected from:
The compound of any one of embodiments 1-59, wherein the compound is a compound of formula (W-IV):
or a pharmaceutically acceptable salt thereof.
The compound of embodiment 60, wherein the compound is a compound of formula (W-IVA)
or a pharmaceutically acceptable salt thereof.
The compound of any one of embodiments 1-59, wherein the compound is a compound of formula (W-V):
or a pharmaceutically acceptable salt thereof.
The compound of embodiment 62, wherein the compound is a compound of formula (W-VA):
or a pharmaceutically acceptable salt thereof.
The compound of any one of embodiments 1-59, wherein the compound is a compound of formula (W-VI):
or a pharmaceutically acceptable salt thereof.
The compound of embodiment 64, wherein the compound is a compound of formula (W-VIA):
or a pharmaceutically acceptable salt thereof.
The compound of any one of embodiments 1-59, wherein the compound is a compound of formula (W-VII):
or a pharmaceutically acceptable salt thereof.
A compound selected from Table P. or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of any one of embodiments 1-67 and a pharmaceutically acceptable carrier.
The pharmaceutical composition of embodiment 68, further comprising one or more additional therapeutic agents.
The pharmaceutical composition of embodiment 68, wherein the one or more additional therapeutic agents is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
The pharmaceutical composition of embodiment 68, wherein the one or more additional therapeutic agents is a poly (ADP-ribose) polymerase (PARP) inhibitor including but not limited to olaparib, niraparib, rucaparib, talazoparib; an androgen receptor ligand binding domain inhibitor including but not limited to enzalutamide, apalutamide, darolutamide, bicalutamide, nilutamide, flutamide, ODM-204, TAS3681; an inhibitor of CYP17 including but not limited to galeterone, abiraterone, abiraterone acetate; a microtubule inhibitor including but not limited to docetaxel, paclitaxel, cabazitaxel (XRP-6258); a modulator of PD-1 or PD-L1 including but not limited to pembrolizumab, durvalumab, nivolumab, atezolizumab; a gonadotropin releasing hormone agonist including but not limited to cyproterone acetate, leuprolide; a 5-alpha reductase inhibitor including but not limited to finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111; a vascular endothelial growth-factor inhibitor including but not limited to bevacizumab (Avastin); a histone deacetylase inhibitor including but not limited to OSU-HDAC42; an integrin alpha-v-beta-3 inhibitor including but not limited to VITAXIN; a receptor tyrosine kinase including but not limited to sunitumib; a phosphoinositide 3-kinase inhibitor including but not limited to alpelisib, buparlisib, idealisib; an anaplastic lymphoma kinase (ALK) inhibitor including but not limited to crizotinib, alectinib; an endothelin receptor A antagonist including but not limited to ZD-4054; an anti-CTLA4 inhibitor including but not limited to MDX-010 (ipilimumab); an heat shock protein 27 (HSP27) inhibitor including but not limited to OGX 427; an androgen receptor degrader including but not limited to ARV-330, ARV-110; a androgen receptor DNA-binding domain inhibitor including but not limited to VPC-14449; a bromodomain and extra-terminal motif (BET) inhibitor including but not limited to BI-894999, GSK25762, GS-5829; an N-terminal domain inhibitor including but not limited to a sintokamide; an alpha-particle emitting radioactive therapeutic agent including but not limited to radium 233 or a salt thereof; niclosamide; or related compounds thereof, a selective estrogen receptor modulator (SERM) including but not limited to tamoxifen, raloxifene, toremifene, arzoxifene, bazedoxifene, pipindoxifene, lasofoxifene, enclomiphene; a selective estrogen receptor degrader (SERD) including but not limited to fulvestrant, ZB716, OP-1074, elacestrant, AZD9496, GDC0810, GDC0927, GW5638, GW7604; an aromitase inhibitor including but not limited to anastrazole, exemestane, letrozole; selective progesterone receptor modulators (SPRM) including but not limited to mifepristone, lonaprison, onapristone, asoprisnil, lonaprisnil, ulipristal, telapristone; a glucocorticoid receptor inhibitor including but not limited to mifepristone, COR108297, COR125281, ORIC-101, PT150; CDK4/6 inhibitors including palbociclib, abemaciclib, ribociclib; HER2 receptor antagonist including but not limited to trastuzumab, neratinib; or a mammalian target of rapamycin (mTOR) inhibitor including but not limited to everolimus, temsirolimus.
A method for modulating androgen receptor activity, comprising administering a compound of any one of embodiments 1-67, to a subject in need thereof.
The method of embodiment 71, wherein the modulating androgen receptor activity is for treating a condition or disease selected from prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
A method for treating cancer, comprising administering a compound of any one of embodiments 1-67, to a subject in need thereof.
A compound of formula (Q):
PLM-LI-PTC (Q);
or a pharmaceutically acceptable salt thereof, wherein:
The compound of embodiment 75, wherein the linker LI corresponds to formula
-LXA-(CH2)m1—(CH2—CH2-LXB)m2—(CH2)m3-LXC-, wherein:
The compound of embodiment 76, wherein LXA is absent (a bond), —CH2C(O)NR20—, or —NR20C(O)CH2—; wherein R20 is hydrogen or C1-C3 alkyl.
The compound of embodiment 76 or 77, wherein LXB is absent (a bond), —CH2—, —O— or —N(R20)—; wherein R20 is hydrogen or C1-C3 alkyl.
The compound of any one of embodiments 76-78, wherein LXC is absent (a bond), —CH2—, —O—, or —NH—.
The compound of any one of embodiments 76-79, wherein
The compound of any one of embodiments 76-80, wherein sum of m1, m2, and m3 is less than or equal to 24.
The compound of any one of embodiments 76-80, wherein sum of m1, m2, and m3 is less than or equal to 12.
The compound of embodiment 76, wherein the linker LI corresponds to formula:
—(CH2—CH2—O)m2—CH2CH2-LXC-;
—CH2C(O)NH—(CH2—CH2)m2—CH2CH2-LXC-;
—CH2C(O)NH—(CH2—CH2—O)m2—CH2-LXC-;
—CH2C(O)NH—(CH2—CH2—O)m2—CH2CH2-LXC-; or
—CH2C(O)NH—CH2—(CH2—CH2—O)m2—CH2CH2CH2-LXC-; wherein —(CH2—CH2—O)m2 or —CH2C(O)NH or is covalently bound to the PTC or PLM, and LXC- is covalently bound to the PLM or PTC;
The compound of any one of embodiments 76-83, wherein the total number of atoms in a straight chain of LI connecting PTC and PLM is 20 or less.
The compound of embodiment 75, wherein the linker LI corresponds to formula
—(CH2)m1-LX1-(CH2—CH2-LX2)m2—(CH2)m3—C(LX3)-, wherein:
The compound of embodiment 85, wherein LX1, LX2, and LX3 are —O—.
The compound of embodiment 85, wherein the sum of m1, m2, and m3 is less than or equal to 24.
The compound of embodiment 75, wherein the linker LI is a polyethylene glycol chain ranging in size from about 1 to about 12 ethylene glycol units, wherein each —CH2— in the the polyethylene glycol is optionally substituted.
The compound of embodiment 88, wherein the linker LI is a polyethylene glycol chain ranging in size from about 2 to about 10 ethylene glycol units, wherein each —CH2— in the the polyethylene glycol is optionally substituted.
The compound of embodiment 88, wherein the linker LI is a polyethylene glycol chain ranging in size from about 3 to about 5 ethylene glycol units, wherein each —CH2— in the the polyethylene glycol is optionally substituted.
The compound of embodiment 75, wherein the linker LI corresponds to the formula:
-LI-LII(q)-,
wherein:
The compound of embodiment 91, wherein q is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24.
The compound of embodiment 91 or 92, wherein LI and LII are independently selected from a bond, —(CH2)i—O—, —(CH2)i—O—, —O—(CH2)i—, —(CH2)i—S—, —(CH2)i—N—(CH2)i—, —S—, —S(O)—, —S(O)2—, —OP(O)O—(CH2)i—, —Si—(CH2)i—, wherein i is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and at least one of LI and LII is not a bond.
The compound of embodiment 75, wherein the linker LI is selected from Table L1, wherein LI is covalently bound to PLM by replacing a hydrogen from LI with a covalent bond and wherein LI is covalently bound to PTC by replacing a hydrogen from LI with a covalent bond.
The compound of embodiment 75, wherein the linker LI is selected from Table L2.
The compound of any one of embodiments 75-95, wherein the PLM is a von Hippel-Lindau (VHL) binding group, an E3 ligase substrate receptor cereblon (CRBN), a mouse double minute 2 homolog (MDM2), or an inhibitor of apoptosis (IAP).
The compound of any one of embodiments 75-95, wherein the PLM is a von Hippel-Lindau (VHL) binding group.
The compound of any one of embodiments 75-97, wherein the PLM has the formula (E3B):
The compound of any one of embodiments 75-97, wherein the PLM has the formula (E3D):
The compound of embodiment 99, wherein the PLM has the following connectivity to the linker LI:
The compound of any one of embodiments 75-97, wherein the PLM has the formula (E3E):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
The compound of any one of embodiments 75-97, wherein the PLM has the formula (E3F):
or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
The compound of embodiment 101 or 102, wherein X is —C(C1-3 alkyl)2.
The compound of any one of embodiments 75-97, wherein the PLM is selected from
The compound of any one of embodiments 75-97, wherein the PLM is selected from
The compound of any one of embodiments 75-95 wherein the PLM is
The compound of any one of embodiments 75-106, wherein the PTC has the formula
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 107, wherein C is 5- to 7-membered heteroaryl comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member.
The compound of embodiment 107 or 108 wherein C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, or pyrimidyl.
The compound of any one of embodiment 107-109, wherein C, which is optionally substituted with R3, is selected from
wherein R3a is C1-C3 alkyl.
The compound of any one of embodiments 107-110, wherein:
The compound of any one of embodiments 107-111, wherein X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, or —CH2CH2—.
The compound of any one of embodiments 107-112, wherein R1 and R2 are each independently halogen, —CN, —CF3, —OH, methyl, methoxy, or —CONH2.
The compound of any one of embodiments 107-113, wherein R3 is selected from hydrogen, F, Cl, Br, I, oxo, ═S, ═NR16, —CN, —CF3, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, —S(C1-C3 alkyl), —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NHSO2CH3, —N(CH3)SO2CH3, —CH2NHSO2CH3, —CH2N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —N(CH3)CO(C1-C3 alkyl).
The compound of any one of embodiments 107-114, wherein at least one of R3 is —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3.
The compound of embodiment 107, wherein the PTC has the structure of formula (II):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 116 wherein C is 5- to 7-membered heteroaryl comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member.
The compound of embodiment 116 or 117, wherein C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, or pyrimidyl.
The compound of embodiment 116, wherein C, which is optionally substituted with R3, is selected from
wherein R3a is C1-C3 alkyl.
The compound of any one of embodiments 116-119, wherein A has a meta or para connectivity with X and Y.
The compound of any one of embodiments 116-120, wherein B has a meta or para connectivity with X and Z.
The compound of any one of embodiments 116-121, wherein A and B are each phenyl.
The compound of any one of embodiments 116-122, wherein —Z—V-L is —Z—CH2CH2C1, —Z—CH2CH2CH2C1, —Z—CH2CH2NH2, or —Z—CH2CH2CH2NH2, wherein Z is a bond, —O—, —NH—, or —N(COCH3)—.
The compound of any one of embodiments 116-123, wherein —Y—W— is a bond, —OCH2—, —OCH2CH2—, —OCH(CH3)—, —NH—, —NHCH2—, —NHC(═O)—, or —C(═O)NH—.
The compound of any one of embodiments 116-124, wherein X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, or —CH2CH2—.
The compound of embodiment 107, wherein the PTC has the structure of formula (III)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein.
The compound of embodiment 126, wherein C is 5- to 7-membered monocyclic heteroaryl comprising 1, 2, or 3 heteroatoms selected from O, S, or N as a ring member.
The compound of embodiment 126 or 127, wherein —V-L is —CH2CH2C1, —CH2CH2CH2C1, —CH2CH2NH2, or —CH2CH2CH2NH2.
The compound of any one of embodiments 126-128, wherein —Y—W— is a bond, —OCH2—, —OCH2CH2—, —OCH(CH3)—, —NH—, —NHCH2—, —NHC(═O)—, or —C(═O)NH—.
The compound of any one of embodiments 126-129, wherein X is a bond, —CH2—, —C(CH3)H—, —C(CH3)2—, or —CH2CH2—.
The compound of embodiment 107, wherein the PTC has the structure of formula (IV)
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 131, wherein R3 is selected from hydrogen, F, Cl, Br, I, —CN, —CF3, —OH, methyl, methoxy, —S(C1-C3 alkyl), —SO2(C1-C3 alkyl), —NH2, —NHSO2CH3, —NHSO2CF3, —N(CH3)SO2CH3, —SO2NH2, —CONH2, —CON(C1-C3 alkyl)2, —CONH(C1-C3 alkyl), —NHCO(C1-C3 alkyl), or —NHCO(C1-C3 alkyl).
The compound of embodiment 106, wherein the compound has the structure of formula (V):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of any one of embodiments 75-105, wherein the PTC is selected from Table A.
The compound of any one of embodiments 75-105, wherein the PTC is selected from Table B.
The compound of any one of embodiments 75-105, wherein the PTC has the structure of formula (i):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 136, wherein R is W.
The compound of embodiment 136 or 137, wherein W is hydrogen, halogen, —CF3, or —NR13R14.
The compound of any one of embodiments 136-138, wherein L is -E-R3.
The compound of any one of embodiments 136-139, wherein R3 is selected from hydrogen, —C1-C3 alkyl, —NR16SO(C1-C3 alkyl), —NR16SO2(C1-C3 alkyl), —SONR14R15, —SO2NR14R15, —SOR18, or —SO2R18.
The compound of any one of embodiments 136-140, wherein R3 is selected from —NHSO2(C1-C3 alkyl), —NCH3SO2(C1-C3 alkyl), or —SO2(C1-C3 alkyl).
The compound of embodiment 136, wherein the PTC has the structure of formula (ii):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 136, wherein the PTC has the structure of formula (iii):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of embodiment 142 or 143, wherein W is Cl, Br, I, or F.
The compound of any one of embodiments 142-144, wherein D is —CH2—, —CH(CH3)—, —C(CH3)2—, or —CH2CH2—.
The compound of embodiment 142, wherein q is 0.
The compound of any one of embodiments 142-146, wherein E is —CH2—, —CH(CH3)—, —C(CH3)2—, —CH2CH2—, or —CH2CH2CH2—.
The compound of any one of embodiments 142-147, wherein g is 0.
The compound of any one of embodiments 142-148, wherein R3 is selected from —NHSO2(C1-C3 alkyl), —NCH3SO2(C1-C3 alkyl), or —SO2(C1-C3 alkyl).
The compound of any one of embodiments 142-149, wherein R6 and R7 are each independently H, halogen, —CN, or methyl.
The compound of any one of embodiments 142-150, wherein X is a bond, —CH2—, —C(CH3)2—, —CH2CH2—, —NH—, —N(CH3)—, —N(iPr)-, or —N(COCH3)—.
The compound of any one of embodiments 142-151, Z is —CH2—, —O—, —NH—, —NCH3—, or —N(COCH3)—.
The compound of any one of embodiments 142-152, Y is —CH2—, —O—, —NH—, or —NCH3—.
The compound of any one of embodiments 142-153, wherein at least one of Z and Y is —O—.
The compound of embodiment 132, wherein the PTC has the structure of formula (iv):
or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
The compound of any one of embodiments 75-106, wherein the PTC is selected from Table C.
The compound of any one of embodiments 75-106, wherein the PTC has the structure of formula (a):
wherein:
The compound of embodiment 157, wherein at least two of R11a, R11b, R11c and R11d are methyl, F, Cl, Br, I, or 123I.
The compound of embodiment 157, wherein R11c and R11d are each independently methyl, Cl, or Br.
The compound of embodiment 157, wherein R11c and R11d are each Cl.
The compound of any one of embodiments 157-160, wherein X is —C(R8R9)— and R8 and R9 are each independently C1-C3 alkyl.
The compound of embodiment 161, wherein R8 an R9 are each methyl.
The compound of any one of embodiment 157-162, wherein R1 and R2 are both hydroxyl.
The compound of any one of embodiment 157-163, wherein R3 is an optionally substituted 5 or 6 membered heteroaryl or an optionally substituted 3 to 7 membered heterocylyl, wherein said heteroaryl or said heterocyclyl respectively comprise at least one N atom.
The compound of any one of embodiment 157-163, wherein R3 is selected from a group consisting of pyrrole, furan, thiophene, pyrazole, pyridine, pyridazine, pyrimidine, imidazole, thiazole, isoxazole, oxadiazole, thiadiazole, oxazole, triazole, isothiazole, oxazine, triazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.
The compound of any one of embodiment 157-163, wherein R3 is —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR) or —S(O)nR5.
The compound of any one of embodiment 157-163, wherein R3 is —NH2, —NHC(═O)(C1-C4 alkyl), —N[(C(═O)(C1-C4 alkyl)]2, —NHS(O)n(C1-C3 alkyl), —N[C(═O)(C1-C4 alkyl)][(S(O)n(C1-C3 alkyl)], —N[C1-C6 alkyl][S(O)n(C1-C3 alkyl)], or —S(O)n(C1-C3 alkyl).
The compound of any one of embodiments 75-106, wherein the PTC is selected from Table D.
A pharmaceutical composition comprising a compound of any one of embodiments 75-168 and a pharmaceutically acceptable carrier.
The pharmaceutical composition of embodiment 169, further comprising one or more additional therapeutic agents.
The pharmaceutical composition of embodiment 170, wherein the one or more additional therapeutic agents is for treating prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
The pharmaceutical composition of embodiment 170, wherein the one or more additional therapeutic agents is a poly (ADP-ribose) polymerase (PARP) inhibitor including but not limited to olaparib, niraparib, rucaparib, talazoparib; an androgen receptor ligand binding domain inhibitor including but not limited to enzalutamide, apalutamide, darolutamide, bicalutamide, nilutamide, flutamide, ODM-204, TAS3681; an inhibitor of CYP17 including but not limited to galeterone, abiraterone, abiraterone acetate; a microtubule inhibitor including but not limited to docetaxel, paclitaxel, cabazitaxel (XRP-6258); a modulator of PD-1 or PD-L1 including but not limited to pembrolizumab, durvalumab, nivolumab, atezolizumab; a gonadotropin releasing hormone agonist including but not limited to cyproterone acetate, leuprolide; a 5-alpha reductase inhibitor including but not limited to finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111; a vascular endothelial growth factor inhibitor including but not limited to bevacizumab (Avastin); a histone deacetylase inhibitor including but not limited to OSU-HDAC42; an integrin alpha-v-beta-3 inhibitor including but not limited to VITAXIN; a receptor tyrosine kinase including but not limited to sunitumib; a phosphoinositide 3-kinase inhibitor including but not limited to alpelisib, buparlisib, idealisib; an anaplastic lymphoma kinase (ALK) inhibitor including but not limited to crizotinib, alectinib; an endothelin receptor A antagonist including but not limited to ZD-4054; an anti-CTLA4 inhibitor including but not limited to MDX-010 (ipilimumab); an heat shock protein 27 (HSP27) inhibitor including but not limited to OGX 427; an androgen receptor degrader including but not limited to ARV-330, ARV-110; a androgen receptor DNA-binding domain inhibitor including but not limited to VPC-14449; a bromodomain and extra-terminal motif (BET) inhibitor including but not limited to BI-894999, GSK25762, GS-5829; an N-terminal domain inhibitor including but not limited to a sintokamide; an alpha-particle emitting radioactive therapeutic agent including but not limited to radium 233 or a salt thereof, niclosamide; or related compounds thereof, a selective estrogen receptor modulator (SERM) including but not limited to tamoxifen, raloxifene, toremifene, arzoxifene, bazedoxifene, pipindoxifene, lasofoxifene, enclomiphene; a selective estrogen receptor degrader (SERD) including but not limited to fulvestrant, ZB716, OP-1074, elacestrant, AZD9496, GDC0810, GDC0927, GW5638, GW7604; an aromitase inhibitor including but not limited to anastrazole, exemestane, letrozole; selective progesterone receptor modulators (SPRM) including but not limited to mifepristone, lonaprison, onapristone, asoprisnil, lonaprisnil, ulipristal, telapristone; a glucocorticoid receptor inhibitor including but not limited to mifepristone, COR108297, COR125281, ORIC-101, PT150; CDK4/6 inhibitors including palbociclib, abemaciclib, ribociclib; HER2 receptor antagonist including but not limited to trastuzumab, neratinib; or a mammalian target of rapamycin (mTOR) inhibitor including but not limited to everolimus, temsirolimus.
A method for modulating androgen receptor activity, comprising administering a compound of any one of embodiments 157-168, to a subject in need thereof.
The method of any one of embodiment 173, wherein the modulating androgen receptor activity is for treating a condition or disease selected from prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.
A method for treating cancer, comprising administering a compound of any one of embodiments 157-168, to a subject in need thereof.
The method of embodiment 175, wherein the cancer is selected from prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, endometrial cancer, or salivary gland carcinoma.
The method of embodiment 175, wherein the cancer is prostate cancer.
The method of embodiment 177, wherein the prostate cancer is primary or localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, advanced prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer, and hormone-sensitive prostate cancer.
The method of embodiment 177, wherein the prostate cancer is metastatic castration-resistant prostate cancer.
The method of embodiment 177, wherein the prostate cancer expresses full-length androgen receptor or truncated androgen receptor splice variant.
A compound of formula (Y-IV), (Y-IVA), (Y-V), (Y-VA), (Y-VI), (Y-VIA), (Y-VII), (Y-VIII), (Y-IX), or (Y-X):
or a pharmaceutically acceptable salt thereof, wherein A, B, C, R1, R2, R3, Z, V, L, Y, W, LI, FG, n1, n2, and n3 are as defined in any one of embodiments 1-180.
A compound selected from
or a pharmaceutically acceptable salt thereof, wherein a, b, c, and d are each independently an integer between 1 to 10.
The compound of embodiment 182, wherein a is 5, b is 3, and c is 1.
The compound of embodiment 182, wherein a is 2, b is 5, and c is 1.
The compound of embodiment 182, wherein, a is 2, b is 5, c is 1, and d is 3.
The compound of embodiment 182, wherein a is 5 and c is 1.
The compound of embodiment 182, wherein a is 5.
The compound of embodiment 182, wherein a is 3.
The application claims priority to U.S. Provisional Application No. 62/825,387, filed Mar. 28, 2019, the disclosures of which are hereby incorporated by reference in their entireties for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2020/025542 | 3/27/2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62825387 | Mar 2019 | US |
